

## AUTHOR INDEX

- Abbasi, F., 159, 280, 495  
 Abdella, N., 638  
 Abian, J., 1118  
 Abudula, R., 1378  
 Abuin, A., 1322  
 Acampora, C., 1243  
 Ackermans, M. T., 886  
 Adachi, M., 1113  
 Adams, M. J., 1399  
 Adeli, K., 228  
 Agbaje, O. F., 1349  
 Agren, Å., 1496  
 Ahn, J., 607  
 Ahren, B., 624, 1355  
 Aizawa, T., 949  
 Akanuma, H., 583  
 Akirav, E. M., 1558  
 Alberca, I., 666  
 Albrecht, C., 17  
 Al Daghi, N., 430  
 Alderson, N. L., 969  
 Alemzadeh, R., 441  
 Aljada, A., 330  
 Allick, G., 886  
 Allison, G., 495  
 Alm, R., 1436  
 Almeida, M., 666  
 Almeras, N., 310  
 Alonso-Vale, M. I. C., 500  
 AlRimawy, H., 209  
 Alsacid, M., 638  
 Al-Sheikh, N., 638  
 Alshingiti, A., 727  
 Alstrup, K. K., 1158  
 Altena, T. S., 749  
 Amani, Z., 165  
 Amico, M. C., 1274  
 Anan, F., 777, 1359  
 Andersen, O., 1565  
 Andersen, U. B., 1565  
 Ando, F., 135  
 Andreotti, S., 500  
 Angelini, G. D., 1315  
 Angelini, V., 1081  
 Angelopoulos, T. J., 193  
 Anhê, G. F., 500  
 Antonacci, E., 995  
 Aoki, Y., 868  
 Aparicio, M., 614  
 Apolone, G., 435  
 Aquino, K. A., 215  
 Arai, H., 977  
 Arai, K., 28  
 Araki, A., 353  
 Araújo-Vilar, D., 1462  
 Arcelus, R., 1512  
 Arch, J. R. S., 1322  
 Arii, K., 297  
 Arima, H., 977  
 Arinami, T., 182  
 Arnesen, H., 1574  
 Arosio, M., 740  
 Asahi, T., 733  
 Aso, Y., 693, 1152  
 Asztalos, B. F., 1255  
 Au, C. S., 228  
 Awata, T., 1548  
 Azevedo, J. L., Jr., 284  
 Badiou, S., 989  
 Bai, H., 423  
 Bailey, C. J., 252  
 Baker, A. J., 964  
 Bannister, P., 545  
 Bar, R. S., 1454  
 Barakat, H. A., 1, 247  
 Barash, V., 836  
 Barbara, A., 532  
 Barmada, M. M., 303, 458  
 Barnard, R. J., 377  
 Barnett, A. H., 430  
 Baron, J. A., 578  
 Baron, M. A., 1331  
 Barone, G., 563  
 Barthe, N., 614  
 Basu, R., 1467  
 Batista, M. C., 1255  
 Batta, A. K., 556, 927  
 Baumgartner, M., 809  
 Bausserman, L., 193  
 Bazargan, M., 1166  
 Beck-Peccoz, P., 740  
 Bedno, S., 340  
 Belfort, R., 1233  
 Benavente, M., 1045  
 Ben-Ezra, V., 348  
 Berenson, G. S., 1184  
 Berg, G., 1013  
 Bergeron, J., 310  
 Berglund, G., 1436  
 Bergman, R. N., 1202  
 Berneis, K., 483  
 Bernini, F., 153  
 Bernstein, E. L., 790  
 Berria, R., 1233  
 Bertie, J., 545  
 Best, K., 37  
 Bilbie, C., 193  
 Bilecen, S., 1197  
 Bilz, S., 918  
 Binnert, C., 4  
 Bisschop, P. H., 886  
 Bistran, B. R., 273  
 Blair, S. N., 1066  
 Blanche, P. J., 483  
 Blanco, P. G., 273  
 Blanco-Vaca, F., 1512  
 Bo, M., 984  
 Bodenlenz, M., 1484  
 Bodvarsdottir, T., 441  
 Boerwinkle, E., 1184  
 Bogardus, C., 904  
 Bollati, A., 563  
 Bollheimer, L. C., 1443  
 Bollineni, J., 927  
 Bonfanti, C., 563  
 Booth, S. L., 215  
 Borges-Silva, C. d. N., 500  
 Borgiani, P., 995  
 Born, J., 894, 1449  
 Boston, R. C., 1202  
 Bottini, E., 995  
 Bottini, N., 995  
 Bouchard, C., 108, 1192  
 Braun, C., 799  
 Bravo-Vera, R., 358  
 Brem, A. S., 811  
 Breu, J., 790  
 Brites, F., 1262  
 Brock, B., 1158  
 Broderick, T. L., 1391  
 Brodsky, I. G., 340  
 Brousseau, M. E., 1255  
 Brown, M. D., 673  
 Brown, W. V., 1296  
 Browne, P. O., 11  
 Browning, L. M., 899  
 Buettner, R., 1443  
 Buisson, A., 782  
 Bujo, H., 1095  
 Bullock, M., 1552  
 Burattin, A., 563  
 Burgo, R. M., 666  
 Buse, M. G., 165  
 Byun, S. Y., 1527  
 Byun, Y., 1007  
 Cabezas, M. C., 49, 1197  
 Cabezas-Cerrato, J., 1462  
 Cai, R. Y., 236  
 Calabrese, P. A., 1016  
 Calabresi, L., 153  
 Caldiz, C. I., 382  
 Camacho, R. C., 1290  
 Campbell, K. L., 1107  
 Camps, J., 95  
 Canavan, B., 790  
 Canavesi, M., 153  
 Cano, B., 1045  
 Capasso, A. M., 1081  
 Cappiello, V., 740  
 Carey, A. L., 1492  
 Carhart, R. L., 284  
 Carmines, P. K., 868  
 Caselli, A., 222  
 Cassader, M., 984  
 Cassis, C., 388  
 Casti, A., 1140  
 Castro, C., 594  
 Castro, J., 1262  
 Cattin, L., 1126  
 Cefalu, W., 1331  
 Cha, B. Y., 142  
 Chan, K. W., 955  
 Chan, O., 1558  
 Chang, S. A., 142

## AUTHOR INDEX

- Abbasi, F., 159, 280, 495  
 Abdella, N., 638  
 Abian, J., 1118  
 Abudula, R., 1378  
 Abuin, A., 1322  
 Acampora, C., 1243  
 Ackermans, M. T., 886  
 Adachi, M., 1113  
 Adams, M. J., 1399  
 Adeli, K., 228  
 Agbaje, O. F., 1349  
 Agren, Å., 1496  
 Ahn, J., 607  
 Ahren, B., 624, 1355  
 Aizawa, T., 949  
 Akanuma, H., 583  
 Akirav, E. M., 1558  
 Alberca, I., 666  
 Albrecht, C., 17  
 Al Daghi, N., 430  
 Alderson, N. L., 969  
 Alemzadeh, R., 441  
 Aljada, A., 330  
 Allick, G., 886  
 Allison, G., 495  
 Alm, R., 1436  
 Almeida, M., 666  
 Almeras, N., 310  
 Alonso-Vale, M. I. C., 500  
 AlRimawy, H., 209  
 Alsacid, M., 638  
 Al-Sheikh, N., 638  
 Alshingiti, A., 727  
 Alstrup, K. K., 1158  
 Altena, T. S., 749  
 Amani, Z., 165  
 Amico, M. C., 1274  
 Anan, F., 777, 1359  
 Andersen, O., 1565  
 Andersen, U. B., 1565  
 Ando, F., 135  
 Andreotti, S., 500  
 Angelini, G. D., 1315  
 Angelini, V., 1081  
 Angelopoulos, T. J., 193  
 Anhê, G. F., 500  
 Antonacci, E., 995  
 Aoki, Y., 868  
 Aparicio, M., 614  
 Apolone, G., 435  
 Aquino, K. A., 215  
 Arai, H., 977  
 Arai, K., 28  
 Araki, A., 353  
 Araújo-Vilar, D., 1462  
 Arcelus, R., 1512  
 Arch, J. R. S., 1322  
 Arii, K., 297  
 Arima, H., 977  
 Arinami, T., 182  
 Arnesen, H., 1574  
 Arosio, M., 740  
 Asahi, T., 733  
 Aso, Y., 693, 1152  
 Asztalos, B. F., 1255  
 Au, C. S., 228  
 Awata, T., 1548  
 Azevedo, J. L., Jr., 284  
 Badiou, S., 989  
 Bai, H., 423  
 Bailey, C. J., 252  
 Baker, A. J., 964  
 Bannister, P., 545  
 Bar, R. S., 1454  
 Barakat, H. A., 1, 247  
 Barash, V., 836  
 Barbara, A., 532  
 Barmada, M. M., 303, 458  
 Barnard, R. J., 377  
 Barnett, A. H., 430  
 Baron, J. A., 578  
 Baron, M. A., 1331  
 Barone, G., 563  
 Barthe, N., 614  
 Basu, R., 1467  
 Batista, M. C., 1255  
 Batta, A. K., 556, 927  
 Baumgartner, M., 809  
 Bausserman, L., 193  
 Bazargan, M., 1166  
 Beck-Peccoz, P., 740  
 Bedno, S., 340  
 Belfort, R., 1233  
 Benavente, M., 1045  
 Ben-Ezra, V., 348  
 Berenson, G. S., 1184  
 Berg, G., 1013  
 Bergeron, J., 310  
 Berglund, G., 1436  
 Bergman, R. N., 1202  
 Berneis, K., 483  
 Bernini, F., 153  
 Bernstein, E. L., 790  
 Berria, R., 1233  
 Bertie, J., 545  
 Best, K., 37  
 Bilbie, C., 193  
 Bilecen, S., 1197  
 Bilz, S., 918  
 Binnert, C., 4  
 Bisschop, P. H., 886  
 Bistran, B. R., 273  
 Blair, S. N., 1066  
 Blanche, P. J., 483  
 Blanco, P. G., 273  
 Blanco-Vaca, F., 1512  
 Bo, M., 984  
 Bodenlenz, M., 1484  
 Bodvarsdottir, T., 441  
 Boerwinkle, E., 1184  
 Bogardus, C., 904  
 Bollati, A., 563  
 Bollheimer, L. C., 1443  
 Bollineni, J., 927  
 Bonfanti, C., 563  
 Booth, S. L., 215  
 Borges-Silva, C. d. N., 500  
 Borgiani, P., 995  
 Born, J., 894, 1449  
 Boston, R. C., 1202  
 Bottini, E., 995  
 Bottini, N., 995  
 Bouchard, C., 108, 1192  
 Braun, C., 799  
 Bravo-Vera, R., 358  
 Brem, A. S., 811  
 Breu, J., 790  
 Brites, F., 1262  
 Brock, B., 1158  
 Broderick, T. L., 1391  
 Brodsky, I. G., 340  
 Brousseau, M. E., 1255  
 Brown, M. D., 673  
 Brown, W. V., 1296  
 Browne, P. O., 11  
 Browning, L. M., 899  
 Buettner, R., 1443  
 Buisson, A., 782  
 Bujo, H., 1095  
 Bullock, M., 1552  
 Burattin, A., 563  
 Burgo, R. M., 666  
 Buse, M. G., 165  
 Byun, S. Y., 1527  
 Byun, Y., 1007  
 Cabezas, M. C., 49, 1197  
 Cabezas-Cerrato, J., 1462  
 Cai, R. Y., 236  
 Calabrese, P. A., 1016  
 Calabresi, L., 153  
 Caldiz, C. I., 382  
 Camacho, R. C., 1290  
 Campbell, K. L., 1107  
 Camps, J., 95  
 Canavan, B., 790  
 Canavesi, M., 153  
 Cano, B., 1045  
 Capasso, A. M., 1081  
 Cappiello, V., 740  
 Carey, A. L., 1492  
 Carhart, R. L., 284  
 Carmines, P. K., 868  
 Caselli, A., 222  
 Cassader, M., 984  
 Cassis, C., 388  
 Casti, A., 1140  
 Castro, C., 594  
 Castro, J., 1262  
 Cattin, L., 1126  
 Cefalu, W., 1331  
 Cha, B. Y., 142  
 Chan, K. W., 955  
 Chan, O., 1558  
 Chang, S. A., 142

- Chassereau, C. N., 969  
 Chassin, L. J., 1484  
 Chatterjee, V. K. K., 11  
 Chauveau, P., 614  
 Chen, W., 1184  
 Cheng, C., 1107  
 Cheng, J., 772, 1500  
 Cherrington, A. D., 933  
 Chetty, R., 430  
 Chevalier, S., 388  
 Chiappe De Cingolani, G. E., 382  
 Chiba, H., 942  
 Chinkes, D. L., 128  
 Chiodera, P., 1140  
 Choi, J. H., 1284  
 Choi, S. M., 1054, 1538  
 Choi, Y. O., 269  
 Chong, T., 228  
 Chopra, I. J., 538, 1101  
 Christian, B., 247  
 Christ-Roberts, C. Y., 1233  
 Chu, C. A., 933  
 Chu, C.-H., 1136  
 Chu, J. W., 159  
 Church, T. S., 1066  
 Chuyen, N. V., 1517  
 Cipolla-Neto, J., 500  
 Cittadini, A., 1081  
 Clapham, J. C., 1322  
 Clära, J., 1118  
 Clark, T. A., 1145  
 Clement, S., 54  
 Cochran, C. S., 1202  
 Cochran, E., 513  
 Coggan, A. R., 875  
 Coghlan, M. P., 1322  
 Cohan, P., 1101  
 Coiro, V., 1140  
 Collins, J. N., 1121  
 Considine, R. V., 138  
 Cooper, D. A., 454  
 Corcoran, S. L., 1322  
 Corica, F., 435  
 Corrales, J. J., 666  
 Cossi, S., 1016  
 Cotter, J., 454  
 Coudray, C., 660  
 Cozzi, R., 563  
 Crawford, L., 578  
 Cubero, J. M., 1512  
 Cui, H., 942  
 Cuomo, V., 1522  
 Cuzzolaro, M., 435  
 Ćwikowska, J., 66  
  
 Daido, H., 89  
 Dalgaard, M., 77  
 Damcott, C. M., 303, 458  
 Dandona, P., 54, 330  
 Darwin, C., 1101  
 Das, A. M., 809  
 Date, Y., 84  
 Davidson, M. B., 1166  
 Davis, J., 247  
  
 De Bruin, T. W. A., 187  
 Deeg, M. A., 138  
 De Faria, E. C., 858  
 DeGeitere, C., 1262  
 De Jaegere, P. P. T., 49  
 De Jong, S. A., 318  
 Delannoy, P., 532  
 De La Puerta Vásquez, R., 59  
 De Marco, D., 1243  
 De Martinis, M., 1016  
 De Michele, M., 1243  
 Dengel, D. R., 397  
 Denis, B. G., 532  
 Dennison, E. M., 720  
 Denny, J. C., 1290  
 De Oya, M., 1045  
 Depaoli, A. M., 513  
 De Ruijter-Heijstek, F. C., 187  
 DeRuisseau, L. R., 1417  
 De Souza, J. B., 1048  
 Després, J.-P., 108, 310  
 Devaraj, S., 236  
 Dhillon, K. S., 1101  
 Dhindsa, S., 330  
 Diffenderfer, M. R., 1255  
 Di Minno, G., 852  
 DiSilvestro, R. A., 37  
 Doi, T., 977  
 Dolnikowski, G. G., 215, 520, 1255  
 Donahue, E. P., 933  
 Donahue, O. M., 749, 1365  
 Doy, M., 42  
 Drouin, R., 1027  
 Duckworth, W. C., 1037  
 Dwivedi, M., 1336  
  
 Economides, P. A., 222  
 Edel, A. L., 1145  
 Eid, H. M. A., 1574  
 Elased, K. M., 1048  
 Elbert, A., 1013  
 Elliott, J. L., 17  
 Endert, E., 886  
 Endo, K., 182  
 Erichsen, L., 1349  
 Erkelens, D. W., 187  
 Erkkilä, A. T., 215  
 Esmatjes, E., 1118  
 Evans, S. A., 727  
 Ezaki, O., 942  
  
 Falkner, B. E., 1107  
 Fan, Q., 1473  
 Farmer, B., 933  
 Fawcett, J., 1037  
 Febbraio, M. A., 1492  
 Fee, H., 755  
 Fehm, H. L., 894, 1449  
 Feillet-Coudray, C., 660  
 Feingold, E., 303, 458  
 Felton, C. V., 571  
 Fenicchia, L. M., 284  
 Fernandez, M. L., 823  
 Fernández-Pérez, C., 1411  
  
 Ferrante, E., 740  
 Ferré, N., 95  
 Ferrell, R. E., 303, 458  
 Ferrer-Martínez, A., 1032  
 Field, A., 430  
 Fields, D. A., 875  
 Fiestras-Janeiro, G., 1462  
 Finardi, L., 1140  
 Fineberg, N. S., 138  
 Flakoll, P., 933  
 Flatt, P. R., 252  
 Fledelius, C., 441  
 Flores, L., 1118  
 Flurkey, K., 799  
 Flyvbjerg, A., 1565  
 Fonseca, V. A., 1331  
 Fontaine, R. N., 465  
 Ford, G. C., 340  
 Fowler, B., 809  
 Francescato, M. P., 1126  
 Franceschini, G., 153  
 Franks, P. W., 11  
 Freaney, R., 1251  
 Fredrikson, G. N., 1436  
 Fruchart, J.-C., 1262  
 Fujimoto, M., 1532  
 Fujino, T., 123  
 Fujisawa, Y., 600  
 Fukaya, M., 977  
 Fukushima, M., 831  
 Fukushima, S., 42  
 Fukuzuwa, Y., 260  
 Funabiki, K., 842  
 Furman, M., 340  
 Fusi, S., 1126  
  
 Gaillard, T., 414, 1552  
 Gais, S., 894  
 Galli, P., 1140  
 Gannon, M. C., 241, 1399  
 Garcés, C., 1045  
 García-Berrocal, B., 666  
 García-Estévez, D. A., 1462  
 Garrow, T. A., 594  
 Garvey, W. T., 1296  
 Gault, V. A., 252  
 Geat, M., 1126  
 Gebb, M., 1355  
 Gee, M. K., 1121  
 Geluk, C. A., 49  
 Gemelli, F., 744  
 Gemma, S., 37  
 Genovese, D. J., 1202  
 Gentile, A., 620  
 Gerich, J., 1208  
 Gerich, J. E., 1331  
 German, B., 236  
 Ghanim, H., 330  
 Giavoli, C., 740  
 Gibney, J., 1251  
 Gil, A., 1045  
 Girman, P., 655  
 Giustina, A., 563  
 Gloria-Bottini, F., 995

- Glueck, C. J., 465  
 Gopal, F., 174  
 Goddard, I. F., 571  
 Goel, D. P., 1145  
 Gohda, T., 842, 1473  
 Goldner, W. S., 1454  
 Goldspink, P., 340  
 Gomez, J. E., 638  
 Gómez Foix, A. M., 1032  
 Gomez-Sanchez, C. E., 89  
 González, A. L., 1013  
 González-Buitrago, J. M., 666  
 González-Sánchez, J. L., 1411  
 Gorden, P., 513  
 Gordon, P., 193  
 Goto, Y., 550  
 Gougeon, R., 388  
 Goulding, A., 1372  
 Gouller, A., 358  
 Goyke, E., 1060  
 Gozansky, W. S., 348  
 Gragnoli, C., 959  
 Grassi, V., 1016  
 Graunke, D. M., 799  
 Gray, R., 545  
 Green, B. D., 252  
 Green, J. S., 1192  
 Greer, B., 252  
 Gregersen, S., 73  
 Grinspoon, S., 790  
 Grossi, E., 435  
 Gruppo, R., 465  
 Grusak, M. A., 215  
 Guardasole, V., 1081  
 Gumaa, K. A., 1048  
 Guo, ZK., 794  
 Gushiken, N., 1113  
 Gustavson, S. M., 933
- Haas, M. J., 174, 766, 1342  
 Habener, J. F., 959  
 Hada, T., 772, 1500  
 Hagberg, J. M., 673  
 Hägg, E., 1496  
 Haggan, W. E., 614  
 Hagiwara, S., 842  
 Hahn, J. R., 1527  
 Halkes, C. J. M., 49, 1197  
 Hallman, D. M., 1184  
 Hallschmid, M., 1449  
 Hamaguchi, H., 182  
 Hamido, M. S. M., 209  
 Hamman, R. F., 303, 458  
 Hamsten, A., 852  
 Han, H. S., 1007  
 Han, M., 607, 1284  
 Han, Y.-Q., 22, 912  
 Hanada, T., 84  
 Hancox, J. C., 760  
 Hanif, W., 430  
 Hansen, B. R., 1565  
 Hara, M., 777, 1359  
 Hara, T., 260  
 Harding, A.-H., 11
- Hardy, M. P., 811  
 Harlan, D. M., 403  
 Harper, A. J., 1322  
 Harriott, P., 252  
 Hashimoto, K., 297  
 Hashimoto, N., 1095  
 Hashimoto-Tamaoki, T., 1500  
 Hashizume, K., 949  
 Hatayama, T., 644  
 Hattemer, A., 620  
 Haugaard, S. B., 1565  
 Hauner, H., 632  
 Hawe, E., 852  
 Hayakawa, N., 550  
 Hayashi, T., 650, 1532  
 Hayashi, Y., 84  
 Hayden, J., 280  
 Haynes, W. G., 1454  
 Hedblad, B., 1436  
 Heinemann, L., 1227  
 Heise, T., 1227  
 Heled, Y., 836  
 Heller, S., 1227  
 Henderson, K. K., 140, 1021  
 Henriksen, E. J., 101, 1215  
 Henrotte, J. G., 660  
 Hermansen, K., 73, 77, 1158, 1378, 1522  
 Hermayer, K. L., 969  
 Herron, K. L., 823  
 Heshka, S., 1503  
 Heyliger, C. E., 1145  
 Heymsfield, S. B., 1503  
 Hickner, R., 247  
 Higa, N., 733  
 Higashino, H., 1544  
 Higgins, C. F., 17  
 Higuchi, M., 942  
 Higurashi, M., 1095  
 Hiilemaa, V., 1433  
 Hirano, T., 526, 589, 1113  
 Hirose, H., 879  
 Hirschberg, B., 403  
 Hjerkin, E. M., 1574  
 Ho, S.-C., 1136  
 Hoffer, L. J., 1480  
 Holder, J. C., 1322  
 Holiman, D. A., 140, 1021  
 Holmes, A. G., 1492  
 Holst, J. J., 73, 77, 624  
 Honda, A., 42  
 Horani, M. H., 174, 1342  
 Horikoshi, S., 842  
 Horio, T., 710  
 Horton, E. S., 222  
 Hoshikawa, T., 1223  
 Hosoda, K., 650, 1532  
 Hovorka, R., 1349, 1484  
 Hsia, S., 1331  
 Hsia, S. H., 1166  
 Hsu, S.-P., 1136  
 Huang, M. H., 1177  
 Hubold, C., 1449  
 Hulver, M. W., 1  
 Humphries, S. E., 852
- Hung, N. T. K., 1517  
 Hunter, R. J., 964  
 Hunter, S. J., 1296  
 Hutchison, A. K., 1391  
 Hyodo, T., 1113
- Iannuzzi, A., 1243  
 Ichianagi, K., 583  
 Idei, T., 476  
 Iguchi, T., 476  
 Ikeda, H., 260  
 Ikeda, M., 831  
 Ikeda, Y., 297  
 Ikejiri, A., 1113  
 Ikenaga, H., 868  
 Imamura, S., 550  
 Inaba, M., 1548  
 Inokuchi, T., 772, 1500  
 Inoue, G., 650, 1532  
 Inoue, Y., 260  
 Inouye, K., 1558  
 Inukai, K., 1548  
 Inukai, T., 693, 1152  
 Iovine, C., 620  
 Irwin, N., 252  
 Isaia, G., 984  
 Ishida, H., 488  
 Ishii, N., 868  
 Ishikawa, T., 260  
 Ishimi, Y., 942  
 Ishiwata, Y., 550  
 Ishizuka, T., 89  
 Isomura, Y., 89  
 Itabe, H., 423  
 Itagaki, E., 488  
 Ito, T., 842  
 Itoh, H., 716  
 Itoh, M., 550  
 Itoh, Y., 550  
 Itokawa, M., 476  
 Iversen, J., 1565  
 Izawa, T., 1424
- Jackson, C. L., 760  
 Jafari, M., 687  
 Jahoor, F., 1087  
 Jalbert, S. M., 215  
 James, F. D., 1290  
 James, R. W., 153  
 James-Kracke, M., 749  
 Jang, Y. J., 269  
 Jankowski, C. M., 348  
 Janowska, J., 1268  
 Jansen, H., 187  
 Jebb, S. A., 899  
 Jen, K.-L. C., 782  
 Jenkins, A. J., 969, 1296  
 Jensen, M. D., 1467  
 Jeong, S., 607, 1284  
 Jeppesen, P. B., 73, 1378  
 Jeremy, J. Y., 760, 1315  
 Jia, D., 405  
 Jialal, I., 236  
 Jing, T.-Y., 324



- Johnston, D., 545  
 Johnston, D. G., 17  
 Jolly, M., 545  
 Jones, L. M., 1372  
 Jordan, K., 241  
 Jornayvaz, F. R., 847  
 Jotti, G. S., 1140  
 Joven, J., 95  
 Juhan-Vague, I., 852  
 Jung, T. S., 1527
- Ka, T., 772, 1500  
 Kaaja, R., 1433  
 Kai, Y., 644  
 Kajimura, N., 84  
 Kajiya, F., 335  
 Kakizawa, H., 550  
 Kanaley, J. A., 284  
 Kanatsuka, A., 1095  
 Kaneko, S., 842  
 Kang, S. K., 142  
 Kangawa, K., 84, 710  
 Kaplow, J., 1552  
 Karasová, L., 469  
 Kasa-Vubu, J. Z., 507  
 Kashyap, S., 1233  
 Katagiri, T., 476  
 Katahira, H., 488  
 Katakura, M., 949  
 Katayama, S., 1548  
 Kato, K., 260  
 Kato, T., 550  
 Kato, Y., 1395  
 Katsilambros, N., 222  
 Katsuta, H., 488  
 Kauffman, R. F., 1121  
 Kaul, N., 236  
 Kawagoe, Y., 1382  
 Kawaguchi, A., 589  
 Kawaguchi, M., 1395  
 Kawakami, M., 1517  
 Kawamura, M., 476  
 Kawano, Y., 710  
 Kawasaki, T., 583  
 Kazumi, T., 589  
 Keller, B. T., 927  
 Keller, U., 918  
 Kelley, D. E., 1331  
 Kern, W., 894, 1449  
 Khaothiar, L., 222  
 Kim, B. H., 1284  
 Kim, C., 269  
 Kim, D. R., 1527  
 Kim, D.-H., 863  
 Kim, H. S., 142  
 Kim, J., 1284  
 Kim, K. S., 1054, 1538  
 Kim, M., 607, 1284  
 Kim, S. H., 1007  
 Kim, S. R., 142  
 Kim, S. Y., 1007  
 Kim, T. W., 607  
 Kimoto, S., 716
- Kimura, K., 335  
 King, L. P., 969  
 Kiniwa, M., 680  
 Kinnick, T. R., 1215  
 Kishida, M., 448  
 Kitabchi, A. E., 117  
 Kitagawa, H., 1095  
 Klaude, M., 1076  
 Klein, R. L., 969, 1296  
 Klein, S., 875  
 Knowler, W. C., 904  
 Knudsen, P., 520  
 Ko, S. Y., 142  
 Koba, S., 476  
 Kobayashi, M., 842  
 Kobayashi, Y., 1544  
 Kogure, A., 1223  
 Kohno, M., 710  
 Koide, H., 1382  
 Kolterman, O., 1227  
 Komatsu, M., 949  
 Kondo, K., 1517  
 Kooistra, T., 852  
 Korczynska, J., 1060  
 Koshinaka, K., 22, 912  
 Kosutic, G., 54  
 Koutkia, P., 790  
 Koyama, Y., 1290  
 Koza, R. A., 799  
 Kozak, L. P., 799  
 Kraenzlin, M., 918  
 Krauss, R. M., 483  
 Krebs, J. D., 899  
 Kreisman, S. H., 388  
 Kruer, M. C., 1037  
 Kubota, M., 912  
 Kuk, J. L., 1066  
 Kukowski, J., 340  
 Kulaputana, O., 673  
 Kumagai, K., 423  
 Kumagai, S., 644  
 Kumar, S., 430  
 Kumon, Y., 297  
 Kurihara, S., 1548  
 Kurokawa, T., 260  
 Kuroki, M., 1517  
 Kurose, T., 831  
 Kurtz, T. A., 138  
 Kushner, H., 1107  
 Kushwaha, R. S., 817  
 Kusunoki, M., 260  
 Kwon, H. J., 1007  
 Kwon, H. S., 142
- Laakso, J., 1072  
 Laaksonen, R., 1072  
 La Belle, M., 483  
 Lacy, D. B., 1290  
 Lagasse, M., 278  
 Lailerd, N., 101  
 Laivuori, H., 1433  
 Lamendola, C., 159, 280, 495  
 Lamon-Fava, S., 1255  
 Landauer, H. C., 1443
- Langer, I., 918  
 Langzam, L., 836  
 Latif, S. A., 811  
 Latini, R. A., 744  
 Lavoie, C., 1027  
 Layden, J. D., 203, 1131  
 Le, N.-A., 1296  
 Leary, E. T., 159  
 Leclerc, D., 594  
 Lee, C. C., 507  
 Lee, H., 607, 1284  
 Lee, J. G., 269  
 Lee, K. H., 1527  
 Lee, K. W., 142  
 Lee, W. C., 142  
 Lee, Y.-H., 1136  
 Lee, Y. N., 1527  
 Leem, C. H., 269  
 Legge, M., 1372  
 Lehtimäki, T., 1072  
 Leiter, E. H., 799  
 Lemieux, S., 310  
 Leon, A. S., 108, 1192  
 Levenson, C. W., 727  
 Levy-Marchal, C., 904  
 Li, H., 927  
 Li, R.-S., 600  
 Licenziati, M. R., 1243  
 Lichtenstein, A. H., 215, 520  
 Lima, F. B., 500  
 Lin, S.-Y., 922  
 Lin, Y., 1309  
 Lindgärde, F., 1355  
 Ling, P.-R., 273  
 Lister, C. A., 1322  
 Liu, R., 423  
 Liu, Y., 140, 1021  
 Ljungquist, K., 790  
 Llano, A., 1322  
 Locher, M., 165  
 Lofgren, I. E., 823  
 Lok, K. H., 1296  
 Lorenz, H., 1002  
 Lottenberg, A. M., 858  
 Luan, J., 11  
 Lucarelli, P., 995  
 Lücke, T., 809  
 Lundman, P., 852  
 Lupattelli, G., 744  
 Lussier-Cacan, S., 594  
 Luthra, K., 1336  
 Luzio, S. D., 1349  
 Lyberg, T., 1574  
 Lyons, T. J., 969, 1296
- McBrinn, Y., 1251  
 McCance, D. R., 755  
 McConnaughey, M. M., 247  
 McCormick, M. P., 318  
 McCowen, K. C., 273  
 McCoy, K., 37  
 MacDonald, K. G., 1  
 Macé, K., 1032  
 McEneny, J., 755

- McHenry, M. B., 1296  
 McKenna, T. J., 1251  
 McKenzie, J. A., 673  
 McLaughlin, T., 159, 280, 495  
 McMillan, J. M., 165  
 McNeill, G., 1309  
 McSorley, P. T., 755  
 McTernan, P. G., 430  
 Madsbad, S., 1565  
 Maffei, M. L., 1140  
 Maggs, D., 1227  
 Magotti, M. G., 1140  
 Mai, T. T. T., 1517  
 Maïmoun, L., 989  
 Makita, Y., 842, 1473  
 Malkova, D., 203, 1131  
 Mandarino, L. J., 1233  
 Manetta, J., 989  
 Mannarino, E., 744  
 Mannucci, E., 435  
 Mar, M.-H., 594  
 Marchesi, S., 744  
 Marchesini, G., 435  
 Marengoni, A., 1016  
 Margaglione, M., 852  
 Marie, P. J., 532  
 Marklund, S. L., 1496  
 Marotta, M., 1032  
 Marsh, J. B., 1255  
 Marshall, J. A., 303, 458  
 Martínez-Domínguez, E., 59  
 Martínez-Larrad, M. T., 1411  
 Martini, W. Z., 128  
 Maruyama, M., 488  
 Massicotte, D., 1027  
 Masulli, M., 1522  
 Masuzaki, H., 650, 1532  
 Matarazzo, M., 1081  
 Mather, J. F., 278  
 Matsuda, T., 1382  
 Matsumoto, T., 550  
 Matsumoto, Y., 448  
 Matsuo, K., 977  
 Matsuoka, N., 650  
 Matsutomo, R., 1152  
 Matsuura, K., 448  
 Matsuura, M., 977  
 Matsuura, N., 680  
 Matsuura, T., 831  
 Matsuzaki, Y., 42  
 Matthews, S. G., 1558  
 Mattioli, F., 1274  
 Mawatari, S., 123  
 Mayer, M. C., 1243  
 Maykel, J. A., 273  
 Mazur, A., 660  
 Meijer, A. J., 886  
 Meijer, G. W., 1309  
 Melchionda, N., 435  
 Memoli, A., 1274  
 Menzinger Von Preussenthal, G., 959  
 Merl, V., 894, 1449  
 Merville, P., 614  
 Metso, S., 1072  
 Meyer, C., 1208  
 Meyerovitch, J., 836  
 Michno, A., 66  
 Mikhailidis, D. P., 1315  
 Miles, M., 193  
 Milla, C., 1467  
 Miller, A. L., 760  
 Miller, C. S., 284  
 Milot, M., 1027  
 Mimura, Y., 448  
 Minami, C., 716  
 Miralles, J. M., 666  
 Misra, A., 1336  
 Mittendorfer, B., 875  
 Miyashita, K., 879  
 Miyata, T., 260  
 Miyawaki, T., 650  
 Miyazawa, S., 1095  
 Mizuno, A., 977  
 Mochizuki, S., 335  
 Moffett, S. P., 303, 458  
 Mohamed-Ali, V., 852  
 Mohammed, B. S., 875  
 Mohanty, P., 330  
 Mook, S., 1197  
 Moon, Y.-S., 863  
 Mooney, M. H., 252  
 Mooradian, A. D., 174, 766, 1342  
 Moore, G. B., 1322  
 Mooser, V., 4  
 Morais, J. A., 388  
 Moran, A., 1467  
 Moran, D. S., 836  
 Moran, S. A., 513  
 Morange, P. E., 852  
 Morgan, T. M., 578  
 Morita, H., 89  
 Moriwaki, Y., 772, 1500  
 Morra, F., 984  
 Morris, D. J., 811  
 Morrison, A. D., 1322  
 Morrison, J. A., 465  
 Morton, R. E., 858  
 Moussa, M. A. A., 638  
 Moyna, N., 193  
 Muller, A., 1274  
 Mune, T., 89  
 Murakami, K., 123  
 Murakami, T., 526  
 Muraoka, S., 1532  
 Murayama, S., 1113  
 Murphy, G. J., 1322  
 Murray, B., 1251  
 Nadreau, A., 310  
 Nadler, J. L., 290  
 Nagamatsu, S., 488  
 Nagano, M., 644  
 Nagasaki, M., 912  
 Nagata, M., 550  
 Nair, K. S., 340  
 Nakagawa, M., 1359  
 Nakagawa, Y., 476  
 Nakagawa, Y., 600  
 Nakai, Y., 831  
 Nakamichi, Y., 488  
 Nakamoto, H., 335  
 Nakamura, H., 879  
 Nakamura, T., 260  
 Nakamura, T., 1382  
 Nakanishi, K., 1305  
 Nakanishi, T., 600  
 Nakao, K., 650, 1532  
 Nakatani, T., 942  
 Nakaya, Y., 260  
 Nakazato, M., 84  
 Nam, E.-C., 1007  
 Nam, K.-H., 607  
 Napoli, R., 1081  
 Nasr, I. S., 209  
 Nawata, K., 1395  
 Nawata, T., 1359  
 Neal, D., 933  
 Nestler, J. E., 1331  
 Ngo, T. H., 377  
 Nichaman, M. Z., 1066  
 Nicol, C. J., 1284  
 Niino, N., 135  
 Nikkilä, M., 1072  
 Nilsson, J., 1436  
 Nilsson, J.-Å., 1436  
 Nimmo, M. A., 203, 1131  
 Nishikai, K., 879  
 Nishiki, M., 1395  
 Nishioka, F., 526  
 Nishizawa, M., 933  
 Noacco, C., 1126  
 Nogalska, A., 1060  
 Norberg, M., 1496  
 Norisada, N., 1532  
 Nowotny, P., 1174  
 Nunes, V. S., 858  
 Nuttall, F. Q., 241, 1399  
 Oda, N., 550  
 Ogasawara, J., 1424  
 Ogasawara, Y., 335  
 Ogata, N., 583  
 Ogawa, H., 1382  
 Ogawa, H., 260  
 Ogawa, T., 879  
 Ogawa, Y., 650  
 Ogawa, Z., 868  
 Ogura, T., 448  
 Oh, G. T., 607, 1284  
 Oh, H. H., 1054  
 Ohanna, F., 989  
 O'Harte, F. P. M., 252  
 Ohata, H., 28  
 Ohkubo, T., 1548  
 Ohkuwa, T., 716  
 Ohmori, K., 680  
 Ohmori, R., 1517  
 Ohsawa, I., 22  
 Ohzeki, T., 600  
 Okabayashi, N., 260  
 O'Keefe, M. P., 1215  
 Ollero, M., 273

- Olsson, T., 624  
 Olszanecka-Glinianowicz, M., 1268  
 Oltmanns, K. M., 894, 1449  
 Ono, Y., 550  
 Onuma, S., 1305  
 Ooie, T., 777, 1359  
 O'Rahilly, S., 11  
 Oral, E. A., 513  
 Ordix, F., Jr., 782  
 Ordoñez-Llanos, J., 1512  
 Orfao, A., 666  
 Orini, S., 1016  
 Orsi, E., 740  
 Ørskov, H., 1565  
 Ortega, E., 1512  
 Osaki, F., 297  
 Osei, K., 414, 1552  
 Oshida, Y., 22, 912  
 Oshiro, Y., 733, 1405  
 Ota, K., 297  
 Otagiri, A., 28  
 Otake, K., 260  
 Otani, M., 405  
 Otsuka, F., 448  
 Otsuki, M., 405  
 Overton, J. M., 727, 1417  
 Owens, D. R., 1349  
 Ozawa, S., 488
- Pacak, K., 1202  
 Pacini, G., 624  
 Pacioni, D., 620  
 Päivä, H., 1072  
 Palou, A., 1411  
 Pan, H.-J., 799  
 Pan, L., 927  
 Pandey, R. M., 1336  
 Panesar, N. S., 955  
 Papaioannou, G. I., 278  
 Paris, F., 989  
 Park, C. S., 269  
 Park, J.-J., 673  
 Park, J.-Y., 673  
 Parnau, J., 1032  
 Parsons, A. D., 1417  
 Patel, V. B., 964  
 Patten, N., 513  
 Patterson, N. B., 403  
 Pearce, N. J., 1322  
 Pelikánová, T., 469, 655  
 Pellizzon, M., 782  
 Pencek, R. R., 1290  
 Peres, S. B., 500  
 Pérez, A., 1512  
 Perez, F. R., 1215  
 Pérez-Cerdá, C., 809  
 Péronnet, F., 1027  
 Pescatello, L., 193  
 Peters, A., 894, 1449  
 Peters, J. C., 454  
 Peterson, J. W., 215  
 Petro, A. E., 454  
 Peuler, J. D., 147  
 Phares, D. A., 673
- Phelps, L. E., 147  
 Phillips, D. I. W., 720  
 Phillips, G. B., 324  
 Piché, M.-È., 310  
 Pieber, T. R., 1484  
 Pierce, G. N., 1145  
 Pinkernell, B. H., 324  
 Pirro, M., 744  
 Playfair, J. H. L., 1048  
 Plokker, T. W. M., 49  
 Ploutz-Snyder, L. L., 284  
 Poiesi, C., 563  
 Poli, L., 984  
 Poretsky, L., 358  
 Pories, W. J., 1  
 Porretti, S., 740  
 Potaux, L., 614  
 Pratipanawatr, T., 1233  
 Pratipanawatr, W., 1233  
 Pratley, R. E., 904  
 Preedy, V. R., 964  
 Premkumar, A., 513  
 Privette, J., 247  
 Proenza, A. M., 1411  
 Puech, A.-M., 989  
 Pulkki, P., 1433  
 Purkayastha, D., 1331  
 Putz, D. M., 1454
- Qiu, W., 228  
 Quintão, E. C. R., 858
- Rabbani, A., 687  
 Rademacher, T. W., 1048  
 Ramis, J. M., 1411  
 Rankin, S. E., 1121  
 Rankinen, T., 108, 1192  
 Rao, D. C., 108, 1192  
 Rask, E., 624  
 Rasmussen, B. M., 77  
 Raspo, S., 984  
 Raszeja-Specht, A., 66  
 Rayssiguier, Y., 660  
 Reaven, G. M., 159, 280, 495  
 Reaven, P. D., 280  
 Rector, R. S., 140, 1021  
 Refai, T. M. K., 638  
 Reifsnnyder, P. C., 799  
 Reynolds, J., 513  
 Reynolds, T. H., IV, 397  
 Rhinesmith, S., 414  
 Riccardi, G., 620, 1522  
 Riddell, M. C., 1558  
 Riu, F., 95  
 Rivellese, A. A., 620, 1522  
 Rizk, M. M., 209  
 Rizzo, M., 483  
 Robert, G., 1027  
 Roberts, C. K., 377  
 Robinson, S., 545  
 Rodela, S., 1118  
 Rodriguez, R., 817  
 Rodriguez-Espinosa, J., 1512  
 Röhrig, K., 632
- Rolandsson, O., 1496  
 Rolfsen, S. E. D., 1378  
 Romanelli, L., 1274  
 Romijn, J. A., 886  
 Ronchi, C. L., 740  
 Rooyackers, O. E., 1076  
 Roscini, A. R., 744  
 Ross, R., 1066  
 Rossi, M., 989  
 Rother, K. I., 403  
 Roxbee-Dox, L., 1322  
 Rozen, R., 594  
 Rudrum, M., 1309  
 Ruiz-Gutiérrez, V., 59  
 Ruokonen, I., 1072  
 Russo, V., 1243  
 Rutkowski, B., 1060  
 Ryu, H. J., 269
- Saavedra-González, Á., 1462  
 Saccà, L., 1081  
 Saengsirisuwan, V., 101  
 Saikawa, T., 777, 1359  
 Saito, I., 879  
 Saito, K., 123  
 Saito, Y., 1095  
 Sakai, T., 583  
 Sakakibara, F., 260  
 Sakane, N., 335  
 Saku, K., 423  
 Sakurai, T., 1424  
 Saleh, O., 1  
 Salehi, M., 358  
 Salen, G., 42, 556, 927  
 Salvatore, V., 1243  
 Sampson, S. R., 836  
 Sánchez Perona, J., 59  
 Sander, S., 809  
 Sarnak, M. J., 1255  
 Saruta, T., 868, 879  
 Sasaki, H., 644  
 Sasaki, H., 977  
 Sasamoto, K., 353  
 Sasse, M., 809  
 Sato, Y., 22, 912  
 Sato, Y., 949  
 Sauerwein, H. P., 886  
 Savini, G., 1274  
 Scarponi, A. M., 744  
 Schaefer, E. J., 520, 1255  
 Schaller, H. C., 1484  
 Schaupp, L. A., 1484  
 Scheaffer, S. E., 348  
 Scholl, S., 809  
 Schölmerich, J., 1443  
 Schreier, L., 1013  
 Schultes, B., 894, 1449  
 Schuster, D., 414, 1552  
 Schwahn, B. C., 594  
 Schweimer, J., 1443  
 Sebring, N., 513  
 Seino, Y., 831  
 Seip, R. L., 193

- Sekizuka, K., 1382  
 Seljeflot, I., 1574  
 Selz, R., 847  
 Semler, A. J., 1296  
 Serrano-Ríos, M., 1411  
 Shalev, A., 403  
 Shames, D. M., 483  
 Shang, Q., 927  
 Shangraw, R. E., 1087  
 Shani, Y., 836  
 Shapiro, Y., 836  
 Sharman, M., 823  
 Sheets, K. A., 247  
 Shefer, S., 42, 927  
 Sheikh, A., 358  
 Sheu, W.-H. H., 922  
 Shibasaki, T., 28  
 Shigematsu, S., 1359  
 Shiina, K., 842  
 Shike, T., 1473  
 Shimabukuro, M., 733, 1405  
 Shimajiri, Y., 1405  
 Shimokata, H., 135  
 Shin, C., 607  
 Shin, S. U., 1538  
 Shirabe, S., 353  
 Shukla, N., 1315  
 Siepi, D., 744  
 Sierksma, A., 1309  
 Simon-Vermot, I., 17  
 Sinzinger, H., 744  
 Sirtori, C. R., 153  
 Sivitz, W. L., 1454  
 Skarulis, M. C., 513  
 Skibová, J., 469  
 Skibowska, A., 66  
 Skinner, J. S., 108, 1192  
 Sloniger, J. A., 101  
 Smith, B. K., 749, 1365  
 Smith, K. L., 465  
 Smith, S. A., 1322  
 Smith, T. P., 1251  
 Söderberg, S., 624  
 Soga, T., 28  
 Sohmiya, M., 1395  
 Soliman, A. T., 209  
 Son, H. S., 142  
 Son, H.-Y., 142  
 Song, D.-K., 863  
 Song, Y.-H., 607  
 Sonntag, M., 1177  
 Souness, G. W., 811  
 Sparks, C., 222  
 Sparks, J. D., 228  
 Sposito, A. C., 858  
 Sprangers, F., 886  
 Srinivasan, S. R., 1184  
 Stanforth, P. R., 1192  
 Stefan, N., 904  
 Stelmanska, E., 1060  
 Stentz, F. B., 117  
 Stevenson, J. C., 571  
 Still, J. G., 54  
 Stoeckli, R., 918  
 Stoll, D., 4  
 Stoller, A., 578  
 St-Onge, M.-P., 1503  
 Striffler, J. S., 290  
 Strobel, S., 1227  
 Stroop, D., 465  
 Stumvoll, M., 904  
 Stupar, G., 1126  
 Sturek, M. S., 140, 1021  
 Sturis, J., 441  
 Sucunza, N., 1512  
 Suehiro, T., 297  
 Suga, S.-i., 710  
 Suga, T., 868  
 Suliman, A. M., 1251  
 Sultan, C., 989  
 Sumner, A. E., 1202  
 Sun, G. Y., 749, 1021, 1365  
 Supiano, M. A., 397, 507  
 Surwit, R. S., 454  
 Surwit, S. J., 454  
 Sutherland, W. H. F., 318  
 Suwa, M., 644  
 Suzara, D., 340  
 Suzuki, A., 550  
 Suzuki, H., 831  
 Swaim, W. R., 1399  
 Swierczynski, J., 1060  
 Syddall, H. E., 720  
 Syed, T., 330  
 Szolkiewicz, M., 1060  
 Szutowicz, A., 66  
 Taira, T., 1113  
 Takahashi, K., 1095  
 Takahashi, N., 777, 1359  
 Takahashi, S., 772, 1500  
 Takahashi, Y., 1382  
 Takahashi-Yasuno, A., 650  
 Takakura, Y., 1223  
 Takami, R., 89  
 Takano, T., 423  
 Takasu, N., 733, 1405  
 Takata, N., 1548  
 Takaya, J., 1544  
 Takebayashi, K., 693, 1152  
 Takeda, E., 977  
 Takeda, N., 89  
 Takei, M., 1424  
 Taketani, Y., 977  
 Takizawa, M., 488  
 Taman, K. H., 209  
 Tanaka, N., 42  
 Tanaka, T., 488  
 Taniguchi, A., 831  
 Tanimoto, M., 842, 1473  
 Tappy, L., 4, 847  
 Tapsell, L., 1522  
 Taskinen, M.-R., 520  
 Tataranni, P. A., 904  
 Taylor, C. M., 1322  
 Taylor, J. A., 140  
 Tervonen, R., 1072  
 Theintz, G. E., 847  
 Thomas, T. R., 140, 749, 1021, 1365  
 Thompson, C. S., 1315  
 Thompson, P. D., 193, 278  
 Thomsen, C., 77  
 Thorpe, S. R., 969  
 Thu, N. N., 1517  
 Thunblad, L., 1076  
 Tikkanen, M. J., 1433  
 Tilly-Kiesi, M., 520  
 Tint, G. S., 556, 927  
 Tischler, M. E., 1215  
 Tobe, K., 448  
 Toda, H., 1223  
 Togashi, K., 108  
 Tohma, T., 1405  
 Tokudome, T., 710  
 Tokuyama, Y., 1095  
 Tomino, Y., 842, 1473  
 Toshinai, K., 84  
 Toskulkao, C., 101  
 Toth, D., 578  
 Tous, M., 95  
 Trautwein, E. A., 1309  
 Tremblay, A., 310  
 Tremblay, A. J., 310  
 Tremoli, E., 852  
 Tripathy, D., 330  
 Troll, S., 1443  
 Tsai, L.-P., 1136  
 Tsai, P.-J., 1136  
 Tsongalis, G. J., 193  
 Tsui, B. T., 1037  
 Tsukada, T., 84  
 Tsutsumi, K., 260  
 Tsutsumi, Z., 772, 1500  
 Tsuzura, S., 297  
 Tulipano, G., 563  
 Tura, A., 624  
 Turazzi, S., 563  
 Turini, M., 1032  
 Ueda, H., 1424  
 Ugarte, M., 809  
 Um, S. J., 1007  
 Umekawa, T., 1223  
 Urano, Y., 1424  
 Usami, M., 831  
 Uusitupa, M., 1522  
 Vaccaro, O., 1522  
 Valabhji, J., 17  
 Valle, D., 563  
 Valsamakis, G., 430  
 Van Beek, A. P., 187  
 Vandeberg, J. F., 817  
 Vandeberg, J. L., 817  
 Van der Wielen, R. P. J., 1309  
 Van Harlelen, V., 632  
 Van Herle, A., 1101  
 Vaudo, G., 744  
 Vega, G. L., 1202  
 Vega-López, S., 236  
 Venkatesan, S., 545  
 Verona, J., 1262

- Vesali, R. F., 1076  
 Vessby, B., 1522  
 Veves, A., 222  
 Viana, A. Y. I., 912  
 Vierhapper, H., 1174  
 Vikram, N. K., 1336  
 Vilella, E., 95  
 Villa, B., 153  
 Visich, P., 193  
 Viturro, E., 1045  
 Vlasáková, Z., 469  
 Volek, J. S., 823  
 Volpi, J. R., 1140  
 Von Mach, M.-A., 918  
 Vranic, M., 1558  
  
 Wagner, A., 228  
 Wagner, J. D., 1121  
 Wakabayashi, S., 1152  
 Waldhäusl, W., 1174  
 Walgren, J. L., 165  
 Wang, M. H., 1177  
 Wang, P., 465  
 Wang, X., 942  
 Wang, Y., 1227  
 Wang, Y.-Y., 922  
 Ward, A. M. V., 720  
 Wareham, N. J., 11  
 Warfield, R. K. N., 147  
 Wargent, E., 1322  
 Wasserman, D. H., 1290  
 Watanabe, H., 583  
 Watanabe, M., 1548  
 Watanabe, M., 1532  
 Watanabe, R. M., 1202  
 Watanabe, T., 476  
 Watt, M. J., 1492  
 Wegge, J. K., 377  
 Weinstock, R. S., 284  
 Weiss, E. P., 673  
 Welshons, W. V., 140  
 Welty, F. K., 520, 1255  
 Wendel, U., 594  
 Wernerman, J., 1076  
 Weverling, G. J., 886  
 Weyer, C., 904, 1227  
  
 Whelan, A. P., 318  
 Widén, I., 1355  
 Wikinski, R., 1013, 1262  
 Wilinska, M. E., 1484  
 Williams, M. J. A., 318  
 Williams, P. T., 700  
 Wilmore, J. H., 108, 1192  
 Witchel, H. J., 760  
 Woerle, H. J., 1208  
 Wohl, P., 655  
 Wolf, F. I., 660  
 Wolfe, R. R., 128  
 Won, J. Y., 1007  
 Wong, N. C. W., 174, 766, 1342  
 Wong, N. L. M., 1177  
 Wood, P. J., 720  
 Wrede, C. E., 1443  
 Wu, J., 942  
 Wuolijoki, E., 1072  
 Wutzke, K. D., 1002  
  
 Xiao, J., 1378  
 Xu, G., 42, 927  
  
 Yagui, K., 1095  
 Yamada, H., 680  
 Yamada, K., 942  
 Yamada, Y., 135  
 Yamada, Y., 831  
 Yamaguchi, S., 488  
 Yamakawa, M., 1405  
 Yamakawa-Kobayashi, K., 182  
 Yamakita, N., 89  
 Yamamoto, A., 680  
 Yamamoto, A., 772, 1500  
 Yamamoto, K., 550  
 Yamamoto, M., 405  
 Yamamoto, T., 716  
 Yamamoto, T., 772, 1500  
 Yamamoto, Y., 879  
 Yamanouchi, T., 353, 583  
 Yamato, F., 1544  
 Yamazaki, Y., 716  
 Yanagawa, T., 353  
 Yanagi, H., 182  
 Yang, H. S., 1054, 1538  
  
 Yang, S.-P., 1136  
 Yang, Y., 933  
 Yasuda, A., 680  
 Yasuda, K., 89  
 Yates, J. W., 1322  
 Yeo, K.-T. J., 578  
 Ylikorkala, O., 1433  
 Yoneda, F., 1532  
 Yoo, S. J., 1007  
 Yoo, S. J., 142  
 Yoon, K. H., 142  
 Yoon, M., 607, 1284  
 Yoon, Y., 1054, 1538  
 Yoshida, R., 716  
 Yoshida, S., 1095  
 Yoshida, T., 42  
 Yoshida, T., 335, 1223  
 Yoshida, Y., 1095  
 Yoshihara, F., 710  
 Yoshimasa, Y., 650  
 Yoshimatsu, H., 777, 1359  
 Yoshimoto, K., 488  
 Yoshino, G., 589, 1113  
 Yoshioka, K., 1223  
 Young, I. S., 755  
 Young, J. R., 513  
 Yu, C.-H., 1136  
 Yu, YX., 182  
 Yudkin, J. S., 852  
 Yufu, K., 1359  
  
 Zahorska-Markiewicz, B., 1268  
 Zaratini, A. C. M., 858  
 Zarra, E., 1081  
 Zeisel, S. H., 594  
 Zhang, B., 423  
 Zhang, L., 1121  
 Zheng, D., 1296  
 Zhou, L., 794  
 Zhu, S., 1503  
 Zoeller, R., 193  
 Zou, B., 644  
 Zuo, C. S., 222  
 Zurakowski, Z., 1268

## SUBJECT INDEX

- AA, *see* Amino acids
- ABCA1 gene  
 expression of leukocyte, associated with fasting glucose concentration in normoglycemic men, 17-21  
 serum HDL-C or apo A-I levels associated with polymorphism of, in Japanese school-age children, 182-186
- Abdominal adipose tissue (AT)  
 exercise effects on, *see* Abdominal adipose tissue, exercise effects on  
 in lipodystrophic HIV-infected subjects, 1567  
 and metabolic risk in non-obese premenopausal women, 1066-1071  
 in obese NIDDM subjects, bezafibrate effects on, 408
- Abdominal adipose tissue (AT), exercise effects on  
 on body composition, MS and, in PM women on or not on ERT, 1192-1196  
 in older hypertensive subjects, 399
- Abdominal aorta of obese children, preclinical changes in, 1243-1246
- Acanthosis nigricans in PCOS, 366
- ACAT (acyl-coenzyme A:cholesterol acyltransferase), role of cholesterol absorption and activity of hepatic, in lipemic response to HF/HC diet, 817-822
- ACE, *see* Angiotensin-converting enzyme inhibitors
- Acetyl-coenzyme A (CoA), platelet, ATPCL role in metabolism and function of, in DM, 66-72
- Acetyl-coenzyme A (CoA) carboxylase mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- $\alpha_1$  (alpha<sub>1</sub>)-Acid glycoprotein (AGP) in inflammation of chronic disease, 901, 902
- Acid phosphatase locus 1 (ACPI) polymorphism, interaction between adenosine deaminase and, in NIDDM, 995-1001
- Acidemia, late-onset propionic, fatal outcome and, 809-810
- Acipimox, effects of, on plasma NEFAs during exercise at cold temperature, 1131-1135
- ACPI (acid phosphatase locus 1) polymorphism, interaction between adenosine deaminase and, in NIDDM, 995-1001
- ACT ( $\alpha_1$ -antichymotrypsin) in inflammation of chronic disease, 901, 902
- ACTH, *see* Adrenocorticotropin hormone
- Activated CD4<sup>+</sup> (and CD8<sup>+</sup>) T lymphocytes, emergence of growth factor receptors in, 117-122
- Acute effects  
 of nicotine on serum glucose, insulin, GH, and cortisol, 578-582  
 of wine drinking, *see* Acute effects of wine drinking
- Acute effects of wine drinking  
 absence of red wine drinking, on vascular reactivity, 1081-1086  
 of red and white wine drinking on circulating inflammation-sensitive molecules in men with CAD, 318-323
- Acute insulin-induced hypoglycemia, effects of normoglycemic hyperinsulinemia and, on glucose retinal uptake and ocular metabolism, 1274-1283
- Acute regulatory protein mRNA (messenger ribonucleic acid), low temperature blocking stimulatory effects of hCG on testosterone production but not on cAMP production in tumor cells, 955-958
- Acute spinal cord injury (SCI), circulating leptin as marker of fat mass in, 989-994
- Acyl-coenzyme A:cholesterol acyltransferase (ACAT), role of cholesterol absorption and activity of hepatic, in lipemic response to HF/HC diet, 817-822
- ADA (adenosine deaminase), interaction between ACPI polymorphism and, in NIDDM, 995-1001
- Adaptability of AT to fasting, pinealectomy effects on, 500-506
- Adaptive thermogenesis, resistance to obesity and, 1417-1423
- Adenosine deaminase (ADA), ACPI polymorphism interaction with, in NIDDM, 995-1001
- Adenosine monophosphate (AMP)  
 HF diet effects on protein kinase activated by, 914  
*see also* cAMP
- Adenosine triphosphate-citrate lyase (ATPCL), role of, in platelet acetyl-CoA metabolism and function in DM, 66-72
- Adenosine triphosphate-citrate lyase (ATPCL) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Adhesion molecules, *see* Circulating cell adhesion molecules; Intercellular adhesion molecule-1; Vascular cell adhesion molecule
- Adipocyte(s)  
 hypertension with IR and GLUT<sub>4</sub> of, 382-387  
 restricted diet effects on, 30  
*see also* Adipocytokines; Preadipocytes; Resistin
- Adipocyte precursor cells, *see* Preadipocytes
- Adipocyte-secreted factor, *see* Resistin
- Adipocytokines, serum, effects of moderate weight loss and orlistat or sibutramine on waist circumference and, in obese women, 430-434
- Adipogenic properties of FPFS-410, 1532-1537
- Adiponectin  
 CRP and, *see* Adiponectin, CRP and  
 ethnic differences in levels of, 1-3  
 G276T polymorphism of, in Japanese NIDDM subjects with incipient nephropathy, 1223-1226  
 NEFAs regulating, 790-793  
 in obesity, *see* Adiponectin in obesity  
 plasma, *see* Plasma adiponectin  
 Pro12Ala PPAR $\gamma$ 2 polymorphism associated with concentrations of, in young Japanese men, 1548-1551  
 serum, *see* Serum adiponectin
- Adiponectin, CRP and  
 IR and, in postpubertal Asian Indian adolescents, 1336-1341  
 in obesity, NIDDM, and monodrug therapy, 1454-1461
- Adiponectin, effects of moderate weight loss by obese women on by insulin-resistant obese women, 280-283  
 with sibutramine or orlistat therapy, 432
- Adiponectin in obesity  
 CRP, NIDDM, monodrug therapy and, 1454-1461  
*see also* Adiponectin, effects of moderate weight loss by obese women on
- Adipose tissue (AT)  
 abdominal, *see* Abdominal adipose tissue  
 diet and, *see* Adipose tissue, diet and  
 distribution, *see* Adipose tissue distribution  
 exercise effects on, *see* Adipose tissue, exercise effects on  
 in hyperinsulinemic young men, whole-body protein synthesis and, 389  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 isotretinoin effects on, 5  
 in LBW Pima Indians with normal glucose tolerance, 906  
 in lipodystrophic HIV-infected subjects, 1567  
 MHN-01 effects on, 980, 981  
 in non-obese subjects, *see* Adipose tissue in non-obese subjects



- Adipose tissue (AT) (*Continued*)  
 in obesity, *see* Adipose tissue in obesity  
 in overweight women, 1269  
 pinealectomy effects on adaptability of, to fasting, 500-506  
 in SCI men with MS, 1373, 1374  
 serum adiponectin association with, in young men, 590, 591  
 in severe lipodystrophy, effects of leptin replacement therapy on, 514  
 in Vietnamese children, apo E polymorphism and, 1519  
*see also* Fat mass and entries beginning with element: Adip-
- Adipose tissue (AT), diet and  
 correlation between food intake, serum leptin and, in sixth-month period following kidney transplantation, 614-619  
 effects of LF versus HF diet and caloric intake on, in obese NIDDM subjects, 455  
 relationship between alcohol intake, exercise and, to HDL-C levels, 700-709  
 restricted diet effects on glucocorticoid receptor and PPAR $\gamma$  signaling in, 28-36
- Adipose tissue (AT), exercise effects on  
 apo E genotype changes and, 195, 198, 199  
 effects of moderate exercise and soy isoflavone on bone loss and accumulation of, in postmenopausal subjects, 942-948  
 relationship between exercise, alcohol intake, and AT to HDL-C levels, 700-709
- Adipose tissue (AT) distribution  
 Pro12Ala polymorphism of PPAR $\gamma$ 2 effects on, in Korean women, 1538-1543  
*see also* Subcutaneous adipose tissue; Total adipose tissue; Visceral adipose tissue; White adipose tissue
- Adipose tissue (AT) in non-obese subjects  
 liver, in non-obese premenopausal women, metabolic risk and, 1066-1071  
 as predictor of fibrinogen level in non-obese men, 984-988
- Adipose tissue (AT) in obese NIDDM subjects  
 effects of LF versus HF diet and caloric intake on, 455  
 total, bezafibrate effects on, 407
- Adipose tissue (AT) in obesity  
 obese adolescents, 864  
 obese women, 1269  
*see also* Adipose tissue in obese NIDDM subjects; Obesity;  
 Omental adipose tissue, subcutaneous and, in obese subjects
- Adipsin mRNA (messenger ribonucleic acid), CL316,243 effects on, in diabesity, 804
- Adjustable silicone gastric banding (ASGB), RYBG and, for morbid obesity, changes in BMC after, 918-921
- ADMA, *see* Asymmetric dimethylarginine
- Adolescents  
 IDDM Kuwaiti, cardiovascular disease risk factors associated with serum sialic acid in, 638-643  
 postpubertal Asian Indian, adiponectin, CRP, and IR in, 1336-1341  
*see also* Adolescents, obese
- Adolescents, obese  
 Japanese male adolescents, 448-453  
 serum TNF- $\alpha$  levels and components of MS in, 863-867
- ADR, *see* entries beginning with terms: Adrenergic receptor
- Adrenal androgens, cortisol and, in obese PCOS women, 361
- Adrenal (ovarian) hypothesis of PCOS, 360, 361
- Adrenal insufficiency, hypoglycemia effects on plasma PTH levels in, 1251-1254
- Adrenaline, *see* Epinephrine
- $\beta$  (beta)-Adrenergic blockers in CAD, 319
- $\beta$  (beta)-Adrenergic receptor (ADR), racial differences in density of, in subcutaneous and omental AT from obese women, 247-251
- $\beta_2$  (beta<sub>2</sub>)-Adrenergic receptor (ADR), interaction of  $\beta_2$ -ADR Trp64Arg and Arg16Gly polymorphisms with, serum lipid profile and, 1184-1191
- $\beta_3$  (beta<sub>3</sub>)-Adrenergic receptor (ADR), Trp64Arg polymorphism of association of increased leptin levels with, but not with -3826A $\rightarrow$ G polymorphism of UCP-1 gene in Spanish subjects, 1411-1416  
 in GDM Taiwanese women, 1136-1139  
 interaction of Arg16Gly  $\beta_2$ -ADR polymorphism with, serum lipid profile and, 1184-1191
- Adrenocortical disorders, plasma cortisol in, in 89-94
- Adrenocorticotropin hormone (ACTH; corticotropin)  
 circulating, and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and sepsis, 209-214  
 nighttime and daytime differences in counterregulation of hypoglycemia and, 895  
 plasma, *see* Plasma adrenocorticotropin hormone
- ADSF (adipocyte-secreted factor), *see* Resistin
- Adult cystic fibrosis (CF) with impaired glucose tolerance, insulin regulating kinetics of NEFAs in, 1467-1472
- Advanced non-insulin-dependent diabetes mellitus (NIDDM)  
 nephropathy, resting metabolic rate in, 1395-1398
- Adverse reactions to Pancreatic Tonic, 1170
- Aerobic capacity, *see* VO<sub>2max</sub>, during exercise
- Aerobic exercise, effects of low-fat, high-fiber diet and, on inflammatory and adhesion molecules in postmenopausal women on ERT and at risk for CAD, 377-381
- African Americans, *see* Race and ethnicity
- 1,5-AG (1,5-anhydroglucitol) in NIDDM, microalbuminuria and, 354
- Age  
 of acromegalic subjects, 565  
 adiponectin and, *see* Age, adiponectin and  
 $\beta_2$ -ADR Arg16Gly polymorphism and, 1184, 1185  
 of at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 2  
 of CAD men, *see* Age of CAD men  
 carotid atherosclerosis, vascular dementia and, 477  
 of children with glycoprotein PC-1 K121Q polymorphism, 467  
 of chronic renal disease subjects, 1256  
 of CT subjects, 557  
 CV disease risk factors and, *see* Age, CV disease risk factors and  
 diet and, *see* Age, diet and  
 of DM subjects, *see* Age of DM subjects  
 of Ecuadorian Amazon Shur women, 1356  
 effects of, on HbA<sub>1c</sub>, 1497  
 and effects of interaction between FABP-4 and PPAR $\gamma$ -activated receptor polymorphism, 305, 306  
 and erythrocyte membrane lipid composition, 574  
 exercise and, *see* Age, exercise and  
 gestational, *see* Gestational age  
 of HD subjects, 1014  
 of HL-deficient subjects, 522  
 of hypercholesterolemic subjects, *see* Age of hypercholesterolemic subjects  
 of hypogonadic men, 1175  
 of IGT subjects, *see* Age of IGT subjects  
 of insulin-resistant subjects, *see* Age of insulin-resistant subjects  
 and isotretinoin effects on insulin sensitivity and plasma TGs, 5  
 of Japanese subjects, *see* Age of Japanese subjects  
 of kidney transplantation recipients, 615

Age (*Continued*)

- of LBW Pima Indians with normal glucose tolerance, 906
- leptin levels and, 1412-1414
- of lipodystrophic subjects, *see* Age of lipodystrophic subjects
- of MS subjects, *see* Age of MS subjects
- on non-obese subjects, *see* Age of non-obese subjects
- of normoglycemic men, and *ABCA1* expression-fasting glucose relationship, 19
- of obese subjects, *see* Age of obese subjects
- and pioglitazone effects on carotid artery IMT and stiffness in NIDDM nephropathy, 1383
- and plasma LDL clearance, 484
- and plasma vitamin K transport, 216
- of PM women, *see* Age of PM women
- and PPAR $\gamma$ 2 Pro12Ala polymorphism on AT distribution in Korean women, 1539
- and pregnancy, *see* Age, pregnancy and
- of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
- of premenopausal women, sex steroids and plasma Lp and, 189
- and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by overweight subjects, 1450
- of primary hyperthyroidism subjects, 1102
- $\omega$ -3 PUFA effects and, *see* Age,  $\omega$ -3 PUFA effects and
- smoking effects and, *see* Age, and effects of smoking
- and uncoupling protein-3 polymorphism-body composition association, 460
- and WPG effects on normal or mildly elevated plasma cholesterol, 1311
- see also specific age groups; for example: Adolescents, Children*
- Age, adiponectin and
  - adiponectin levels, ethnic differences and, 2
  - C-reactive protein and, in obese NIDDM subjects, 1456
  - and NEFAs regulation by, 791
- Age, CV disease risk factors and
  - diet and, 1437
  - of hypothyroid subjects, 278
- Age, diet and
  - acute effects of red wine drinking and food intake on vascular reactivity and, 1082
  - and PP TG response to different nutrients, 621
  - PPAR $\gamma$  Pro12Ala polymorphism effects on dietary fat-physical activity association with fasting insulin level, 13, 14
  - red and white wine drinking effects on circulating inflammation-sensitive molecules, 319
  - see also* Age, wine drinking and
- Age, and effects of  $\omega$ -3 PUFAs with exercise
  - on HDL and LDL subfractions, 750
  - on PP lipemia, 1366
- Age, and effects of smoking
  - acute effects of nicotine, 579
  - on intravascular remodeling of HDL particles, 860
- Age, exercise and
  - cholesterol efflux in soccer players and, 1263
  - effects of apo E genotype changes on  $\dot{V}O_{2max}$  and, 195, 198, 199
  - insulin concentration and CHO requirement in IDDM during moderate exercise, 1127
  - OC effects on glucoregulatory responses to exercise and, 350
  - by overweight nondiabetic subjects, 1236
  - and plasma nitrate/nitrite assessment during OGTT, 675
  - and PPAR $\gamma$  Pro12Ala polymorphism effects on dietary fat-physical activity association with fasting insulin level, 13, 14
  - $\omega$ -3 PUFAs and, *see* Age, and effects of  $\omega$ -3 PUFAs with exercise

Age, exercise and (*Continued*)

- see also* Age, resistance exercise effects and
- Age, pregnancy and
  - GDM Taiwanese women with  $\beta_3$ -ADR Trp64Arg polymorphism, 1137
  - leucine turnover and, 546
  - and preeclampsia, 1434
- Age,  $\omega$ -3 PUFA effects and
  - anti-inflammatory effects of  $\omega$ -3 PUFAs alone or combined with all-rac  $\alpha$ -tocopherol, 237
  - see also* Age, and effects of  $\omega$ -3 PUFAs with exercise
- Age, resistance exercise effects and
  - in NIDDM women, 285
  - in older hypertensive subjects, 399
- Age, wine drinking and
  - acute effects of red wine drinking and food intake on vascular reactivity and, 1082
  - red and white wine drinking effects on circulating inflammation-sensitive molecules, 319
- Age of CAD men
  - red and white wine drinking effects on circulating inflammation-sensitive molecules and, 319
  - risk factors for myocardial infarction and, 325, 326
  - serum HDL-C, oxidized LDLs and, 424-426
- Age of DM subjects
  - of GDM Taiwanese women with  $\beta_3$ -ADR Trp64Arg polymorphism, 1137
  - and relation between plasma VEGF, ET-1 concentration, and glycemic control, 551
  - see also* Age of IDDM subjects; Age of NIDDM subjects
- Age of hypercholesterolemic subjects
  - of hypercholesterolemic women, simvastatin effects and, 745
  - of mildly hypercholesterolemic subjects, 1073
  - serum LPL concentration and, 527, 528
- Age of IDDM subjects
  - energy substrate oxidation and, 656
  - and glycemic control effects on  $F_2$  isoprostane level at IDDM onset, 1119
  - and insulin concentration and CHO requirement during moderate exercise, 1127
  - of Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
  - oxidation of glycated and nonglycated LDLs and, 970
- Age of IGT subjects
  - of IGT first-degree relatives of African American NIDDM subjects, 415
  - of non-obese IGT subjects, 625, 1553
- Age of insulin-resistant obese subjects
  - with IGT or normal FPG, 1096
  - of insulin-resistant obese Japanese men, 651, 652
  - of insulin-resistant obese women, and moderate weight loss effects on plasma adiponectin, 281
- Age of insulin-resistant subjects, 1109
  - fatty acid TG content and VAT accumulation and, 311, 312
  - with LVH, 778, 779
  - with NIDDM, cardiovascular autonomic dysfunction, microalbuminuria and, 1360
  - and relationship between BMI, beta-cell function, and IR, 1463
  - serum GPI-PLD and, 139
  - see also* Age of insulin-resistant obese subjects
- Age of Japanese men
  - 1562C $\rightarrow$ T MMP-9 gene polymorphism association with BMD and, 136

Age of Japanese men (*Continued*)

Pro12Ala PPAR $\gamma$ 2 polymorphism and adiponectin concentrations in young men, 1549

## Age of Japanese NIDDM subjects

with incipient nephropathy, 1224

insulin secretion and sensitivity and, 832

## Age of Japanese subjects

with beta-cell dysfunction, 950-952

of Japanese men, *see* Age of Japanese men

with NIDDM, *see* Age of Japanese NIDDM subjects

and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883

## Age of lipodystrophic subjects

with HIV infection, 1567

with severe lipodystrophy, 514

## Age of MS subjects

with CHD, 853

with CRH, 722

with liver cirrhosis, 923, 924

with SCI, 1373

## Age of NIDDM subjects

alcohol effects on PP lipemia and, 78

and association of corrected QT intervals with carotid artery IMT, 1153, 1155

and in at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224

bezafibrate effects on lipids and glucose metabolism in NIDDM and, 411

glyburide and nateglinide effects on NIDDM and, 1332

HbA<sub>1c</sub>-RBC membrane lipid composition correlation and, 124

with IGT, 646

and insulin therapy effects on serum high-sensitive CRP, 694, 697

of Japanese subjects, *see* Age of Japanese NIDDM subjects

metformin effects on risk factors for CV disease and, 160

with microalbuminuria, *see* Age of NIDDM subjects with microalbuminuria

NIDDM women, and resistance exercise effects on glycemic control, 285

obese, *see* Age of obese NIDDM subjects

overweight subjects, exercise effects in, 1236

with retinopathy, 585, 586

serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301

## Age of NIDDM subjects with microalbuminuria

and cardiovascular autonomic dysfunction, and IR, 1360

glycemic control and, 354

## Age of non-obese subjects

non-obese men, AT as level fibrinogen level and, 985, 986

of non-obese premenopausal women, 1068

and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting, 1450

## Age of obese NIDDM subjects

adiponectin, C-reactive protein and, 1456

bezafibrate effects on lipids and glucose metabolism and, 411

## Age of obese subjects

adolescents, 864

children, 1244

Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1055

proliferation and differentiation of adipocyte precursor cells and, 633, 634

Age of obese subjects (*Continued*)

and relationship between BMI, beta-cell function, and insulin resistance, 1463

and smoking-ADMA-obesity relationship, 1575

women, *see* Age of obese women

*see also* Age of insulin-resistant obese subjects; Age of obese NIDDM subjects

## Age of obese women

with IR, and moderate weight loss effects on plasma adiponectin, 281

with NIDDM, bezafibrate effects on lipids and glucose metabolism and, 411

PM women, fluvastatin effects on endothelial function and, 735 and serum TNF soluble receptors, TNF- $\beta$ , and NO, 1269

## Age of PM women

hypercholesterolemic women, simvastatin effects and, 745

insulin sensitivity and, 508

obese, and fluvastatin effects on endothelial function, 735

sex steroids, plasma Lp and, 189

Aging subjects, *see* Older subjects

AGP ( $\alpha_1$ -acid glycoprotein) in inflammation of chronic disease, 901, 902

Agricultural lifestyle, effects of traditional versus, on leptin in Ecuadorian Amazon Shuar women, 1355-1358

AICAR (5-aminoimidazole-4-carboxamide-1- $\beta$ -D-ribofuranose), glucose transport in SM stimulated by, 514

Akt1/protein kinase  $\beta\alpha$  (Akt1/PK $\beta\alpha$ ), insulin regulation of hepatic apo B production independently of mass or activity of, 228-236

## Alanine (Ala)

plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

*see also* Alanine aminotransferase; Pro12Ala polymorphism of PPAR $\gamma$ ; Pro12Ala polymorphism of PPAR $\gamma$ 2

## Alanine aminotransferase (ALT)

in dyslipidemic CRF subjects on HD, 1116

in hyperuricemic Japanese male adolescents, 450

in liver cirrhosis with IR, 923

in obese subjects, *see* Alanine aminotransferase in obese subjects

plasma, NO-1886 effects on, in STZ-DM, 261

WPG effects on, 1312

## Alanine aminotransferase (ALT) in obese subjects

in hyperuricemic Japanese male adolescents, 450

Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057

## Albumin

in chronic renal disease, 1256

and IR in liver cirrhosis, 923

in Korean women, AT distribution and, 1541

in Kuwaiti IDDM children and adolescents, CV disease risk

factors and, 640, 641

plasma, and HHcy in disabled hospitalized older subjects, 1018

serum, *see* Serum albumin

in 6-month period following kidney transplantation recipients, 617

*see also* Albuminuria

## Albuminuria

in IDDM, oxidation of glycated and nonglycated LDLs and, 970

in NIDDM, corrected QT intervals association with carotid artery IMT and, 1155

in NIDDM nephropathy, pioglitazone effects on, 1382-1386

in NIDDM retinopathy, 586

*see also* Microalbuminuria; Proteinuria

## Alcohol

bile, in CTX, treatment effects on, 558, 559

Alcohol (*Continued*)

differential effects of glucose and, on ROS generation and intranuclear nuclear factor- $\kappa$ B in mononuclear cells, 330-334  
*see also* Alcohol intake

## Alcohol intake

atherosclerosis and, *see* Alcohol intake, atherosclerosis and  
 by disabled hospitalized older subjects, HHcy and, 1018  
 drinking and, *see* Drinking  
 effects of, on risk for metabolic syndrome, 1506-1508  
 IR and, 722

in mild hypercholesterolemia, 1073, 1311

by NIDDM subjects, *see* Alcohol intake by NIDDM subjects  
 normal plasma cholesterol and, 1311

relationship of exercise, adiposity and, to HDL-C levels, 700-709

## Alcohol intake, atherosclerosis and

carotid atherosclerosis, vascular dementia and, 477  
 by normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia, 51

## Alcohol intake by NIDDM subjects

effects of, on PP lipemia and PP incretin levels, 77-83  
 by IGT NIDDM subjects, as risk factor for CHD, 646

## Alkaline phosphatase (ALP)

in PM women, simvastatin effects on BMD and, 745, 746  
 in primary hyperthyroidism, 1102  
 in severe lipodystrophy, leptin replacement therapy effects on, 516  
 SR effects on, in MC3T3-E1 osteogenic cells, bone matrix mineralization and, 533

in STZ-DM, effects of oral vanadate with tea extract on, 1148

ALP, *see* Alkaline phosphatase

Alpha<sub>1</sub> ( $\alpha_1$ )-acid glycoprotein (AGP) in inflammation of chronic disease, 901, 902

Alpha<sub>1</sub> ( $\alpha_1$ )-antichymotrypsin (ACT) in inflammation of chronic disease, 901, 902

7 $\alpha$  (7 $\alpha$ )-hydroxylase, cholesterol, effects of ileal bile transport inhibition on plasma C level through FXR inactivation and stimulation of, 927-932

17 $\alpha$  (17 $\alpha$ )-hydroxylase/17,20-lyase deficiency, mutant CYP17 genes in, 1527-1531

3n3 Alpha ( $\alpha$ )-linolenic acid in MS, 312

Alpha-lipoprotein, *see* High-density lipoprotein

Alpha-lipoprotein-cholesterol, *see* High-density lipoprotein-cholesterol

Alpha-tocopherol, *see*  $\alpha$ -Tocopherol

ALT, *see* Alanine aminotransferase

Alveolar macrophages, effects of caffeine on, via its effects on synthesis of cAMP and prostaglandin, 687-692

Amazon Shuar women, Ecuadoran, effects of agricultural versus traditional lifestyle on, 1355-1358

Amenorrhea, sex steroids and plasma Lp in, 189

## Amino acids (AA)

plasma concentrations of, and whole-body protein synthesis in hyperinsulinemic young men, 388-396

*see also* specific amino acids

5-Aminoimidazole-4-carboxamide-1- $\beta$ -D-ribofuranoside (AICAR), glucose transport stimulated in SM stimulated by, 514

bis(*o*-Aminophenoxy)ethane-N,N,N',N' tetraacetic acetoxymethyl ester (dimethyl-BAPTA/AM), effects of, on IR and spontaneous hypertension, high-fat diet and, 269-272

4-Aminopyridine (4AP), effects of, on delayed vasorelaxation by troglitazone, 147-152

Aminoterminal propeptide type I collagen in adrenal insufficiency, 1252

Aminotransferase, *see* Alanine aminotransferase; Aspartate aminotransferase

AMP, *see* Adenosine monophosphate

Amyloid A, serum, aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380

## Androgen(s)

aging NIDDM men with partial deficiency of, glycemic control and, 666-672

role of, in estrogen-deficient state, 187-192

*see also* Androgen(s) in PCOS; Androgenicity

## Androgen(s) in PCOS

adrenal, 361

in obese PCOS women, antiandrogenic therapy of, 366, 370  
 ovarian, 360, 361

Androgenicity, independent association of obesity and, with insulin sensitivity in postmenopausal women, 507-512

## Androstenedione

in premenopausal women, plasma Lp and, 189, 190

*see also* Androstenedione in PM women

## Androstenedione in PM women

obese, insulin sensitivity and, 508-509

plasma Lp and, 189, 190

Androsterone glucuronide in PCOS, 366

## Angiotensin-converting enzyme (ACE) inhibitors

in CAD, 319

in NIDDM, effects of, on microalbuminuria, 354

Anglo subjects, *see* Race and ethnicity

1,5-Anhydroglucitol (1,5-AG) in NIDDM, microalbuminuria and, 354

Antiandrogenic therapy of PCOS in obese women, 366, 370

$\alpha_1$  ( $\alpha_1$ )-Antichymotrypsin (ACT) in inflammation of chronic disease, 901, 902

Antidiabetic medications, *see* Glycemic control of DM

Antigen, tPA- and PAI-, in NIDDM, 224

Antihyperglycemic effects, *see* Glycemic control of DM

Anti-inflammatory effects of  $\omega$ -3 polyunsaturated fatty acids alone or combined with *all-rac*  $\alpha$ -tocopherol, 236-240

## Aorta

abdominal, preclinical changes in, in obese children, 1243-1246

effects of micromolar copper concentrations on endothelium-dependent relaxation of, in DM, 1315-1321

4-AP (4-aminopyridine), effects of, on delayed vasorelaxation by troglitazone, 147-152

Apo(s), *see* specific apolipoproteins

## Apolipoprotein A-1 (apo A-1)

*ABCA1* gene and, *see* Apolipoprotein A-1, *ABCA1* gene and

carotid atherosclerosis, vascular dementia and, 477

in chronic kidney disease with obesity and MS, 1255-1261

in dyslipidemic CRF subjects on HD, 1114

in erythrocyte membrane, 574

exercise and, *see* Apolipoprotein A-1, exercise and

and fat mass in acute SCI subjects, 991

in FCHL,  $\omega$ -3 PUFA effects on, 154

in hepatoma cells, *see* HepG2 cells, apo A-1 and

in hypercholesterolemia, serum LPL concentration and, 528

in IDDM, *see* Apolipoprotein A-1 in IDDM

in IR, serum GPI-PLD and, 139

plasma, *see* Plasma apolipoprotein A-1

in PM women, *see* Apolipoprotein A-1 in PM women

in premenopausal women, sex steroids and, 189

serum, in CAD men, 425

serum adiponectin and, in young men, 590

smoking effects on, 859, 860

Apolipoprotein A-1 (apo A-1), *ABCA1* gene and

*ABCA1* expression relation with fasting glucose in normoglycemic men, 19



- Apolipoprotein A-1 (apo A-1), *ABCA1* gene and (*Continued*)  
*ABCA1* polymorphism in Japanese school-age children, 182-186
- Apolipoprotein A-1 (apo A-1), exercise and  
 apo E polymorphism- $\dot{V}O_{2\max}$  association and, 111-113  
 endurance exercise, 196, 198-200  
 in soccer players, 1264
- Apolipoprotein A-1 (apo A-1) in IDDM  
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641  
 plasma apo C-3 polymorphisms and, 1299
- Apolipoprotein A-1 (apo A-1) in PM women  
 obese women, fluvastatin effects on, 736  
 and sex steroids, 189
- Apolipoprotein A-2 (apo A-2)  
 erythrocyte membrane, 574  
 in FCHL,  $\omega$ -3 PUFA effects in, 154  
 in obese PM women, fluvastatin effects on, 736  
 serum, in CAD men, 425  
 in soccer players, 1264
- Apolipoprotein A-2 (apo A-2) promoter, SFA effects on Sp1 induction of, 1342-1348
- Apolipoprotein B (apo B)  
 atherosclerosis and, *see* Apolipoprotein B in atherosclerosis  
 in dyslipidemic CRF subjects on HD, 1114, 1115  
 erythrocyte membrane, 574  
 exercise and, *see* Apolipoprotein B, exercise and  
 and fat mass in acute SCI subjects, 991  
 in FCHL,  $\omega$ -3 PUFA effects in, 154  
 hepatic, insulin regulating production of, independently of PKB $\alpha$ /Akt1 mass or activity, 228-236  
 in hypercholesterolemia, serum LPL concentration and, 528  
 in IDDM, *see* Apolipoprotein B in IDDM  
 in IR, plasma NEFA regulation and, 1198  
 levels of, associated with *ABCA1* polymorphism in Japanese school-age children, 183  
 in MS, 312, 313, 315  
 in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301  
 plasma, in premenopausal women, sex steroids and, 189  
 in PM women, *see* Apolipoprotein B in PM women  
 smoking effects on, 860  
 in subclinical hypothyroidism, 1513  
 in young men, serum adiponectin and, 590
- Apolipoprotein B (apo B), exercise and  
 apo E polymorphism- $\dot{V}O_{2\max}$  association and, 111-113  
 endurance exercise, 196, 198-201  
 soccer playing, 1264
- Apolipoprotein B (apo B) in atherosclerosis  
 in normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia, 50  
 vascular dementia and carotid atherosclerosis, 477
- Apolipoprotein B (apo B) in IDDM  
 in Kuwaiti children and adolescents, CV disease risk factors and, 640, 641  
 plasma apo C-3 polymorphisms and, 1299, 1301
- Apolipoprotein B (apo B) in PM women  
 obese women, fluvastatin effects on, 736  
 sex steroids and, 189
- Apolipoprotein B-48 (apo B-48) in chronic kidney disease, obesity, and MS, 1255-1261
- Apolipoprotein B-100 (apo B-100)  
 in chronic kidney disease, obesity, and MS, 1255-1261  
 in HL deficiency, 522, 523
- Apolipoprotein C-2 (apo C-2) (*Continued*)  
 in dyslipidemic CRF subjects on HD, 1114  
 in hypercholesterolemia, serum LPL concentration and, 528  
 in obese PM women, fluvastatin effects on, 736  
 serum, in CAD men, 425
- Apolipoprotein C-3 (apo C-3)  
 in dyslipidemic CRF subjects on HD, 1114, 1115  
 in hypercholesterolemia, serum LPL concentration and, 528  
 in obese PM women, fluvastatin effects on, 736  
 polymorphisms of plasma, in IDDM, 1296-1304  
 serum, *see* Serum apolipoprotein C-3
- Apolipoprotein E (apo E)  
 carotid atherosclerosis, vascular dementia and, 477  
 in dyslipidemic CRF subjects on HD, 1114  
 effects of circulating blood cells on atherosclerosis in apo E deficiency, 95-100  
 in hypercholesterolemia, serum LPL concentration and, 528  
 in obese PM women, fluvastatin effects on, 736  
 serum, in CAD men, 425  
*see also* Apolipoprotein E genotype; Apolipoprotein E polymorphism
- Apolipoprotein E (apo E) genotype, changes in serum lipids and  $\dot{V}O_{2\max}$  during endurance exercise and, 193-202
- Apolipoprotein E (apo E) polymorphism  
 and changes in blood lipids and  $\dot{V}O_{2\max}$  association in sedentary and exercising subjects, 108-116  
 in Vietnamese children, relationship of, to plasma lipids and Lps, 1517-1521
- Appropriate-for-gestational-age newborns, normal, circulating ACTH and cortisol concentrations in newborns with respiratory distress and sepsis versus, 209-214
- Arachidonic acid  
 effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177  
 erythrocyte membrane lipid composition in men associated with, insulin sensitivity and, 571-577
- Arg, *see* Arginine
- Arg16Gly polymorphism,  $\beta_2$ -ADR, interaction of  $\beta_3$ -ADR Trp64Arg polymorphism with, serum lipid profile and, 1184-1191
- Arginase, effects of different glucose levels on NO production and activity of, in renal cortex, 868-874
- Arginine (Arg)  
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392  
*see also*  $\beta_3$ -Adrenergic receptor, Trp64Arg polymorphism of; Arg16Gly polymorphism of  $\beta_2$ -ADR; Arginine-vasopressin; Asymmetric dimethylarginine; Lys109Arg and Gln223Arg polymorphisms
- Arginine-vasopressin (AVP)  
 and 4AP effects on delayed vasorelaxation by troglitazone, 147-152  
 response of, to exercise by nondiabetic and IDDM smokers, 1140-1144
- Arginine-vasopressin $_2$  (AVP $_2$ ) mRNA (messenger ribonucleic acid) in IMCD, ET effects on, 1177-1183
- Arterial pressure, *see* Blood pressure
- Arterial stiffness, pioglitazone effects on carotid IMT and, in NIDDM nephropathy, 1382-1386
- Arteriosclerosis obliterans in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 299
- Arylesterase, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, in NIDDM, 301
- Ascorbic acid, *see* Vitamin C

- ASGB (adjustable silicone gastric banding), RYBG and, for morbid obesity, changes in BMC after, 918-921
- Asian Indian adolescents, postpubertal, adiponectin, CRP, and IR in, 1336-1341
- Asparagine (Asn), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Aspartate aminotransferase (AST)  
in dyslipidemic CRF subjects on HD, 1116  
in obese Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057  
plasma, NO-1886 effects on, in STZ-DM, 261  
WPG effects on, 1312
- Aspirin therapy of CAD, 319
- AST, *see* Aspartate aminotransferase
- Asymmetric dimethylarginine (ADMA)  
plasma, diet composition as determinant of, in mild hypercholesterolemia, 1072-1074  
relationship between smoking, obesity and, 1574-1579
- AT, *see* Adipose tissue
- Atherogenic particles of LDLs, HC diet effects on, 823-830
- Atherosclerosis  
in apo E-deficient subjects, effects of circulating blood cells on, 95-100  
carotid, sdLDLs, vascular dementia and, 476-482  
premature, normocholesterolemia and daytime hypertriglyceridemia in first-degree relatives of subjects with, 49-53  
*see also* Coronary artery disease  
-3826A→G polymorphism of UCP-1, effects of, on LDL-C level in obese Korean subjects, 1054-1059
- Athletes, *see* Exercise
- Atorvastatin, effects of, on lipids, LDLs, and CRPs in dyslipidemic CRF subjects on HD, 1113-1117
- ATPCL, *see* Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA
- At-rest subjects, *see* Sedentary subjects
- Autonomic dysfunction, cardiovascular, microalbuminuria, IR and, in NIDDM, 1359-1364
- AVP, *see* Arginine-vasopressin
- Ayurvedic herbal supplement (Pancreatic Tonic), effects of, in NIDDM, 1166-1173
- Beer ingestion, effects of sauna bathing and, on plasma concentration of purine bases, 772-776
- Beta ( $\beta$ )-adrenergic blockers in CAD, 319
- Beta ( $\beta$ )-adrenergic receptor, racial differences in density of, in subcutaneous and omental AT of obese women, 247-251
- Beta<sub>2</sub> ( $\beta_2$ )-adrenergic receptor (ADR), interaction of  $\beta_2$ -ADR Trp64Arg polymorphism with Arg16Gly polymorphism of, serum lipid profile and, 1184-1191
- Beta<sub>3</sub>-adrenergic receptor, *see*  $\beta_3$ -Adrenergic receptor, Trp64Arg polymorphism of
- Beta ( $\beta$ )-carboxy terminal telopeptide of type I collagen in adrenal insufficiency, 1252
- Beta ( $\beta$ ) cells  
dysfunctional, and development of hyperglycemia in Japanese subjects, 943-954  
pioglitazone effects on insulin secretion and loss of mass of, in obese NIDDM subjects, 488-494  
of relationship between BMI, IR, and function of, 1462-1466
- 7Beta ( $\beta$ )-hydroxy bile acids, hydrophilic, effectiveness of lovastatin, cholestyramine, chenodeoxycholic acid and, in cerebrotendinous xanthomatosis, compared, 556-562
- 11Beta ( $\beta$ )-hydroxysteroid dehydrogenase 1 (11 $\beta$ -HSD1) mRNA (messenger ribonucleic acid)  
11Beta ( $\beta$ )-hydroxysteroid dehydrogenase 1 (11 $\beta$ -HSD1) mRNA (messenger ribonucleic acid) (*Continued*)  
in AT, effects of restricted diet on, 30-31  
hepatic, responsiveness of body weight and, to 11 $\beta$ -HSD1 inhibition by glycyrrhetic acid, 600-606
- 11Beta ( $\beta$ )-hydroxysteroid dehydrogenase 2 (11 $\beta$ -HSD2) mRNA (messenger ribonucleic acid), renal, responsiveness of body weight and, to 11 $\beta$ -HSD1 inhibition by glycyrrhetic acid, 600-606
- Betaine in cystathionine- $\beta$ -synthase deficiency, 594-599
- Beta lipoprotein, *see* Low-density lipoprotein
- Beta lipoprotein-cholesterol, *see* Low-density lipoprotein-cholesterol
- Bezafibrate, effects of, on lipids and glucose metabolism in obese NIDDM subjects, 405-413
- BF (blood flow), medullary, tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308
- Bile, hepatic, plasma 27-hydroxycholesterol and plasma 7 $\alpha$ -hydroxy-4-cholesten-3-one as markers of synthesis of, dietary cholesterol and, 42-48
- Bile acids, hydrophilic 7 $\beta$ -hydroxy, effectiveness of lovastatin, cholestyramine, chenodeoxycholic acid and, in cerebrotendinous xanthomatosis, compared, 556-562
- Bile alcohols in CTX, treatment effects on, 558, 559
- Bile duct ligation, effects of galactosamine-induced liver disease and, on cardiac protein synthesis, 964-968
- Bile transport, effects of inhibition of ileal, on plasma cholesterol level through hepatic farnesoid X receptor inactivation and cholesterol 7 $\alpha$ -hydroxylase stimulation, 927-932
- Bilirubin  
serum, *see* Serum bilirubin  
total, *see* Total bilirubin  
WPG effects on, in normal and mildly elevated plasma cholesterol, 1312
- Binding protein, *see* Fatty acid-binding protein-4; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s); Insulin-like growth factor-binding protein 3 protease; Retinoic acid binding protein-1 mRNA; Sterol regulatory element binding protein-1
- Biphosphatase, fructose-1,6-, *P. yoelli* GPI effects on, in STZ-DM with obesity, 1050
- Birth weight  
low, in normal glucose-tolerant Pima Indians, insulin secretion and insulin sensitivity in, 904-911  
relation of intracellular cord blood platelet magnesium to, 1544-1547
- Black Americans, *see* Race and ethnicity
- Blood cells, effects of circulating, on atherosclerosis in apo E-deficient subjects, 95-100
- Blood cholesterol (C)  
apo E polymorphism association with VO<sub>2max</sub> and, in exercising and sedentary subjects, 111-113  
*see also* Hypercholesterolemia
- Blood flow (BF), increase of medullary, and tempol effects on hypertension and hyperinsulinemia, 1305-1308
- Blood glucose  
in early NIDDM nephropathy, 1476  
fasting, *see* Fasting blood glucose  
with high-sucrose diet, NOS inhibition and pioglitazone effects on, 23  
in postmenopausal women on ERT and at risk for CAD, 378  
in treatment-seeking obese insulin-resistant subjects, 436  
*see also* Blood glucose in STZ-DM; Glycemic control of DM; Hyperglycemia; Hypoglycemia and entries beginning with term: Normoglycemic



- Blood glucose in STZ-DM  
  leptin effects on, 1559  
  with obesity, 1050
- Blood high-density lipoprotein<sub>3</sub>-cholesterol (HDL<sub>3</sub>-C), apo E polymorphism association with VO<sub>2max</sub> and, in exercising subjects, 111-113
- Blood lipids  
  apo E polymorphism and changes in VO<sub>2max</sub> and, in sedentary and exercising subjects, 108-116  
  *see also* Dyslipidemia in NIDDM; High-fat/high-cholesterol diet, lipemic response to; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia; Postprandial lipemia, exercise effects on
- Blood low-density lipoprotein-cholesterol (LDL-C), apo E polymorphism and changes in VO<sub>2max</sub> and, during exercise and in sedentary subjects, 111-113
- Blood pressure (BP)  
  and *ABCA1* gene expression-fasting glucose relationship in normoglycemic men, 19  
  in adolescents, *see* Blood pressure in adolescents  
  and AT distribution in Korean women, 1539  
  in atherosclerosis, *see* Blood pressure in atherosclerosis  
  in CAD men, *see* Blood pressure in CAD men  
  CV disease risk factors and, *see* Blood pressure, CV disease risk factors and  
  diet and, *see* Blood pressure, diet and  
  and erythrocyte membrane lipid composition, 574  
  of exercising PM women on or not on ERT, 1194  
  HPA and, 722  
  in hypothyroidism, T<sub>4</sub> therapy effects on endothelial function and, 279  
  in IDDM, *see* Blood pressure in IDDM  
  in IGT first-degree relatives of African American NIDDM subjects, 1553  
  in IR, *see* Blood pressure in IR  
  of Japanese subjects, *see* Blood pressure in Japanese subjects  
  in mild hypercholesterolemia, 1073, 1074  
  in MS, 312, 313, 315  
  in NIDDM, *see* Blood pressure in NIDDM  
  in NIDDM nephropathy, *see* Blood pressure in NIDDM nephropathy, pioglitazone effects on  
  in NIDDM retinopathy, 585, 586  
  of non-obese subjects, *see* Blood pressure of non-obese subjects  
  in obesity, *see* Blood pressure in obesity  
  PP, stevioside effects on, 75  
  in preeclampsia, 1434  
  and smoking-ADMA-obesity relationship, 1575, 1576  
  smoking effects, 860  
  of young subjects, *see* Blood pressure of young subjects
- Blood pressure (BP), CV disease risk factors and  
  diet, lifestyle, and plasma CRPs associated with CV disease risk factors, 1437, 1438  
  in Kuwaiti children, 640, 641  
  in overweight and non-obese insulin-resistant subjects, 498
- Blood pressure (BP), diet and  
  acute effects of red wine drinking and food intake on vascular reactivity and, 1082  
  lifestyle, plasma CRPs, and diet associated with CV disease risk factors and, 1437, 1438
- Blood pressure (BP) in adolescents  
  in Kuwaiti adolescents, 640, 641  
  in postpubertal Asian Indian adolescents, 1338, 1339  
  *see also* Blood pressure of obese adolescents
- Blood pressure (BP) in atherosclerosis (*Continued*)  
  carotid atherosclerosis, 477  
  in normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia and in their first-degree relatives, 50
- Blood pressure (BP) in CAD men  
  effects of red and white wine drinking on, 319, 320  
  as risk factor for myocardial infarction, 325, 326
- Blood pressure (BP) in IDDM  
  of Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641  
  oxidation of glycated and nonglycated LDLs and, 970
- Blood pressure (BP) in IR  
  CHD and, 853-855  
  and cilostazol effects on microalbuminuria, 1407  
  and CV disease risk factors in overweight and non-obese subjects, 498  
  HPA dysfunction and, 722, 724  
  with LVH, 778, 779  
  measures of IR and, 1524  
  plasma NEFA regulation and, 1198  
  *see also* Blood pressure in obesity with IR
- Blood pressure (BP) in Japanese subjects  
  with beta-cell dysfunction, 950  
  and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883
- Blood pressure (BP) in NIDDM  
  association of corrected QT intervals with carotid artery IMT and, 1153, 1155, 1156  
  and in at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224  
  with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362  
  insulin therapy effects on, 694, 697  
  metformin effects on, 160  
  with microalbuminuria, 354  
  in obesity, *see* Blood pressure in obesity  
  Pancreas Tonic effects on, 1169  
  PP, stevioside effects on, 75  
  renal cortex oxygenation, endothelial function and, 224  
  *see also* Blood pressure in NIDDM nephropathy
- Blood pressure (BP) in NIDDM nephropathy  
  incipient nephropathy in Japanese subjects, 1224  
  *see also* Blood pressure in NIDDM nephropathy, pioglitazone effects on
- Blood pressure (BP) in NIDDM nephropathy, pioglitazone effects on  
  on carotid artery IMT and stiffness, 1383  
  on early NIDDM nephropathy, 1476
- Blood pressure (BP) of non-obese subjects  
  and AT as fibrinogen level predictor, 985, 986  
  in non-obese premenopausal women, metabolic risk and, 1068-1070
- Blood pressure (BP) of obese adolescents  
  hyperuricemic male adolescents, 450, 452  
  with MS components, TNF and, 864, 865
- Blood pressure (BP) of obese women  
  effects of moderate weight loss and sibutramine or orlistat on, 432  
  fluvastatin effects on, 735
- Blood pressure (BP) in obesity  
  in adolescents, *see* Blood pressure of obese adolescents  
  in children, preclinical changes in abdominal aorta and, 1244

- Blood pressure (BP) in obesity (*Continued*)  
 with IR, *see* Blood pressure in obesity with IR  
 in Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1055, 1056  
 with MS, *see* Blood pressure in obesity with MS  
 in women, *see* Blood pressure of obese women
- Blood pressure (BP) in obesity with IR  
 CV disease risk factors associated with, 498  
 in Japanese subjects, 651
- Blood pressure (BP) in obesity with MS  
 in obese adolescents, 864, 865  
 in treatment-seeking subjects, 436
- Blood pressure (BP) of young subjects  
 with NIDDM parents, and LDL susceptibility to oxidation and circulating adhesion molecules, 756  
 serum adiponectin and, 590  
 in young men with hypertensive parents, 470, 473
- Blood samples kept frozen at  $-80^{\circ}\text{C}$ , analysis of HbA<sub>1c</sub> in, 1496-1499
- Blood triglycerides (TGs)  
 in exercise, apo E polymorphism-VO<sub>2max</sub> association and, 111-113  
*see also* Hypertriglyceridemia
- Blood urea nitrogen, *see* BUN
- BMC (bone mineral content), changes in, after RYBG and ASGB for morbid obesity, 918-921
- BMD, *see* Bone mineral density
- BMI, *see* Body mass and body mass index
- BNP (brain natriuretic peptide) in IR with LVH, candesartan effects on, 778-780
- Body composition  
 L-carnitine effects on fat oxidation, protein turnover and, in slightly overweight subjects, 1001-1006  
 effects of interaction between FABP-4 and PPAR $\gamma$ -activated receptor polymorphism on insulin sensitivity and, in men, 303-309  
 effects of leptin replacement therapy for severe lipodystrophy on, 513-519  
 of Korean women, AT distribution and, 1539  
 in NIDDM, *see* Body composition in NIDDM  
 of PM women, *see* Body composition of PM women, exercise effects on  
 uncoupling protein-3 polymorphism associated with food intake and, 458-464  
*see also* Adipose tissue; Fat mass; Fat-free mass; Skeletal muscle
- Body composition in NIDDM  
 in NIDDM women, resistance training effects on, 286  
 with obesity, effects of LF versus HF diet on, 456
- Body composition of PM women, exercise effects on  
 exercise effects on women on or not on ERT, 1192-1196  
 moderate exercise with soy isoflavone effects, 944-945
- Body fat, *see* Adipose tissue
- Body mass and body mass index (BMI)  
 and ABCA1 gene expression-fasting glucose relationship in normoglycemic men, 19  
 acute effects of nicotine and, 579  
 of acute SCI subjects, 990  
 adiponectin levels and, 2  
 $\beta_2$ -ADR Arg16Gly polymorphism and, 1184, 1185  
 and AT distribution in Korean women, 1539, 1541  
 atherosclerosis and, *see* Body mass and body mass index of atherosclerotic subjects  
 of CAD men, *see* Body mass and body mass index of CAD men  
 of chronic renal disease patients, 1256
- Body mass and body mass index (BMI) (*Continued*)  
 CV disease risk factors and, *see* Body mass and body mass index, CV disease risk factors and  
 CV disease risk factors and  
 diet and, *see* Body mass and body mass index, diet and  
 in disabled hospitalized older subjects, HHcy and, 1018  
 of DM subjects, *see* Body mass and body mass index of DM subjects  
 of exercising subjects, *see* Body mass and body mass index, exercise and  
 of HD subjects, 1014  
 of HL-deficient subjects, 522  
 of hypercholesterolemic subjects, *see* Body mass and body mass index of hypercholesterolemic subjects  
 of hypogonadic men, 1175  
 of insulin-resistant subjects, *see* Body mass and body mass index of insulin-resistant subjects  
 of insulin-sensitive subjects, *see* Body mass and body mass index of insulin-sensitive subjects  
 of Japanese subjects, *see* Body mass and body mass index of Japanese subjects  
 of kidney transplantation recipients, 615  
 of LBW Pima Indians with normal glucose tolerance, 906  
 leptin levels and, 1412, 1413  
 of lipodystrophic subjects, *see* Body mass and body mass index of lipodystrophic subjects  
 lipodystrophic subjects  
 in obesity, *see* Body mass and body mass index in obesity  
 plasma LDL clearance and, 484  
 plasma vitamin K transport and, 216  
 of PM women, *see* Body mass and body mass index of PM women  
 in postpubertal Asian Indian adolescents, 1338-1340  
 of pregnant subjects, *see* Body mass and body mass index of pregnant subjects  
 of premenopausal women, sex steroids, plasma Lp and, 189  
 and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by overweight subjects, 1450  
 rhGH therapy effects on, in GH-deficient subjects, 741  
 and risk for metabolic syndrome and, 1505, 1506; *see also* Body mass and body mass index of MS subjects  
 of slightly overweight subjects, effects of L-carnitine and, 1002  
 of smokers, *see* Body mass and body mass index of smokers  
 of subclinical hypothyroidism subjects, 1513  
 and UCP-3 polymorphism-body composition association, 460  
 of Vietnamese children with apo E polymorphism and, 1519  
 and WPG effects on normal or mildly elevated plasma cholesterol, 1311  
 of young men, *see* Body mass and body mass index of young men
- Body mass and body mass index (BMI), CV disease risk factors and diet and, 1437, 1438  
 in Kuwaiti children and adolescents, 640, 641  
 in NIDDM insulin-resistant overweight and normoponderal subjects, 495-498
- Body mass and body mass index (BMI), diet and  
 CV disease risk factors and, 1437, 1438  
 effects of  $\omega$ -3 PUFAs alone or combined with *all-rac*  $\alpha$ -tocopherol, 237  
 high-fiber, low-fat diet and aerobic exercise effects in PM women on ERT and at risk for CAD, 378  
 and PP TG response to different nutrients, 621  
 PPAR $\gamma$  Pro12Ala polymorphism effects on dietary fat association with fasting insulin and physical activity, 13, 14  
 relationship between exercise, alcohol intake, and adiposity to HDL-C levels and, 704, 706

- Body mass and body mass index (BMI), diet and (*Continued*)  
see also Body mass and body mass index, wine drinking and
- Body mass and body mass index (BMI), exercise and  
and apo E polymorphism association with changes in blood lipids  
and  $VO_{2max}$ , 110  
in IDDM, insulin concentration and CHO requirement during  
moderate exercise, 1127  
OC effects on, 350  
of older hypertensive subjects, resistance exercise effects on, 399  
and plasma nitrate/nitrite assessment during OGTT, 675  
of PM women, see Body mass and body mass index of exercising  
PM women on ERT  
and PPAR $\gamma$  Pro12Ala polymorphism effects on dietary fat  
association with fasting insulin and physical activity, 13, 14  
 $\omega$ -3 PUFA with exercise effects on, 1366  
relationship of exercise, alcohol intake, and adiposity to HDL-C  
levels and, 704, 706  
of soccer players, 1263
- Body mass and body mass index (BMI), wine drinking and  
and acute effects of red wine drinking and food intake on vascular  
reactivity, 1082  
and red and white wine drinking effects in CAD men, 319
- Body mass and body mass index (BMI) of atherosclerotic subjects  
carotid atherosclerotic subjects, 477  
prematurely atherosclerotic subjects with normocholesterolemia  
and daytime hypertriglyceridemia, 50
- Body mass and body mass index (BMI) of CAD men  
red and white wine drinking effects on, 319  
as risk factor for myocardial infarction, 325, 326  
serum HDL-C, oxidized LDLs and, 424, 425
- Body mass and body mass index (BMI) of DM subjects  
and relation between plasma VEGF, ET-1 concentration, and  
glycemic control, 551  
see also Body mass and body mass index of IDDM subjects;  
Body mass and body mass index of NIDDM subjects
- Body mass and body mass index (BMI) of exercising PM women on  
ERT  
or not on ERT, 1194  
in women at risk for CAD, aerobic exercise and high-fiber, low-  
fat diet effects, 378
- Body mass and body mass index (BMI) of hypercholesterolemic  
subjects  
of mildly hypercholesterolemic subjects, 1073  
serum LPL concentration and, 527, 528
- Body mass and body mass index (BMI) of IDDM subjects  
energy substrate oxidation and, 656  
of IDDM men, and AT as fibrinogen level predictor, 985, 986  
insulin concentration and CHO requirement during moderate  
exercise and, 1127  
of Kuwaiti IDDM children and adolescents, CV disease risk  
factors and, 640, 641  
oxidation of glycated and nonglycated LDLs and, 970  
plasma apo C-3 polymorphisms and, 1299
- Body mass and body mass index (BMI) of insulin-resistant subjects  
with cardiovascular autonomic dysfunction and microalbuminuria,  
1360, 1362  
and CV risk factors in overweight and normal weight insulin-  
resistant NIDDM subjects, 495-498  
with liver cirrhosis, 923, 924  
with LVH, 778, 779  
minimal model analysis of relationship between beta-cell function,  
IR and, 1462-1466  
plasma NEFA regulation and, 1198  
serum GPI-PLD and, 139
- Body mass and body mass index (BMI) of insulin-resistant subjects  
(*Continued*)  
see also Body mass and body mass index of non-obese insulin-  
resistant subjects; Body mass and body mass index in obese  
insulin-resistant subjects
- Body mass and body mass index (BMI) of insulin-sensitive subjects  
estimates of insulin sensitivity and, 1109  
and isotretinoin effects on insulin sensitivity, 5
- Body mass and body mass index (BMI) of Japanese subjects  
with beta-cell dysfunction, 950, 952  
Japanese men, -1562C $\rightarrow$ T MMP-9 polymorphism association  
with BMD and, 136  
Japanese school-age children, *ABCA1* gene polymorphism and,  
183  
with NIDDM and incipient nephropathy, 1224  
and relationship between leptin receptor gene Lys109Arg and  
Gln223Arg polymorphisms, HOMA IR index, serum soluble  
leptin receptor, serum leptin, serum adiponectin, and lipids,  
881-883
- Body mass and body mass index (BMI) of lipodystrophic subjects  
with HIV infection, 1567  
with severe lipodystrophy, 514, 515
- Body mass and body mass index (BMI) of MS subjects  
central HPA dysregulation and, 722, 723  
with CHD, 853-855  
effects of exercise on MS in PM women, 1194  
fatty acid TG content, VAT and, 312, 313
- Body mass and body mass index (BMI) of NIDDM subjects  
adiponectin, CRP and, 1456, 1457  
alcohol effects on, 78  
and association of corrected QT intervals with carotid artery IMT,  
1153, 1155  
with cardiovascular autonomic dysfunction, microalbuminuria, and  
IR, 1360, 1362  
correlation between serum PON1 polymorphism, vascular  
complications, plasma oxidized LDLs and, 299  
CV disease risk factors and, see Body mass and body mass index  
of NIDDM subjects, CV disease risk factors and  
and glyburide and nateglinide effects on NIDDM, 1332  
with IGT, 646  
insulin therapy effects on, 697, 698  
Japanese subjects, insulin secretion and insulin sensitivity and, 832  
microalbuminuria and, 354  
and Pancreas Tonic effects, 1169  
with retinopathy, 585, 586
- Body mass and body mass index (BMI) of NIDDM subjects, CV  
disease risk factors and  
in insulin-resistant overweight and normal weight subjects, 495-  
498  
metformin effects on, 160
- Body mass and body mass index (BMI) in non-obese insulin-  
resistant subjects  
in NIDDM Korean subjects, 142-146  
and preservation of circadian rhythm of serum insulin  
concentration at low plasma glucose during fasting by non-  
obese subjects, 1450
- Body mass and body mass index (BMI) in obese insulin-resistant  
subjects  
CV disease risk factors and, 495-498  
Japanese men, 651  
with IGT or normal FPG, 1096, 1097
- Body mass and body mass index (BMI) of obese PM women  
androgenicity, insulin sensitivity and, 508, 509  
fluvastatin effects on, 735, 736

- Body mass and body mass index (BMI) of obese women  
androgenicity, insulin sensitivity and, 508, 509  
effects of moderate weight loss and sibutramine or orlistat on, 432  
PM women, *see* Body mass and body mass index of obese PM women  
serum TNF soluble receptors, TNF- $\beta$ , NO and, 1269
- Body mass and body mass index (BMI) in obesity  
in hyperuricemic Japanese male adolescents, 452  
with IR, *see* Body mass and body mass index in obese insulin-resistant subjects  
Korean subjects, -3826A $\rightarrow$ G UCP-1 polymorphism effects on level of LDL-C and, 1055, 1056  
minimal model analysis of relationship between IR, beta-cell function and, 1462-1466  
with NIDDM, adiponectin and C-reactive protein and, 1456, 1457  
obese women, *see* Body mass and body mass index of obese women  
preadipocyte differentiation and proliferation and, 633, 634  
and smoking-ADMA-obesity relationship, 1575, 1576
- Body mass and body mass index (BMI) of PM women  
on ERT, *see* Body mass and body mass index of exercising PM women on ERT  
obese, *see* Body mass and body mass index of obese PM women  
sex steroids, plasma Lp and, 189
- Body mass and body mass index (BMI) of pregnant subjects  
leucine turnover and, 546  
with preeclampsia, 1434, 1435
- Body mass and body mass index (BMI) of smokers  
acute effects of nicotine and, 579  
and smoking-ADMA-obesity relationship, 1575, 1576
- Body mass and body mass index (BMI) of young men  
insulin sensitivity and, 470  
Japanese, Pro12Ala PPAR $\gamma$ 2 polymorphism, adiponectin and, 1549, 1550  
serum adiponectin, HDL-C, LDL-C particle size, TGs and, 590
- Body weight (BW)  
of acute SCI subjects, 990  
and AT distribution in Korean women, 1539, 1541  
at birth, *see* Birth weight  
of children with glycoprotein PC-1 K121Q polymorphism, 467  
of chronic renal disease subjects, 1256  
diet effects on, *see* Body weight, diet effects on  
of early NIDDM nephropathy subjects, 1476  
of Ecuadorian Amazon Shur women, 1356  
and erythrocyte membrane lipid composition, 574  
exercise effects on, *see* Body weight, exercise effects on  
gain of, *see* Weight gain  
of hyperinsulinemic subjects, *see* Body weight of hyperinsulinemic subjects  
of IGT subjects, *see* Body weight of IGT subjects  
and isotretinoin effects on insulin sensitivity and plasma TGs, 5  
of Japanese subjects with beta-cell dysfunction, 950  
of lipodystrophic subjects, leptin replacement therapy effects on, 515-516  
loss of, *see* Weight loss  
of NIDDM subjects, *see* Body weight of NIDDM subjects  
NN414 and DZ effects on, compared, 442  
NO-1886 effects on, 261  
and plasma vitamin K transport, 216  
of PM women, *see* Body weight of PM women  
responsiveness of, to 11 $\beta$ -HSD inhibition by glycyrrhetic acid, 600-606  
and risk for metabolic syndrome and, 1505  
of smokers, *see* Body weight of smokers
- Body weight (BW) (*Continued*)  
and WPG effects on normal or mildly elevated plasma cholesterol, 1311  
*see also* Non-obese subjects; Obesity; Overweight
- Body weight (BW), diet effects on  
beer ingestion and sauna bathing effects on, 774  
HF diet, *see* Body weight, HF diet effects on  
high-fiber, low-fat diet and aerobic exercise effects in PM women on ERT and at risk for CAD, 378  
high-sucrose diet effects, 23-24  
restricted diet effects, 30  
*see also* Body weight, wine drinking and
- Body weight (BW), exercise effects on  
apo E genotype and changes in serum lipids and  $\text{VO}_{2\text{max}}$  and, 195, 198, 199  
and OC effects on glucoregulatory responses to exercise, 350  
and plasma nitrate/nitrite assessment during OGTT, 675  
with  $\omega$ -3 PUFAs, 750, 1366  
*see also* Body weight of PM women, exercise effects on
- Body weight (BW), HF diet effects on  
effects of LF versus HF diet and caloric intake, 455-456  
and intracellular  $\text{Ca}^{2+}$  chelator effects on IR and spontaneous hypertension, 270, 271  
reduced glucose transport in SM and, 913  
and skeletal muscle, 1033
- Body weight (BW), wine drinking and  
and acute effects of red wine drinking and food intake on vascular reactivity, 1082  
red and white wine drinking effects on, in CAD men, 319
- Body weight (BW) of exercising PM women on ERT  
or not on ERT, 1194  
with risk for CAD, high-fiber, low-fat diet and aerobic exercise effects on, 378
- Body weight (BW) of hyperinsulinemic subjects  
with hypertension, 1306  
young men, whole-body protein synthesis and, 389
- Body weight (BW) of IGT subjects  
IGT first-degree relatives of African American NIDDM subjects, 415, 417, 1553  
non-obese subjects, 625
- Body weight (BW) of insulin-resistant subjects  
and cilostazol effects on microalbuminuria, 1407  
obese subjects with normal FPG or IGT, 1096, 1097
- Body weight (BW) of NIDDM subjects  
and of at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224  
insulin therapy effects on, 694, 695, 697  
obese, *see* Body weight of obese NIDDM subjects
- Body weight (BW) of obese NIDDM subjects  
bezafibrate effects on, 407  
LF versus HF diet and caloric intake effects on, 455-456  
women, effects of resistance exercise on glycemic control and, 285  
*see also* Body weight of obese women
- Body weight (BW) of obese subjects  
insulin-resistant subjects with normal FPG or IGT, 1096, 1097  
and preclinical changes in abdominal aorta of obese children, 1244  
*see also* Body weight of obese insulin-resistant subjects; Body weight of obese NIDDM subjects; Body weight of obese women
- Body weight (BW) of obese women  
fluvastatin effects on, 735, 736



- Body weight (BW) of obese women (*Continued*)  
 with NIDDM, effects of resistance exercise on glycemic control and, 285  
 serum TNF soluble receptors, TNF- $\beta$ , and NO and, 1269
- Body weight (BW) of PM women  
 exercise and, *see* Body weight of PM women, exercise effects on hypercholesterolemic women, simvastatin effects on BMD and, 745  
 obese women, fluvastatin effects on, 735, 736
- Body weight (BW) of PM women, exercise effects on  
 on abdominal AT, body composition and, in PM on or not on ERT, 1192-1196  
*see also* Body weight of exercising PM women on ERT
- Body weight (BW) of smokers  
 acute effects of nicotine and, 579  
 and smoking effects on intravascular remodeling of HDL particles, 860
- Bone loss, moderate exercise and soy isoflavone effects on AT accumulation and, in postmenopausal subjects, 942-948
- Bone matrix, strontium ranelate-induced mineralization of, in MC3T3-E1 osteogenic cells, 532-537
- Bone mineral content (BMC), changes in, after RYBG and ASGB for morbid obesity, 918-921
- Bone mineral density (BMD)  
 -1562C $\rightarrow$ T MMP-9 polymorphism associated with, in Japanese men, 135-137  
 in obesity, *see* Bone mineral density in obesity  
 in PM women, *see* Bone mineral density in PM women  
 in severe lipodystrophy, leptin replacement therapy effects on, 516-517
- Bone mineral density (BMD) in obesity  
 CL316.243 effects on, in polygenic obesity with NIDDM, 801  
 after RYBG and ASGB for morbid obesity, 920
- Bone mineral density (BMD) in PM women  
 effects of moderate exercise and soy isoflavone on, 945  
 in hypercholesterolemic PM women, simvastatin effects on, 744-748
- Bone mineralization  
 strontium ranelate-induced bone matrix, in MC3T3-E1 osteogenic cells, 532-537  
*see also* Bone mineral density
- Born small-for-gestational-age children, oral glucose metabolism and whole-body glucose oxidation in, 847-851
- BP, *see* Blood pressure
- Brain natriuretic peptide (BNP) in IR with LVH, candesartan effects on, 778-780
- Bread, PP TG response to, 622
- BUN (blood urea nitrogen)  
 in NIDDM nephropathy, pioglitazone effects on, 1383  
 in STZ-DM, effects of oral vanadate with tea extract on, 1148
- Butter, PP TG response to, 621, 622
- (+)-(S)-p-[1-(p-tert-Butylphenyl)-2-oxo-4-pyrrolidinyl] methoxybenzoic acid (S-2E), effects of PRV and, in mixed hyperlipidemia, compared, 680-685
- BW, *see* Body weight
- Bypass, Roux-en-Y, changes in BMC after ASGB and, for morbid obesity, 918-921
- C, *see* Cholesterol
- Ca, *see* Calcium
- Cachexia, melanoma-associated, ghrelin mRNA in, 84-88
- CAD, *see* Coronary artery disease
- Caffeine, effects of, on alveolar macrophages via its effects on synthesis of cAMP and prostaglandin, 687-692
- Calcium (Ca)  
 in adrenal insufficiency, 1252  
 serum, in severe lipodystrophy, leptin replacement therapy effects on, 516  
*see also* Eucalcemia and entries beginning with term: Calcium
- Calcium channel blockers (CCBs), effects of dihydropyridine, on microalbuminuric NIDDM, 354
- Calcium (Ca)-dependent rebaudioside A, effects on insulin secretion, 1378-1381
- Calcium<sup>2+</sup> (Ca<sup>2+</sup>), primary hyperthyroidism and, 1102
- Calcium<sup>2+</sup> (Ca<sup>2+</sup>) chelator, effects of intracellular, on IR and in spontaneous hypertension subjects on high-fat diet, 269-272
- Caloric intake  
 CV disease risk factors and, 1439  
 effects of leptin replacement therapy and, in severe lipodystrophy, 515  
 with obesity-inducing diet, 783  
 role of HF and/or LF diet and, in NIDDM and obesity development, 454-457  
 and UCP-3 polymorphism-body composition association, 461  
*see also* Diet
- cAMP (cyclic adenosine monophosphate)  
 effects of caffeine on alveolar macrophages via its effects on synthesis of prostaglandin and, 687-692  
 low temperature blocking testosterone production and stimulatory effects of hCG on steroidogenic acute regulatory protein mRNA but not on production of, in tumor cells, 955-958
- Candesartan, effects of, on LVH and IR, 777-781
- Carbohydrate(s) (CHO)  
 oxidation of, during exercise at cold temperature, 204, 205  
*see also* Carbohydrate intake and specific carbohydrates
- Carbohydrate (CHO) intake  
 insulin concentration and requirement in, by IDDM subjects during moderate exercise, 1126-1130  
 with obesity-inducing diet, 783  
 and plasma ADMA in mild hypercholesterolemia, 1073, 1074  
 PP TG response to, 620-623  
 by prematurely atherosclerotic normocholesterolemic and daytime hypertriglyceridemic subjects, 51  
 and risk for metabolic syndrome, 1505-1506, 1508  
 by Vietnamese children, apo E polymorphism and, 1519
- Carboxykinase, hepatic phosphoenolpyruvate, effects of exercise on hepatic insulin signaling and activity of, in diabetes-prone subjects, 836-841
- Carboxylase, acetyl-coenzyme A, upregulation of mRNA of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- $\beta$  (beta)-Carboxy terminal telopeptide of type I collagen in adrenal insufficiency, 1252
- Cardiac fibroblasts, high glucose and insulin effects on DNA and collagen synthesis in, 710-715
- Cardiac function in prediabetic subjects, 1391-1394
- Cardiac myocytes, high glucose and insulin effects on protein synthesis in, 710-715
- Cardiac protein, effects of galactosamine-induced liver disease and bile duct ligation on synthesis of, 964-968
- Cardiorespiratory fitness, contribution of visceral AT and, to hyperinsulinemia, dyslipidemia, and hypertension in IGT NIDDM subjects, 644-649
- Cardiovascular autonomic dysfunction, microalbuminuria, IR and, in NIDDM, 1359-1364
- Cardiovascular disease, *see* Risk factors for CV disease
- L-Carnitine, effects of, on fat oxidation, protein turnover, and body composition in slightly overweight subjects, 1001-1006

- Carotene, association between lifestyle, plasma CRPs, CV disease risk factors, and intake of, 1439
- Carotid artery(ies)  
effects of elevated plasma Hcy on endothelial function recovery after denudation of, 760-765  
*see also* Carotid artery intimal-media thickness; Carotid atherosclerosis
- Carotid artery intimal-media thickness (IMT)  
in NIDDM, associated of corrected QT intervals with, 1152-1157  
in NIDDM nephropathy, pioglitazone effects on arterial stiffness and, 1382-1386
- Carotid atherosclerosis, sdLDLs, vascular dementia and, 476-482
- Casein in obesity-inducing HF diet, 783
- Cataracts in STZ-DM, effects of oral vanadate with tea extract on, 1145-1151
- Catecholamines  
pramlintide effects on response of glucagon and, and symptoms of hypoglycemia, 1227-1232  
*see also* Epinephrine; Norepinephrine
- CBS (cystathionine- $\beta$ -synthase) deficiency, betaine effects on, 594-599
- CCBs (calcium channel blockers), effects of dihydropyridine, on microalbuminuric NIDDM, 354
- CD4<sup>+</sup> (and CD8<sup>+</sup>) T lymphocytes, activated, emergence of growth factor receptors in, 117-122
- CDCA, *see* Chenodeoxycholic acid
- Cell differentiation, adipocyte precursor, from omental and subcutaneous AT of obese subjects, compared, 632-637
- Cell proliferation  
adipocyte precursor, from omental and subcutaneous AT of obese subjects, compared, 632-637  
in head and neck squamous cell carcinoma, effects of cellular CRABP-I mRNA on CYP2-mediated catabolism of A11-*trans* retinoic acid and, 1007-1012
- Cellular retinoic acid binding protein-1 (CRABP-1) mRNA (messenger ribonucleic acid), effects of, on CYP2-mediated catabolism of A11-*trans* retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012
- Cellulose in HF diet, 783, 1033
- Central hypothalamic-pituitary-adrenal axis (HPA), CRH test of relation between MS and dysregulation of, 720-726
- Central (luteinizing hormone) hypothesis of PCOS, 359-361
- Cerebral vascular disease in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Cerebrotendinous xanthomatosis (CTX), effectiveness of chenodeoxycholic acid, hydrophilic 7-hydroxy bile acids, lovastatin, and cholestyramine in, compared, 556-562
- Ceruloplasmin, plasma, and effects of Cu enzymes on CF before and after Cu supplementation with or without zinc, 37-41
- CETP, *see* Cholesteryl ester transfer protein
- CF, *see* Cystic fibrosis
- CHD, *see* Coronary heart disease
- Chemoattractant protein-1, *see* Monocyte chemoattractant protein-1
- Chenodeoxycholic acid (CDCA)  
effectiveness of hydrophilic 7 $\beta$ -hydroxy bile acids, lovastatin, and cholestyramine in CTX, compared, 556-562  
effects of, on 11 $\beta$ -hydroxysteroid dehydrogenase in various tissues, 811-816
- Children  
born small-for-gestational-age, oral glucose metabolism and whole-body glucose oxidation in, 847-851  
obese, preclinical changes in abdominal aorta of, 1243-1246  
*see also* Newborns; Race and ethnicity of children
- D-Chiro-inositol for obese PCOS women, 369-370
- Chloride, serum, beer ingestion and sauna bathing effects on urinary excretion of, 774
- CHO(s), *see* Carbohydrate(s)
- Cholestanol, plasma, in CTX, 558
- Cholesterol (C)  
blood, *see* Blood cholesterol  
in CAD men, as risk factor for myocardial infarction and, 325, 326  
CV disease risk factors and, 1438  
dietary, *see* Dietary cholesterol  
erythrocyte membrane, 574  
and glycemic control effects on F<sub>2</sub> isoprostane level at IDDM onset, 1119  
and GSK-3 $\beta$  in transgenic subjects, 1328  
in HD subjects, 1014  
in IR, serum GPI-PLD and, 139  
MHN-01 effects on concentration of, 981  
in NIDDM, *see* Cholesterol in NIDDM  
in obesity, adiponectin, CRP and, 1456, 1457  
plasma, *see* Plasma cholesterol  
 $\omega$ -3 PUFA and exercise effects on, 751  
serum, *see* Serum cholesterol  
smoking effects on, 860  
in soccer players, 1262-1267  
in STZ-DM, *see* Cholesterol in STZ-DM  
total, *see* Total cholesterol  
in young men with hypertensive parents, 470, 473  
*see also* Cholesterol acyltransferase; Cholesterol 7 $\alpha$ -hydroxylase; Cholesteryl ester transfer protein; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Low-density lipoprotein-cholesterol; Normocholesterolemia; Reverse cholesterol transport; Very-low-density lipoprotein-cholesterol
- Cholesterol (C) acyltransferase  
role of cholesterol absorption and activity of hepatic acyl-coenzyme A:, in lipemic response to HF/HIC diet, 817-822  
*see also* Lecithin:cholesterol acyltransferase
- Cholesterol 7 $\alpha$ -hydroxylase (CYP7A1), effects of ileal bile transport inhibition on plasma C level through FXR inactivation and stimulation of, 927-932
- Cholesterol (C) in NIDDM  
with dyslipidemia, rosiglitazone effects on, 1123  
in obese subjects, adiponectin and C-reactive protein and, 1456, 1457  
PP, alcohol effects on, 78, 79
- Cholesterol (C) in STZ-DM  
effects of oral vanadate with tea extract on, 1148  
NO-1886 effects on, 261
- Cholesteryl ester transfer protein (CETP)  
plasma, smoking effects on concentration of, 858-862  
*see also* Cholesteryl ester transfer protein,  $\omega$ -3 PUFA effects on
- Cholesteryl ester transfer protein (CETP),  $\omega$ -3 PUFA effects on  
in FCHL, 155  
and on LDL and HDL subfractions, 752
- Cholestyramine, effectiveness of hydrophilic 7-hydroxy bile acids, lovastatin, and chenodeoxycholic acid in CTX, compared, 556-562
- Choline bitartrate in obesity-inducing HF diet, 783
- Choline in HF diet, 1033
- Cholinephosphotransferase (CHPT) mRNA (messenger ribonucleic acid), renal, in NIDDM, 842-846



- Chorionic gonadotropin, human, low temperature blocking  
stimulatory effects of, on steroidogenic acute regulatory  
protein mRNA and testosterone production but not on cAMP  
production in tumor cells, 955-958
- CHPT (cholinephosphotransferase) mRNA (messenger ribonucleic  
acid), renal, in NIDDM, 842-846
- Chronic disease, inflammatory markers in inflammation of, 899-903
- Chronic renal disease with obesity and MS, apo A-1, apo B-48, and  
apo B-100 metabolism in, 1255-1261
- Chronic renal failure (CRF)  
atorvastatin effects on lipids, LDLs, and CRPs in dyslipidemic  
CRF subjects on HD, 1113-1117  
upregulation of lipogenic enzyme and SREBP-1 mRNA in WAT  
of subjects with, 1060-1065
- Chylomicrons in IDDM, plasma apo C-3 polymorphisms and, 1299,  
1301
- Cilostazol, effects of, on microalbuminuria in IR, 1405-1410
- Circadian rhythm  
of leptin after weight loss to reduce HF diet-induced obesity,  
leptin therapy to augment, 782-789  
of serum insulin concentration at low plasma glucose during  
fasting by lean and overweight subjects, 1449-1453
- Circulating adrenocorticotropin (ACTH: corticotropin), cortisol  
concentrations and, in normal appropriate-for-gestational-age  
newborns versus newborns with respiratory distress and  
sepsis, 209-214
- Circulating blood cells, effects of, on atherosclerosis in apo  
E-deficient subjects, 95-100
- Circulating cell adhesion molecules, and LDL susceptibility to  
oxidation in young Japanese subjects with NIDDM parents,  
755-759
- Circulating inflammation-sensitive molecules in men with CAD,  
acute effects of red and white wine drinking on, 318-323
- Circulating leptin, as marker of fat mass in acute spinal cord injury,  
989-994
- Cirrhosis  
DCA-induced hypolactatemia in, 1087-1094  
serum soluble TNF-R level associated with IR in, 922-926
- Citrate lyase, *see* Adenosine triphosphate-citrate lyase; Adenosine  
triphosphate-citrate lyase mRNA
- Citrulline, plasma, effects of, on whole-body protein synthesis in  
hyperinsulinemic young men, 392
- CK (creatinine kinase) in dyslipidemic CRF subjects on HD, 1116
- CL (citrate lyase), role of adenosine triphosphate-, in platelet acetyl-  
CoA metabolism and function in DM, 66-72
- CL316,243, effects of, on development of diabetes, 799-808
- Clinical manifestations  
of PCOS in obese and non-obese women, 365-367  
*see also specific conditions*
- Coenzyme A, *see* Acetyl-coenzyme A; Acetyl-coenzyme A  
carboxylase mRNA; Hepatic acyl-coenzyme A:cholesterol  
acyltransferase
- Cold temperature, *see* Exercise at cold temperature, NEFA oxidation  
during
- Collagen  
high glucose and insulin effects on synthesis of, in cardiac  
fibroblasts, 710-715  
and SR effects on bone matrix mineralization in MC3T3-E1  
osteogenic cells, 533
- Collagen (a<sub>1</sub>) IV, expression of renal, in IR, cilostazol effects on,  
1405-1410
- Collagen type I, aminoterminal propeptide in adrenal insufficiency,  
1252
- Collard greens, deuterium-labeled, plasma vitamin K transport and  
intake of, by men, 215-221
- Collecting duct, inner medullary, ET effects on AVP<sub>2</sub> mRNA in,  
1177-1183
- Combined hyperlipidemia, familial,  $\omega$ -3 PUFA effects on levels of  
plasma HDL<sub>2</sub>-C and paraoxonase in, 153-158
- Conscious subjects  
effects of hyperglycemia, glucagon, and epinephrine on renal  
glucose release in, 933-941  
portal venous hyperinsulinemia effects on gut glucose absorption  
in, 1290-1295
- Contraceptives, *see* Oral contraceptives
- Contractile protein, breakdown of skeletal muscle, [<sup>3</sup>H]-3-  
methylhistidine estimation of, 1076-1080
- Copper (Cu), effects of micromolar concentrations of, on  
endothelium-dependent aorta relaxation in DM, 1315-1321
- Copper (Cu) enzymes, effects of, on CF before and after Cu  
supplementation with or without zinc, 37-41
- Cord blood platelets, relationship between intracellular magnesium  
of, and birth weight, 1544-1547
- Cornstarch in obesity-inducing HF diet, 783
- Coronary artery disease (CAD)  
effects of exercise and high-fiber, low-fat diet on inflammatory  
and adhesion molecules in PM women on ERT and at risk  
for, 377-381  
in men, *see* Coronary artery disease in men  
*see also* Atherosclerosis
- Coronary artery disease (CAD) in men, 318-329  
acute effects of red and white wine drinking on circulating  
inflammation-sensitive molecules in, 318-323  
risk factors for myocardial infarction as predictors of, 324-329  
serum HDL-C level effects on association between plasma  
oxidized LDLs and, 423-429
- Coronary flow in early DM, effects of C-peptide and insulin on,  
335-339
- Coronary heart disease (CHD)  
high plasma HDL-C level in Spanish children, and low CHD  
mortality in Spain, 1045-1047  
low-grade inflammation and MS with, 852-857  
*see also* Coronary heart disease in NIDDM
- Coronary heart disease (CHD) in NIDDM  
with IGT, contribution of visceral AT and cardiorespiratory fitness  
to risk factors for, 644-649  
serum PON1 polymorphism, vascular complications, plasma  
oxidized LDL level and, 299
- Corrected QT intervals, association of carotid artery IMT with, in  
NIDDM, 1152-1157
- Cortex, *see* Renal cortex
- Corticosterone  
leptin effects on, in STZ-DM, 1560  
plasma, effects of 11 $\beta$ -HSD inhibition by glycyrrhetic acid on,  
602, 604
- Corticotropin, *see* Adrenocorticotropin hormone
- Corticotropin-releasing hormone (CRH) test of relation between  
central HPA dysregulation, MS and, 720-726
- Cortisol (hydrocortisone)  
acute effects of nicotine on, 578-582  
adrenal androgens and, in PCOS, 361  
circulating ACTH and concentrations of, in normal appropriate-  
for-gestational-age newborns versus newborns with  
respiratory distress and sepsis and, 209-214  
in hypoglycemia, 895  
in IR, 722  
in men, *see* Cortisol in men

- Cortisol (hydrocortisone) (*Continued*)  
 plasma, in adrenocortical disorders, 89-94  
 response of, to exercise in nondiabetic and IDDM smokers, 1142
- Cortisol (hydrocortisone) in men  
 with hypogonadism, 1174-1176  
 obese men, NEFA effects on levels of, 892
- COX (cyclooxygenase), effects of inhibition of, on apo A-1  
 promoter activity in hepatoma cells, 174-181
- CP, *see* C-peptide
- C-peptide (CP)  
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1090  
 in DM, *see* C-peptide in DM  
 fasting, *see* Fasting C-peptide  
 in IGT first-degree relatives of obese African American NIDDM subjects, 415  
 and IR in liver cirrhosis, 923  
 in obese men, NEFA effects on levels of, 892
- C-peptide (CP) in DM  
 effects of insulin and, on coronary flow in early DM, 335-339  
*see also* C-peptide in NIDDM
- C-peptide (CP) in NIDDM  
 glyburide and nateglinide effects on NIDDM and, 1332  
 in older NIDDM men with partial androgen deficiency, 670
- CRABP-1 (cellular retinoic acid binding protein-1) mRNA  
 (messenger ribonucleic acid), effects of, on CYP26-mediated catabolism of A11-*trans* retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012
- C-reactive protein (CRP)  
 adiponectin and, *see* Adiponectin, CRP and  
 atorvastatin effects on lipids, LDLs and, in dyslipidemic CRF subjects on HD, 1113-1117  
 in CHD, 853, 854  
 effects of  $\omega$ -3 PUFAs alone or with *all-rac*  $\alpha$ -tocopherol on, 236-240  
 in hypothyroidism, *see* C-reactive protein in hypothyroidism  
 in inflammation of chronic disease, 901, 902  
 in NIDDM, *see* C-reactive protein in NIDDM  
 in non-obese men, and AT as predictor of fibrinogen level, 985, 986  
 in obesity, *see* C-reactive protein in obesity  
 plasma, association between lifestyle, cardiovascular risk factors and, 1436-1442  
 PP, OC effects on, 350, 351  
 serum, *see* Serum C-reactive protein
- C-reactive protein (CRP) in hypothyroidism  
 effects of T<sub>4</sub> therapy on endothelial function and, 279  
 subclinical hypothyroidism, CV disease risk factors and, 1513
- C-reactive protein (CRP) in NIDDM  
 and in at-risk NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224, 226  
 and effects of insulin therapy of NIDDM on serum high-sensitivity, 693-699
- C-reactive protein (CRP) in obesity  
 obese children, 1244  
 obese women, effects of moderate weight loss and sibutramine or orlistat on, 432  
*see also* C-reactive protein in obesity, weight loss effects and
- C-reactive protein (CRP) in obesity, weight loss effects and effects of moderate weight loss and sibutramine or orlistat by obese women and, 432  
 weight loss effects on IR and insulin release in obese subjects with normal FPG or IGT, 1097
- Creatinine  
 and *ABCA1* gene expression-fasting glucose relationship in normoglycemic men, 19  
 beer ingestion and sauna bathing effects on, 773-774  
 in chronic renal disease, 1256  
 in disabled hospitalized older subjects, HHcy and, 1018  
 and IR, *see* Creatinine in IR  
 in NIDDM, *see* Creatinine in NIDDM  
 serum, *see* Serum creatinine  
 in severe lipodystrophy, leptin replacement therapy effects on, 516  
 and smoking-ADMA-obesity relationship, 1575, 1576  
 in STZ-DM, effects of oral vanadate with tea extract on, 1148  
 in subclinical hypothyroidism, 1513
- Creatinine in IR  
 with cardiovascular autonomic dysfunction, microalbuminuria, 1360, 1362  
 and cilostazol effects on microalbuminuria, 1407  
 with liver cirrhosis, 923
- Creatinine kinase (CK) in dyslipidemic CRF subjects on HD, 1116
- Creatinine in NIDDM  
 and at-risk subjects for NIDDM, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 226  
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362  
 effects of glycemic control of NIDDM on, 353-357
- CRF, *see* Chronic renal failure
- CRH (corticotropin-releasing hormone) test of relation between central HPA dysregulation and MS, 720-726
- CRP, *see* C-reactive protein
- CS-045, *see* Troglitazone
- CTX (cerebrotendinous xanthomatosis), effectiveness of chenodeoxycholic acid, hydrophilic 7 $\beta$ -hydroxy bile acids, lovastatin, and cholestyramine in, compared, 556-562
- Cu, *see* Copper; Copper enzymes
- Cyclic adenosine monophosphate, *see* cAMP
- Cyclooxygenase (COX), effects of inhibition of, on apo A-1  
 promoter activity in hepatoma cells, 174-181
- CYP7A1 (cholesterol 7-hydroxylase), effects of ileal bile transport inhibition on plasma C level through FXR inactivation and stimulation of, 927-932
- CYP17 genes, mutant, in 17( $\alpha$ )-hydroxylase/17,20-lyase deficiency, 1527-1531
- CYP26-mediated catabolism of A11-*trans* retinoic acid, CRABP-1 effects on cell proliferation in head and neck squamous cell carcinoma and, 1007-1012
- Cystathionine- $\beta$ -synthase (CBS) deficiency, betaine effects in, 594-599
- Cystic fibrosis (CF)  
 adult, effects of Cu enzymes in, before and after Cu supplementation with or without zinc, 37-41  
 with impaired glucose tolerance, insulin regulating kinetics of NEFAs in, 1467-1472
- L-Cystine in obesity-inducing HF diet, 783
- Daytime hypertriglyceridemia (HTG) in normocholesterolemic and prematurely atherosclerotic subjects and in their first-degree relatives, 49-53
- Daytime hypoglycemia, differences in counterregulation of nighttime and, 894-898
- DCA (dichloroacetate), hypolactatemia induced by, in cirrhotic and noncirrhotic subjects, 1087-1094
- D-CCBs (dihydropyridine calcium channel blockers) in NIDDM, effects of, on microalbuminuria, 354
- Deaminase, adenosine, interaction between ACP1 polymorphism and, in NIDDM, 995-1001

- Dehydroepiandrosterone sulfate (DHEA-S)  
 in premenopausal women, plasma Lp and, 189, 190  
*see also* Dehydroepiandrosterone sulfate in PM women
- Dehydroepiandrosterone sulfate (DHEA-S) in PM women  
 in insulin-sensitive women, 508-509  
 plasma Lp and, 189, 190
- Dehydrogenase  
 lactate, glutamate, and pyruvate, DM effects on, 68  
*see also* Glucose-6-phosphate dehydrogenase mRNA; 6-Phosphogluconate-dehydrogenase mRNA and entries  
*beginning with terms:* 11 $\beta$ -Hydroxysteroid dehydrogenase
- Delayed vasorelaxation by troglitazone, 4AP effects on, 147-152
- Dementia, vascular, sdLDLs, carotid atherosclerosis and, 476-482
- Dense low-density lipoprotein, *see* Small-dense low-density lipoprotein
- Denudation of carotid arteries, effects of elevated plasma Hcy on endothelial function recovery after, 760-765
- Deoxyypyridinol, urinary excretion of, in severe lipodystrophy, leptin replacement therapy effects on, 516
- Deoxyribonucleic acid, *see* DNA synthesis in fibroblasts
- Deuterium-labeled collard greens, plasma vitamin K transport and intake of, by men, 215-221
- Dextrin  
 maltose, in obesity-inducing HF diet, 783  
 in MNH-01 formula, 978
- DHEA-S, *see* Dehydroepiandrosterone sulfate
- Diabetes (maturity-onset hyperinsulinemia and hyperglycemia), CL316.243 effects on, in polygenic obesity, 799-808
- Diabetes mellitus (DM)  
 $\beta_3$ -ADR Trp64Arg polymorphism in Taiwanese women with gestational, 1136-1139  
 in CAD men, 424-426  
 early, effects of C-peptide and insulin on coronary flow in, 335-339  
 effects of exercise on hepatic insulin signaling and hepatic PEPC activity in subjects prone to, 836-841  
 effects of micromolar copper concentrations on aorta endothelium-dependent relaxation in, 1315-1321  
 serum leptin, serum adiponectin, and serum soluble leptin receptor levels in Japanese subjects with, 880, 881  
 stability over time of GHb, glucose, and RBC survival in hematologically stable subjects without, 1399-1403  
*see also* Diabetes; Glycemic control of DM; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Parental diabetes mellitus; Prediabetic subjects; Streptozotocin-induced diabetes mellitus and entries  
*beginning with term:* Diabetic
- Diabetic microangiopathies in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 300
- Diabetic nephropathy, *see* Non-insulin-dependent diabetes mellitus nephropathy
- Diabetic retinopathy, *see* Non-insulin-dependent diabetes mellitus retinopathy
- Dialysis, *see* Hemodialyzed subjects
- Diamine oxidase, plasma, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Diastolic pressure, *see* Blood pressure
- Diazoxide (DZ), effects of NN414 and, on glucose tolerance and lipids in obesity, compared, 441-447
- Dichloroacetate (DCA), hypolactatemia induced by, in cirrhotic and noncirrhotic subjects, 1087-1094
- Diet  
 association between lifestyle, cardiovascular risk factors, plasma CRPs and, 1436-1442
- Diet (Continued)  
 composition of, as determinant of ADMA in mild hypercholesterolemia, 1072-1075; *see also* specific food groups and dietary substances  
*see also* Caloric intake; Drinking; Dysphagia; Energy intake; Fasting; Food intake; Total parenteral nutrition and entries  
*beginning with terms:* Dietary, Postprandial
- Dietary carbohydrates, *see* Carbohydrate intake
- Dietary cholesterol (C)  
 CV disease risk factors and, 1438  
 intake of, by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51  
 plasma 27-hydroxycholesterol and plasma 7 $\alpha$ -hydroxy-4-cholesten-3-one as markers for hepatic bile synthesis and, 42-48  
*see also* High-cholesterol diet
- Dietary fat  
 apo E polymorphism in Vietnamese children and intake of, 1519  
 L-carnitine effects on protein turnover, body composition and, in slightly overweight subjects, 1001-1006  
 CV disease risk factors and intake of, 1439  
 PPAR $\gamma$  Pro12Ala polymorphism effects on association of exercise and, with fasting insulin level, 11-16  
 uncoupling protein-3 polymorphism and intake of, 460, 461  
 WPG and, 1312  
*see also* Fatty acid(s); High-fat diet; Low-fat diet and specific types of dietary fats
- Dietary fiber, *see* Fiber
- Dietary oils, *see* specific dietary oils
- Dietary proline (Pro) with and without glucose, metabolic response to, 241-246
- Dietary protein intake  
 apo E polymorphism and, by Vietnamese children, 1519  
 effects of, on whole-body protein synthesis in hyperinsulinemic young men, 389  
 with HF diet, 783, 1033  
 in MNH-01 formula, 978  
 by normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia and by their first-degree relatives, 51  
 plasma ADMA in mild hypercholesterolemia and, 1073  
 restricted, effects of, on proteasome production in skeletal muscle, 340-347
- Dietary restriction  
 effects of, on PPAR $\gamma$  and glucocorticoid receptor signaling in AT, 28-36  
 effects of protein, on proteasome production in skeletal muscle, 340-347  
 of zinc, effects of, on metabolic rate and substrate utilization, 727-732
- Differentiation, proliferation and, of adipocyte precursor cells from omental and subcutaneous AT of obese subjects, compared, 632-637
- Dihydropyridine calcium channel blockers (D-CCBs) in NIDDM, effects of, on microalbuminuria, 354
- 3,3'-Diiodothyronine sulfate (3,3'-T<sub>2</sub>S) in thyroidal diseases, nonthyroidal diseases, pregnancy, and fetal/neonatal life, 538-543
- Dimethylarginine, *see* Asymmetric dimethylarginine
- Dimethyl-BAPTA/AM [bis(o-aminophenoxy)ethane-N,N',N') tetraacetic acetoxymethyl ester], effects of, on IR and spontaneous hypertension, high-fat diet and, 269-272
- Dimethylbiguanide, *see* Metformin

- Dimethylsulfonylacetate (DMSA), effects of, in cystathionine- $\beta$ -synthase deficiency, 594-599
- Dipeptylpeptidase (DPP) IV, effects of Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution in GLP-1(7-36) amide on resistance of, with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Disabled older subjects, hospitalized, HHcy in, 1016-1020
- Dismutase, erythrocyte superoxide, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Distress, respiratory, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with sepsis and, 209-214
- Diuresis, changes in renal cortex oxygenation and endothelial function induced by water in NIDDM and in at-risk for NIDDM subjects, 222-227
- DM, *see* Diabetes mellitus
- DMSA (dimethylsulfonylacetate), effects of, in cystathionine- $\beta$ -synthase deficiency, 594-599
- DNA (deoxyribonucleic acid) synthesis in fibroblasts in cardiac fibroblasts, high glucose and insulin effects on collagen, 710-715 and myocytes, 128-133
- Dose-dependent rebaudioside A, effects of, on insulin secretion, 1378-1381
- DPP (dipeptylpeptidase) IV, effects of Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution in GLP-1(7-36) amide on resistance of, with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Drinking effects of sauna bathing and beer, on plasma concentration of purine bases, 772-776 *see also* Alcohol intake; Wine drinking
- Dyslipidemia  
  FFFS-410 effects on, 1532-1537  
  *see also* Dyslipidemia in NIDDM; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia
- Dyslipidemia in NIDDM  
  with IGT, contribution of cardiorespiratory fitness and visceral AT to hyperinsulinemia, hypertension and, 644-649  
  rosiglitazone effects on insulin regulation in, 1121-1125
- Dysphagia, leptin effects on HPA axis activity, weight loss and, in STZ-DM, 1558-1564
- DZ (diazoxide), effects of NN414 and, on glucose tolerance and lipids in obesity, compared, 441-447
- E<sub>2</sub>, *see* Estradiol
- Early diabetes mellitus (DM), C-peptide and insulin effects on coronary flow in, 335-339
- Early non-insulin-dependent diabetes mellitus (NIDDM) nephropathy, pioglitazone effects on, 1473-1479
- Early-onset non-insulin-dependent diabetes mellitus (NIDDM), triple mutations of *HNF-4a* gene associated with, in Filipino family, 959-963
- ECs (endothelial cells) in omental and subcutaneous AT in obese subjects, compared, 635
- Ecuadoran Amazon Shuar women, effects of agricultural versus traditional lifestyle on leptin in, 1355-1358
- EFA, *see* Essential fatty acids
- Elaidic acid, effects of, on Sp1-induced apo A-1 promoter, 1344
- Elderly subjects, *see* Older subjects
- Endometrial cancer, risk for, in obese PCOS women, 366
- Endothelial cells (ECs) in omental and subcutaneous AT in obese subjects, compared, 635
- Endothelial function  
  effects of elevated plasma Hcy on recovery of, after denudation of carotid arteries, 760-765  
  effects of thyroxine therapy of hypothyroidism on, 278-279  
  fluvastatin effects on, in obese PM women via sdLDL reduction, 733-739  
  water diuresis-induced changes in renal cortex oxygenation and, in NIDDM and in at-risk for NIDDM subjects, 222-227
- Endothelial growth factor, plasma vascular, relation between concentration of plasma VEGF, glycemic control and, in DM, 550-555
- Endothelial nitric oxide synthase (eNOS) in early NIDDM nephropathy, 1474
- Endothelin (ET)  
  effects of, on AVP<sub>2</sub> mRNA in IMCD, 1177-1183  
  plasma, relation between concentration of plasma VEGF, glycemic control and, in DM, 550-555
- Endothelin-1 (ET-1)  
  high glucose and insulin effects on expression of, in cardiac fibroblasts, 712  
  in NIDDM and in at-risk for NIDDM subjects, 224, 226
- Endothelium-dependent relaxation of aorta in DM, effects of micromolar copper concentrations on, 1315-1321
- Endurance exercise  
  apo E genotype and changes in serum lipids and VO<sub>2max</sub> during, 193-202  
  plasma nitrate/nitrite assessment during OGTT in sedentary subjects after, 673-679
- Energy expenditure  
  in endurance training, VO<sub>2max</sub> and, 195  
  *see also* Resting energy expenditure
- Energy intake  
  with HF diet, 1033  
  by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51  
  by Vietnamese children, apo E polymorphism and, 1519  
  WPG and, 1312  
  *see also* Diet
- Energy substrate oxidation in IDDM, 655-659
- eNOS (endothelial nitric oxide synthase) in early NIDDM nephropathy, 1474
- Epidemiology of PCOS, 358-359
- Epinephrine (adrenaline)  
  effects of glucagon, hyperglycemia and, on renal glucose release in conscious subjects, 933-941  
  effects of ionomycin and, on skeletal muscle IL-6 mRNA and protein release, compared, 1492-1495  
  nighttime and daytime differences in counterregulation of hypoglycemia and, 895  
  in obese men, NEFA effects on levels of, 892  
  plasma, leptin effects on, in STZ-DM, 1560
- ERT (estrogen replacement therapy), *see* Postmenopausal women on ERT, exercise effects in
- Erythrocyte(s) (red blood cell; RBC)  
  stability over time of GHb, glucose, and survival of, in hematologically stable subjects without DM, 1399-1403  
  WPG effects on, 1312  
  *see also* Erythrocyte magnesium; Erythrocyte membrane, lipid composition of; Erythrocyte superoxide dismutase
- Erythrocyte (red blood cell; RBC) folate in subclinical hypothyroidism, 1513
- Erythrocyte (red blood cell; RBC) magnesium (Mg), levels of, and Mg metabolism, 660-665



- Erythrocyte (red blood cell; RBC) membrane, lipid composition of associated with arachidonic acid in men, insulin sensitivity and, 571-577  
in NIDDM, HbA<sub>1c</sub> correlation with, 123-127
- Erythrocyte (red blood cell; RBC) superoxide dismutase (SOD), effects of Cu enzymes in CF before and after Cu supplementation with or without zinc, 37-41
- Essential fatty acids (EFA)  
regulation of serum lipids deficient in, in short-gut subjects on lipid-containing total parenteral nutrition, 273-277  
*see also* Arachidonic acid; Linoleic acid;  $\gamma$ -Linolenic acid; 3n3  $\alpha$ -Linolenic acid
- Established preeclampsia, IR and inflammation in, 1433-1435
- Estradiol (E<sub>2</sub>)  
carotid atherosclerosis, vascular dementia and, 477  
in PM and premenopausal women, plasma Lp and, 189
- Estrogen  
in PCOS, 361-362  
and role of androgens in estrogen-deficient state, 187-192
- Estrogen receptor modulators, effects of selective, on GH secretion, 563-570
- Estrogen replacement therapy, *see* Postmenopausal women on ERT, exercise effects in
- Estrone in PM and premenopausal women, plasma Lp and, 189
- Estrous cycle, Lp during, 140-141
- ET, *see* Endothelin
- ET-1, *see* Endothelin-1
- Ethanol, *see* Alcohol
- Eucalcemia, serum PTH relation to vitamin D profile in, after parathyroidectomy for primary hyperthyroidism, 1101-1106
- Evening primrose oil (PO), effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
- Exendin (9-39), effects of Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution in GLP-1(7-36) amide on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and, 252-259
- Exercise  
at cold temperature, *see* Exercise at cold temperature, NEFA oxidation during  
endurance, *see* Endurance exercise  
moderate, *see* Moderate exercise  
by nondiabetic and IDDM smokers, pituitary response to, 1140-1144  
OC effects on glucoregulatory responses to, 348-352  
 $\dot{V}O_{2max}$  during, *see*  $\dot{V}O_{2max}$  during exercise  
*see also* Exercise, effects of; Physical activity
- Exercise, effects of  
on cholesterol efflux in soccer players, 1262-1267  
on glycogen synthase activity and GLUT<sub>4</sub> mRNA but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242  
hypoxic, on hepatic 8-OHdG and GSH levels, 716-719  
on inhibitory effects of NE on insulin secretion, 1424-1432  
on PP lipemia after high-fat/high-cholesterol meal, 1021-1026  
on risk for metabolic syndrome, 1505, 1508  
of swimming exercise on hepatic glucose production in response to glucagon, 1027-1031  
*see also* Exercise, effects of diet and; Postmenopausal women on ERT, exercise effects in; Resistance exercise effects
- Exercise, effects of diet and  
of dietary fat association with fasting insulin level and, Pro12Ala polymorphism of PPAR $\gamma$  on, 11-16  
effects of soy isoflavone with, on AT accumulation and bone loss in postmenopausal subjects, 942-948
- Exercise, effects of diet and (*Continued*)  
on hepatic insulin signaling and hepatic PEPCK activity in diabetes-prone subjects, 836-841  
of high-fiber/low-fat diet and exercise, inflammatory and adhesion molecules in postmenopausal women on ERT and at-risk for CAD, 377-381  
moderate exercise and soy isoflavone effects on AT accumulation and bone loss in PM subjects, 942-948; *see also* Postmenopausal women, effects of diet with exercise in;  
Postmenopausal women on ERT, exercise effects in  
on PP lipemia after high-fat/high-cholesterol meal, 1021-1026  
relationship between alcohol intake, adiposity and, on HDL-C levels, 700-709  
*see also* Exercise, effects of  $\omega$ -3 PUFAs with
- Exercise, effects of  $\omega$ -3 PUFAs with  
on LDL and HDL subfractions, 749-754  
on postprandial lipemia, 1365-1371
- Exercise at cold temperature, NEFA oxidation during  
acipimox-induced plasma NEFA oxidation, 1131-1136  
and substrate oxidation, 203-208
- Exogenous insulin, *see* Insulin therapy
- Exposure, long-term, to *cis* and *trans* FAs, on insulin secretion and FA oxidation in INS-1 cells, 1158-1165
- F, *see* Fructose
- F<sub>2</sub> isoprostane, effects of glycemic control on level of, at IDDM onset, 1118-1120
- FA(s), *see* Fatty acid(s)
- FABP4 (fatty acid-binding protein-4) polymorphism, effects of interaction between PPAR $\gamma$ -activated receptor polymorphism and, on insulin sensitivity and body composition in men, 303-309
- Factor VII in young subjects with NIDDM parents, 756
- Familial combined hyperlipidemia (FCHL),  $\omega$ -3 PUFA effects on levels of plasma HDL<sub>2</sub>-C and paraoxonase in, 153-158
- Familial early-onset non-insulin-dependent diabetes mellitus (NIDDM), triple mutations of *HNF-4 $\alpha$*  gene in Filipino family, 959-963
- Familial hypercholesterolemia, effects of S-2E and PRV in, compared, 680-685
- Farnesoid X receptor (FXR), hepatic, effects of ileal bile transport inhibition on plasma C level through cholesterol 7 $\alpha$ -hydroxylase stimulation and inactivation of, 927-932
- FAS (fatty acid synthase) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Fasting  
by non-obese and overweight subjects, preservation of circadian rhythm of serum insulin concentration at low plasma glucose during, 1449-1453  
pinelectomy effects on AT adaptability to, 500-506  
in preeclampsia, 1434  
*see also* entries beginning with term: Fasting
- Fasting adiponectin in insulin-resistant obese women, effects of moderate weight loss on, 281
- Fasting blood glucose (FBG)  
in adolescents, *see* Fasting blood glucose in adolescents  
in GH-deficient subjects, rhGH therapy effects on, 741  
in Korean women, AT distribution and, 1541  
in Kuwaiti IDDM children, CV disease risk factors and, 640  
in NIDDM, *see* Fasting blood glucose in NIDDM  
in obesity, *see* Fasting blood glucose in obesity
- Fasting blood glucose (FBG) in adolescents  
Kuwaiti IDDM adolescents, CV disease risk factors and, 640

- Fasting blood glucose (FBG) in adolescents (*Continued*)  
 postpubertal Asian Indian adolescents, 1338
- Fasting blood glucose (FBG) in NIDDM  
 with IGT, 646  
 in Japanese subjects with incipient nephropathy, 1224  
 in older men with partial androgen deficiency, 670
- Fasting blood glucose (FBG) in obesity  
 in Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057  
 in treatment-seeking obese subjects with IR, 436
- Fasting C-peptide (CP)  
 and effects of OCs on glucoregulatory responses to exercise, 350, 351  
 in GDM,  $\beta_3$ -ADR Trp64Arg polymorphism and, 1138  
 in IGT, *see* Fasting C-peptide in IGT  
 in non-obese subjects, *see* Fasting C-peptide in non-obese subjects  
 in older NIDDM men with partial androgen deficiency, 668  
 in overweight subjects, 1451
- Fasting C-peptide (CP) in IGT  
 of first-degree relatives of African American NIDDM subjects, 1553  
 in non-obese subjects, 625, 627, 628
- Fasting C-peptide (CP) in non-obese subjects  
 circadian rhythm of serum insulin concentration at low plasma glucose and, 1451  
 with IGT, 625, 627, 628
- Fasting C-reactive protein (CRP) in normal FPG, IGT, or IR, 1096, 1097
- Fasting gastric inhibitory polypeptide (GIP) in non-obese IGT subjects, 625
- Fasting glucose  
 adiponectin and, *see* Fasting glucose, adiponectin and blood, *see* Fasting blood glucose  
 concentration of, associated with leukocyte *ABCA1* gene expression in normoglycemic men, 17-21  
 and erythrocyte membrane lipid composition, 574  
 exercise and, *see* Fasting glucose, exercise and  
 in GDM Taiwanese women with  $\beta_3$ -ADR Trp64Arg polymorphism, 1138  
 and glycemic control effects on F<sub>2</sub> isoprostane level at IDDM onset, 1119  
 in IDDM, oxidation of glycated and nonglycated LDLs and, 970  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 in IR, *see* Fasting glucose in IR  
 in LBW Pima Indians with normal glucose tolerance, 906  
 in lipodystrophic HIV-infected subjects, 1567  
 in NIDDM, *see* Fasting glucose in NIDDM  
 in non-obese subjects, *see* Fasting glucose in non-obese subjects  
 in obesity, *see* Fasting glucose in obesity  
 in PM women, *see* Fasting glucose in PM women  
 in young subjects, *see* Fasting glucose in young subjects
- Fasting glucose, adiponectin and  
 adiponectin levels and, 2  
 adiponectin regulation by NEFAs and, 791
- Fasting glucose, exercise and  
 exercise effects on, in overweight nondiabetic and NIDDM subjects, 1236  
 and OC effects on glucoregulatory responses to exercise, 350, 351  
 and plasma nitrate/nitrite in sedentary and exercising subjects, 675
- Fasting glucose in IR  
 central HPA dysfunction and, 722, 724  
*see also* Fasting glucose in IR with obesity
- Fasting glucose in NIDDM (*Continued*)  
 and in at-risk for NIDDM subjects, 226  
 exercise effects on, 1236  
 in non-obese insulin-resistant Korean subjects, BMI and, 143  
 with obesity, adiponectin, C-reactive protein and, 1456, 1457  
*see also* Fasting plasma glucose in NIDDM
- Fasting glucose in non-obese insulin-resistant subjects  
 non-obese insulin-resistant Korean subjects, BMI and, 143  
 prevalence of IR and associated CV disease risk factors NS, 498
- Fasting glucose in non-obese subjects  
 with IGT, 625  
 men, and AT as fibrinogen level predictor, 985, 986  
 premenopausal women, metabolic risk and, 1068-1070  
*see also* Fasting glucose in non-obese insulin-resistant subjects
- Fasting glucose in obese insulin-resistant subjects  
 in obese women, effects of moderate weight loss on, 281  
 prevalence of IR and associated CV disease risk factors and, 498
- Fasting glucose in obese women  
 insulin-resistant women, effects of moderate weight loss on, 281  
 insulin-sensitive women and, 508  
 plasma, *see* Fasting plasma glucose  
 PM women, fluvastatin effects on, 735, 736  
 in SCI men, MS and, 1373, 1374  
 in treatment-seeking subjects, 436
- Fasting glucose in obesity  
 in children, 1244  
 with NIDDM, adiponectin, C-reactive protein and, 1456, 1457  
*see also* Fasting glucose in obese insulin-resistant subjects; Fasting glucose in obese women
- Fasting glucose in PM women  
 fluvastatin effects on, 735, 736  
 obese PM women, fluvastatin effects on, 735, 736
- Fasting glucose in young men  
 Pro12Ala PPAR $\gamma$ 2 polymorphism, adiponectin and, in young Japanese men, 1549  
 serum adiponectin and, 590
- Fasting glucose in young subjects  
 with NIDDM parents, 756  
*see also* Fasting glucose in young men
- Fasting immunoreactive insulin (IRI), and effects of weight loss by obesity with normal FPG or IGT on IR and insulin release, 1096, 1097
- Fasting insulin  
 adiponectin and, *see* Fasting insulin, adiponectin and  
 and erythrocyte membrane lipid composition, 574  
 exercise and, *see* Fasting insulin, exercise and  
 in GDM,  $\beta_3$ -ADR Trp64Arg polymorphism and, 1138  
 in GH-deficient subjects, rhGH therapy effects on, 741  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 immunoreactive, and effects of weight loss by obese subjects with normal FPG or IGT on IR and insulin release, 1096-1097  
 insulin sensitivity and, *see* Fasting insulin, insulin sensitivity and  
 in IR, *see* Fasting insulin in IR  
 in LBW Pima Indians with normal glucose tolerance, 906  
 in lipodystrophic HIV-infected subjects, 1567  
 in MS, *see* Fasting insulin in MS  
 in NIDDM, *see* Fasting insulin in NIDDM  
 in non-obese subjects, *see* Fasting insulin in non-obese subjects  
 in obesity, *see* Fasting insulin in obesity  
 plasma, *see* Fasting plasma insulin  
 in PM women, *see* Fasting insulin in PM women  
 in postpubertal Asian Indian adolescents, 1338  
 in young subjects, *see* Fasting insulin in young subjects



- Fasting insulin, adiponectin and  
adiponectin levels and, 2  
adiponectin regulation by NEFAs and, 791
- Fasting insulin, exercise and  
and OC effects on glucoregulatory responses to exercise, 350, 351  
and plasma nitrate/nitrite in sedentary and exercising subjects, 675  
PPAR $\gamma$  polymorphism effects on dietary fat-physical activity  
association with fasting insulin level, 11-16
- Fasting insulin, insulin sensitivity and  
estimates of insulin sensitivity, 1109  
and relationship between BMI, IR, and beta-cell function, 1463
- Fasting insulin in IR  
and associated CV disease risk factors in overweight subjects, 498  
and relationship between obesity, IR, and beta-cell function, 1463  
*see also* Fasting insulin in non-obese insulin-resistant subjects
- Fasting insulin in MS, 312  
in SCI men, 1373, 1374
- Fasting insulin in NIDDM  
exercise effects on, 1236  
with IGT, 646  
in non-obese insulin-resistant NIDDM Korean subjects, BMI and, 142  
in older men with partial androgen deficiency, 668
- Fasting insulin in non-obese insulin-resistant subjects  
in insulin-resistant NIDDM Korean subjects, BMI and, 142  
and prevalence of IR and associated CV disease risk factors, 498
- Fasting insulin in non-obese subjects  
with IGT, 625  
insulin-resistant NIDDM Korean subjects, BMI and, 142  
non-obese men, and AT as fibrinogen level predictor in, 985, 986
- Fasting insulin in obesity  
in children, 1244  
in PM women, fluvastatin effects on, 735, 736  
prevalence of IR and associated CV disease risk factors and, 498
- Fasting insulin in PM women  
insulin sensitivity and, 508, 509  
obese PM women, fluvastatin effects on, 735, 736
- Fasting insulin in young subjects  
with NIDDM parents, 756  
Pro12Ala PPAR $\gamma$ 2 polymorphism, adiponectin and, in young  
Japanese men, 1549  
serum adiponectin and, in young men, 590
- Fasting leptin, effects of weight loss by obese subjects with normal  
FPG or IGT on, 1097
- Fasting nonesterified fatty acids (NEFAs; free fatty acids), serum, in  
obese NIDDM subjects, bezafibrate effects on, 407-408
- Fasting plasma glucose (FPG)  
carotid atherosclerosis, vascular dementia and, 477  
in IR, *see* Fasting plasma glucose in IR  
in Japanese subjects with beta-cell dysfunction, 950-952  
in NIDDM, *see* Fasting plasma glucose in NIDDM  
in obesity, *see* Fasting plasma glucose in obesity  
stevioside effects on, 102
- Fasting plasma glucose (FPG) in IR  
in Japanese subjects, 651, 652  
with LVH, candesartan effects on, 779
- Fasting plasma glucose (FPG) in NIDDM  
and association of corrected QT intervals with carotid artery IMT, 1153  
and in at-risk subjects for NIDDM, 224  
glyburide and nateglinide effects and, 1332  
insulin therapy effects on, 694, 697, 698  
metformin effects on, 160, 161  
microalbuminuria and, 354
- Fasting plasma glucose (FPG) in NIDDM (*Continued*)  
with obesity, pioglitazone effects on, 489-490  
in older men with partial androgen deficiency, 668  
Pancreas Tonic effects on, 1169  
with retinopathy, 583-588
- Fasting plasma glucose (FPG) in obesity  
with NIDDM, pioglitazone effects on, 489-490  
normal, effects of weight loss on insulin release and IR in subjects  
with IGT or, 1095-1100  
obese adolescents, 864, 865
- Fasting plasma insulin (FPI)  
in NIDDM with obesity, pioglitazone effects on, 489-490  
stevioside effects on, 102
- Fasting plasma nitrate/nitrite (NO $_x$ ), OGTT assessment of, in  
sedentary and exercising subjects, 675
- Fasting plasminogen activator inhibitor-1 (PAI-1), effects of weight  
loss by obese subjects with normal FPG or IGT on, 1097
- Fasting serum nonesterified fatty acids (NEFAs) in obese NIDDM  
subjects, bezafibrate effects on, 407-408
- Fasting triglycerides (TGs)  
and adiponectin regulation by NEFAs, 791  
plasma, pioglitazone effects on, 489-490  
*see also* Fasting triglycerides in NIDDM
- Fasting triglycerides (TGs) in Japanese NIDDM subjects  
incipient NIDDM, 1224  
insulin secretion, insulin resistance and, 832
- Fasting triglycerides (TGs) in NIDDM  
Pancreas Tonic effects on, 1169  
*see also* Fasting triglycerides in Japanese NIDDM subjects;  
Fasting triglycerides in obese NIDDM subjects
- Fasting triglycerides (TGs) in obese NIDDM subjects  
bezafibrate effects on, 407-408  
plasma, pioglitazone effects on, 489-490
- Fat-free mass (FFM)  
in acute SCI subjects, 990, 991  
in Ecuadoran Amazon Shur women, 1356  
effects of interaction between FABP-4 and PPAR $\gamma$ -activated  
receptor polymorphism on, in men, 304  
food intake-uncoupling protein-3 polymorphism association and, 460  
of hyperinsulinemic young men, whole-body protein synthesis  
and, 389  
in IGT first-degree relatives of obese African American NIDDM  
subjects, 415, 417  
of LBW Pima Indians with normal glucose tolerance, 906  
in NIDDM, *see* Fat-free mass in NIDDM  
in obesity, *see* Fat-free mass in obesity  
in older hypertensive subjects, resistance exercise effects on  
insulin-mediated glucose disposal and, 399  
and overweight women, serum TNF soluble receptors, TNF- $\beta$ , and  
NO and, 1269  
in severe lipodystrophy, leptin replacement therapy effects on, 516
- Fat-free mass (FFM) in NIDDM  
Pancreas Tonic effects on, 1169  
with polygenic obesity, CL316,243 effects on, 801-802
- Fat-free mass (FFM) in obesity  
in insulin-resistant Japanese subjects, 651  
in Korean subjects, -3826A $\square$ G UCP-1 polymorphism and, 1056  
polygenic obesity, CL316,243 effects on, 801-802  
after RYBG and ASGB for morbid obesity, 920
- Fat mass (FM)  
circulating leptin as marker of, in acute spinal cord injury, 989-  
994  
in Ecuadoran Amazon Shur women, 1356

Fat mass (FM) (*Continued*)

- effects of interaction between FABP-4 and PPAR $\gamma$ -activated receptor polymorphism on, 304
- and food intake-uncoupling protein-3 polymorphism association with body composition, 460
- in IDDM, and insulin concentration and CHO requirement during moderate exercise, 1127
- in IGT first-degree relatives of obese African American NIDDM subjects, 415, 417
- of LBW Pima Indians with normal glucose tolerance, 906
- in lipodystrophy, *see* Fat mass in lipodystrophy
- in MS subjects, 312, 313, 315
- in NIDDM, *see* Fat mass in NIDDM
- in obesity, *see* Fat mass in obesity
- resistance exercise and, *see* Fat mass, resistance exercise effects on
- see also* Adipose tissue
- Fat mass (FM) in lipodystrophy
  - in severe lipodystrophy, leptin replacement therapy effects on, 516
  - total, in lipodystrophic HIV-infected subjects, 1567
- Fat mass (FM), resistance exercise effects on
  - in NIDDM women, 284-289
  - in older hypertensive subjects, 399
- Fat mass (FM) in lipodystrophy
  - in severe lipodystrophy, leptin replacement therapy effects on, 516
  - total, in lipodystrophic HIV-infected subjects, 1567
- Fat mass (FM) in NIDDM
  - Pancreas Tonic effects on, 1169
  - in women, 284-289
- Fat mass (FM) in obesity
  - in insulin-resistant Japanese subjects, 651
  - in Korean subjects, -3826A $\rightarrow$ G UCP-1 polymorphism effects on level of LDL-C and, 1056, 1058
  - in morbid obesity after RYBG and ASGB, 920
  - in NIDDM with polygenic obesity, CL316,243 effects on, 801-802
- FATP-1 (fatty acid transporter protein-1), fiber type- and FA composition-dependent effects of HF diet on content of TAG and, in skeletal muscle, 1032-1036
- Fatty acid(s) (FAs)
  - effects of long-term exposure of INS cells to *cis* and *trans* FAs on oxidation of, 1158-1165
  - serum PP, in NIDDM, alcohol effects on, 79-80
  - VAT accumulation and TG content of, associated with MS components, 310-317
  - see also* Fatty acid-binding protein-4; Fatty acid composition
  - cis* Fatty acid(s), effects of long-term exposure of INS-1 cells to *trans* and, on insulin secretion and oxidation of, 1158-1165
  - trans* Fatty acid(s), effects of, long-term exposure of INS-1 cells to *cis* and, on insulin secretion and oxidation of, 1158-1165
- Fatty acid-binding protein-4 (FABP4), effects of interaction between PPAR $\gamma$ -activated receptor polymorphism and polymorphism of, on insulin sensitivity and body composition in men, 303-309
- Fatty acid (FA) composition
  - fiber type- and FA composition-dependent effects of HF diet on skeletal muscle TAG and FATP-1 content, 1032-1036
  - neutrophil, dietary oil effects on, 59-65
  - see also* Essential fatty acids; Monounsaturated fatty acids; Nonesterified fatty acids; Polyunsaturated fatty acids; Saturated fatty acid(s)
- Fatty acid synthase (FAS) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065

- Fatty acid transporter protein-1 (FATP-1), fiber type- and FA composition-dependent effects of HF diet on content of TAG and, in skeletal muscle, 1032-1036
- Fatty liver in STZ-DM due to high-fat diet, NO-1886 effects on, 260-263
- FBG, *see* Fasting blood glucose
- FBPase (fructose-1,6-biphosphatase), *P. yoelli* GPI effects on, in STZ-DM with obesity, 1050
- FCHL (familial combined hyperlipidemia),  $\square$ -3 PUFA effects on levels of plasma HDL $_2$ -C and paraoxonase in, 153-158
- Fenofibrate, effects of
  - on HF diet-induced weight gain and white adipose tissue in ovariectomized subjects, 1284-1289
  - on obesity and hypertriglyceridemia in LDL-receptor null subjects, 607-613
- Fetal life/neonatal life, 3,3'-T $_2$ S in, 538-543
- FFAs (free fatty acids), *see* Nonesterified fatty acids
- FFM, *see* Fat-free mass
- Fiber
  - CV disease risk factors and intake of, 1439
  - effects of exercise and high-fiber, low-fat diet on inflammatory and adhesion molecules in PM women on ERT and at risk for CAD, 377-381
  - FA composition- and fiber type-dependent effects of HF diet on skeletal muscle TAG and FATP-1 content, 1032-1036
- Fibrinogen
  - adipose tissue in non-obese men and level of, 984-988
  - in CHD, IR and, 853, 854
  - in inflammation of chronic disease, 901, 902
  - insulin therapy effects on, 694, 697
  - plasma, in IDDM, and oxidation of glycated and nonglycated LDLs, 970
  - and smoking effects on intravascular remodeling of LDL particles, 860
  - in young subjects with NIDDM parents, 756
- Fibroblasts, *see* DNA synthesis in fibroblasts
- Fibronectin mRNA (messenger ribonucleic acid)
  - in cardiac fibroblasts, effects of high glucose and insulin on, 712
  - renal, in IR, cilostazol effects on, 1405-1410
- Fibrosis, *see* Cystic fibrosis
- 1562C $\rightarrow$ T polymorphism of MMP-9 associated with BMD in Japanese men, 135-137
- Filipino family, triple *HNF-4 $\alpha$*  gene mutations associated with early-onset NIDDM in, 959-963
- First-degree relatives
  - of normocholesterolemic and daytime hypertriglyceridemic subjects with premature atherosclerosis, 49-53
  - see also* First-degree relatives, IGT, of African American NIDDM subjects
- First-degree relatives, IGT, of African American NIDDM subjects
  - effects of rosiglitazone on insulin sensitivity, insulin secretion, and plasma adiponectin, 1552-1557
  - GITS prevention of NIDDM in relatives of obese African American NIDDM subjects, 414-422
- Fish oil (FO)
  - effects, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
  - see also*  $\omega$ -3 Polyunsaturated fatty acids
- Fitness
  - cardiorespiratory, contribution of visceral AT and, to hyperinsulinemia, dyslipidemia, and hypertension in NIDDM with IGT, 644-649
  - see also* Exercise
- FIZZ3, *see* Resistin

- Flutamine for PCOS in obese women, 370
- Fluvastatin, effects of, on endothelial function in obese postmenopausal women via sdLDL reduction, 733-739
- FM, *see* Fat mass
- FO, *see* Fish oil
- Folate
- in disabled hospitalized older subjects, HHcy and, 1018
  - erythrocyte, in subclinical hypothyroidism, 1513
- Follicle-stimulating hormone (FSH) in PM and premenopausal women, plasma Lp and, 189
- Food intake
- correlation between AT, serum leptin and, during six-month period following kidney transplantation, 614-619
  - lack of acute effects of red wine drinking and, on vascular reactivity, 1081-1086
  - obesity and, *see* Food intake, and obesity
  - see also* Diet
- Food intake, and obesity
- in NIDDM subjects, bezafibrate effects on lipids and glucose metabolism and, 407
  - and NN414 and DZ effects on glucose tolerance in obesity, 442
- FPFS-410, antidiabetic and adipogenic properties of, 1532-1537
- FPG, *see* Fasting plasma glucose
- FPI, *see* Fasting plasma insulin
- Free fatty acids, *see* Nonesterified fatty acids
- Free testosterone
- in older NIDDM men with partial androgen deficiency, 668
  - in PCOS, 366
  - in PM women, insulin sensitivity and, 508, 509
- Free thyroxine ( $T_4$ ) in subclinical hypothyroidism, CV disease risk factors and, 1513
- Free triiodothyronine ( $T_3$ ) in subclinical hypothyroidism, CV disease risk factors and, 1513
- Frequently sampled intravenous glucose tolerance test (FSIVGTT) and insulin resistance indices, 1522-1526
- NEFA multiphasic profile unresponsive to exogenous insulin during, 1202-1207
  - population and individual minimal modeling of, 1349-1354
- Fresh blood samples, analysis of HbA<sub>1c</sub> in, 1497, 1498
- Frozen blood samples kept at  $-80^\circ\text{C}$ , analysis of HbA<sub>1c</sub> in, 1496-1499
- Fructosamine
- effects of ATPCL inhibitors on, 68
  - in older NIDDM men with partial androgen deficiency, 668, 670
- Fructose (F), postprandial plasma, in NIDDM retinopathy, 583-588
- Fructose-1,6-bisphosphatase (FBPase), *P. yoelli* GPI effects on, in STZ-DM with obesity, 1050
- Fruit, PP TG response to, 622
- FSH (follicle-stimulating hormone) in PM and premenopausal women, plasma Lp and, 189
- FSIVGTT, *see* Frequently sampled intravenous glucose tolerance test
- FXR (farnesoid X receptor), hepatic, effects of ileal bile transport inhibition on plasma C level through cholesterol 7 $\alpha$ -hydroxylase stimulation and inactivation of, 927-932
- Galactosamine, effects of liver disease induced by bile duct ligation and, on cardiac protein synthesis, 964-968
- Gamma ( $\gamma$ )-linoleic acid in MS, 312
- Gastric banding, adjustable silicone, changes in BMC after RYBG and, for morbid obesity, 918-921
- Gastric inhibitory polypeptide (GIP)
- insulin secretion, GLP-1 and, after glucose ingestion in IGT, 624-631
  - PP, in NIDDM, stevioside effects on, 75
- GDH (glutamate dehydrogenase), DM effects on, 68
- GDM (gestational diabetes mellitus),  $\beta_3$ -ADR Trp64Arg polymorphism and, in Taiwanese women, 1136-1139
- Gender, *see* Sex
- Gene expression, *see* mRNA
- Genetic variations, *see* Polymorphism
- Genetics
- of PCOS, 358-359
  - see also* DNA synthesis in fibroblasts; First-degree relatives; Genotype; mRNA; Mutations; Parent(s); Polymorphism
  - entries beginning with terms:* Familial, Polygenic, Transgenic
  - specific genes and conditions*
- Genotype, apo E, changes in serum lipids and  $\dot{V}O_{2\text{max}}$  in endurance exercise and, 193-202
- Geriatric subjects, *see* Older subjects
- Gestational age
- birth weight and, 1545
  - circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and sepsis, 209-214
  - whole-body glucose oxidation and oral glucose metabolism in born small-for-gestational-age children, 847-851
- Gestational diabetes mellitus (GDM),  $\beta_3$ -ADR Trp64Arg polymorphism and, in Taiwanese women, 1136-1139
- GF (growth factor) receptors, emergence of, in activated CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes, 117-122
- GFR (glomerular filtration rate) in chronic renal disease, 1256
- GH, *see* Growth hormone
- GHb (glycohemoglobin), stability over time of glucose, RBC survival and, in hematologically stable subjects without DM, 1399-1403
- GHBP (growth hormone-binding protein) in lipodystrophic HIV-infected subjects, 1565-1563
- Ghrelin mRNA (messenger ribonucleic acid) in melanoma-associated cachexia, 84-88
- GIP, *see* Gastric inhibitory polypeptide
- GITS (glipizide gastrointestinal therapeutic system), prevention of NIDDM in IGT first-degree relatives of obese African American NIDDM subjects with, 414-422
- Glargine (insulin analogue), action of, on protein and lipid metabolism, 1037-1044
- Glc, *see* Glucagon
- Glucalide in NIDDM, effects of, on microalbuminuria, 353-357
- Glipizide gastrointestinal therapeutic system (GITS), prevention of NIDDM in IGT first-degree relatives of obese African American NIDDM subjects with, 414-422
- Gln, *see* Glutamine
- Glomerular filtration rate (GFR) in chronic renal disease, 1256
- GLP-1, *see* Glucagon
- Glu, *see* Glutamic acid
- Glucagon (Glc; hyperglycemic-glycogenolytic factor)
- in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1090
  - effects of epinephrine, hyperglycemia and, on renal glucose release in conscious subjects, 933-941
  - effects of swimming on hepatic glucose production in response to, 1027-1031
  - in obese men, NEFA effects on levels of, 892
  - PP, in NIDDM, stevioside effects on, 75
  - short-term effects of NEFAs on secretion of, at low-to-normal glucose concentrations, 1443-1448
  - see also entries beginning with term:* Glucagon-like peptide-1
- Glucagon (Glc; hyperglycemic-glycogenolytic factor) in hypoglycemia

- Glucagon (Glc; hyperglycemic-glycogenolytic factor) in hypoglycemia (*Continued*)  
 and nighttime and daytime differences in counterregulation of hypoglycemia, 895  
 pramlintide effects on response of hypoglycemic symptoms to, 1227-1232
- Glucagon-like peptide-1 (GLP-1)  
 insulin secretion, glucose-dependent insulintropic polypeptide and, after glucose ingestion in IGT, 624-631  
 PP, in NIDDM, stevioside effects on, 75
- Glucagon-like peptide-1(7-36) [GLP-1(7,36)] amide, effects of Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution in, on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Glucagon-like peptide-1(9-36) [GLP-1(9,36)] amide, effects of Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution in GLP-1(7-36) amide on DPP IV resistance with cellular and metabolic actions similar to exendin (9-39) and, 252-259
- Glucocorticoid receptor (GR)  
 leptin effects on mRNA of, in STZ-DM, 1560-1561  
 signaling by, in AT, restricted diet effects on, 28-36
- Glucoregulatory responses to exercise, effects of OCs on, 348-352
- Glucosamine, effects of, on apo A-1 stabilization and expression in HepG2 cells, 766-771
- Glucose  
 blood, *see* Blood glucose  
 diet and, *see* Glucose, diet and  
 differential effects of alcohol and, on ROS generation and intranuclear nuclear factor- $\kappa$ B in mononuclear cells, 330-334  
 effects of different levels of, on arginase activity and NO production in renal cortex, 868-874  
 effects of high insulin and, on protein synthesis in cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts, 710-715  
 in exercise, *see* Glucose in exercise  
 fasting, *see* Fasting glucose  
 glargine effects on, 1038  
 and glycoprotein PC-1 K121Q polymorphism associated with race but not IR in children, 466, 467  
 in hypercholesterolemia, serum LPL concentration and, 528  
 isotretinoin effects on, 7, 8  
 leptin levels and, 1412-1414  
 and leucine turnover in third trimester of uncomplicated pregnancy, 547  
 in overweight women, serum TNF soluble receptors, TNF- $\beta$ , and NO and, 1269  
 plasma, *see* Plasma glucose  
 in PM and premenopausal women, sex steroids and plasma Lps and, 189  
 postprandial, *see* Postprandial glucose  
 proline ingestion with and without, 241-246  
 rebaudioside A effects on insulin secretion dependent on, 1378-1381  
 and relation of intracellular cord blood platelet magnesium to birth weight, 1545  
 and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, in Japanese subjects, 881-883  
 serum, *see* Serum glucose  
 short-term effects of NEFAs on secretion of glucagon at low-to-normal concentrations of, 1443-1448  
 stability over time of GHb, RBC survival and, in hematologically stable subjects without DM, 1399-1403
- Glucose (*Continued*)  
 whole-body, and glucose metabolism in born small-for-gestational-age children, 847-851  
*see also* Glucose, diet and; Glucose, smoking effects on; Glucose-dependent insulintropic polypeptide; Glucose in hyperinsulinemia; Glucose in IR; Glucose in obesity; Glucose-6-phosphatase; Glucose-6-phosphate dehydrogenase; Glucose-stimulated insulin secretion; Glucose tolerance; Glucose transport in SM; GLUT<sub>4</sub> in IR; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus and entries  
 beginning with prefixes: Gluc-, Glyc-
- Glucose, diet and  
 and CV disease risk factors, 1437, 1438  
*see also* Glucose, HF diet effects on
- Glucose, HF diet effects on  
 HF diet effects on, 1034  
 and insulin-nonspecific reduction of glucose transport in SM, 912-917
- Glucose, smoking effects on  
 and smoking-ADMA-obesity relationship, 1575, 1576  
 and smoking effects on intravascular HDL particle remodeling, 860
- Glucose control, *see* Glycemic control of DM
- Glucose-dependent insulintropic polypeptide, alcohol effects on, in NIDDM, 77-83
- Glucose in exercise  
 and acipimox-induced reduction of plasma NEFAs during exercise at cold temperature, 1133  
 in exercising PM women on or not on ERT, 1194  
 hepatic production of, in response to glucagon, effects of swimming on, 1027-1031  
 resistance exercise effects on TNF- $\alpha$  and insulin-mediated glucose disposal in older hypertensive subjects, 397-402
- Glucose-glutamine (Gln) cycle during hypoglycemia and normoglycemic hyperinsulinemia, 1208-1214
- Glucose in hyperinsulinemia  
 portal venous hyperinsulinemia effects on gut absorption of, in conscious subjects, 1290-1295  
*see also* Plasma glucose in hyperinsulinemia
- Glucose intolerance  
 development of, in male transgenic subjects with GSK-3 $\beta$  overexpression in skeletal muscle, 1322-1330  
*see also* Glucose tolerance
- Glucose in IR  
 IR measures and, 1524  
 with liver cirrhosis, 923  
 plasma NEFA regulation and, 1198  
 serum GPI-PLD and, 139
- Glucose in obesity  
 and smoking-ADMA-relationship, 1575  
 in women, serum TNF soluble receptors, TNF- $\beta$ , and NO and, 1269
- Glucose-6-phosphatase (G6Pase), effects of exercise on activity of hepatic, in diabetes-prone subjects, 836-841
- Glucose-6-phosphate dehydrogenase (G6PD) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Glucose-stimulated insulin secretion, LSF effects on, in STZ-DM, prediabetic, and nondiabetic subjects, 290-296
- Glucose tolerance  
 HF diet effects on, 1034  
 insulin secretion and insulin sensitivity at different stages of, in Japanese NIDDM subjects, 831-835



Glucose tolerance (*Continued*)

- LBW Pima Indians with normal, insulin secretion, insulin sensitivity in, 904-911
- in obesity, effects of NN414 and DZ on lipids and, compared, 441-447
- see also* Frequently sampled intravenous glucose tolerance test; Impaired glucose tolerance; Normal glucose tolerance, insulin release and secretion in; Oral glucose tolerance test

## Glucose transport in SM

- HF diet and insulin-nonspecific reduction in, 912-917
- of insulin-sensitive and insulin-resistant subjects, stevioside effects on, 101-107

GLUT<sub>4</sub> in IR

- adipocyte, hypertension and, 382-387
- after 1-day hindlimb suspension, 1217
- GLUT<sub>4</sub> mRNA (messenger ribonucleic acid), exercise effects on glycogen synthase activity and, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242
- Glutamate dehydrogenase (GDH), DM effects on, 68

## Glutamic acid (Glu)

- effects of GLP-1(7-36) amide lys<sup>9</sup>-for-Glu<sup>9</sup> substitution on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

## Glutamine (Gln)

- muscle, changes in release of, during hyperinsulinemia, normoglycemia, and hypoglycemia, 1208-1214
- plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- relation between leptin receptor gene Lys109Arg and Gln 223Arg polymorphisms, HOMA IR index, serum leptin, soluble leptin receptor, serum adiponectin, and lipids in Japanese subjects, 881-883

## Glutathione (GSH), effects of hypoxia and hypoxic training on levels of hepatic, 716-719

Gly, *see* GlycineGlycated hemoglobin, *see* HbA<sub>1c</sub>

## Glycated low-density lipoprotein (LDL), susceptibility to oxidation of nonglycated LDLs and, in IDDM, compared, 969-975

Glycemia, *see* Glycemic control of DM; Hyperglycemia; Hypoglycemia; Normoglycemic hyperinsulinemia; Normoglycemic men

## Glycemic control of DM

- with FPFS-410, 1532-1537
- relation between plasma ET, plasma VEGF concentration and, 550-555
- see also* Glycemic control of IDDM; Glycemic control of NIDDM and specific therapies

## Glycemic control of IDDM

- effects of, on F<sub>2</sub> isoprostane level at IDDM onset, 1118-1120
- with modified insulin, 54-58

## Glycemic control of NIDDM

- effects of, on microalbuminuria, 353-357
- with insulin, effects of, on serum high-sensitivity CRP, 693-699
- in NIDDM women, effects of resistance exercise on, 284-289
- in older men with partial androgen deficiency, 666-672
- see also* specific therapies; for example: Non-insulin-dependent diabetes mellitus, pioglitazone effects on

## Glycerol

- acipimox-induced reduction of, during exercise at cold temperature, 1133
- effects of exercise at cold temperature on, *see* Glycerol, effects of exercise at cold temperature on

Glycerol (*Continued*)

- isotretinoin effects on, 7
- skeletal muscle, in insulin-resistant lipolysis, HF diet and, 794-798
- see also* Triacylglycerol

## Glycerol, effects of exercise at cold temperature on

- acipimox-induced reduction of, 1133
- and substrate oxidation, 204

## Glycine (Gly)

- Arg16Gly  $\beta_2$ -ADR polymorphism interaction with  $\beta_2$ -Arg16Arg and  $\beta_3$ -ADR Trp64Arg polymorphisms, serum lipid profile and, 1184-1191

- plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

Glycogen, *see* Hepatic glycogen

- Glycogen synthase (GS), exercise effects on GLUT<sub>4</sub> mRNA and activity of, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242

Glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ) mRNA (messenger ribonucleic acid) in skeletal muscle of transgenic male subjects, 1322-1330

- Glycohemoglobin (GHb), stability over time of glucose, RBC survival and, in hematologically stable subjects without DM, 1399-1403

## Glycoprotein

- alpha<sub>1</sub>-acid, in inflammation of chronic disease, 901, 902
- PC-1 K121Q polymorphism, association of, with race but not with IR, in children, 465-468

Glycosylphosphatidylinositol (GPI), *P. yoelli*, effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053

## Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), serum, IR effects on, 138-139

Glycyrrhetic acid, responsiveness of body weight, hepatic 11 $\beta$ -HSD1 mRNA, and renal 11 $\beta$ -HSD2 mRNA to 11 $\beta$ -HSD inhibition by, 600-606

## Gonadotropin(s)

- in central hypothesis of PCOS, 359-361
- human chorionic, low temperature blocking stimulatory effects of, on steroidogenic acute regulatory protein mRNA and testosterone production but not on cAMP production in tumor cells, 955-958

## G-6-Pase (glucose-6-phosphatase), effects of exercise on activity of hepatic, in diabetes-prone subjects, 836-841

## G6PD (glucose-6-phosphate dehydrogenase) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065

GPI (glycosylphosphatidylinositol), *P. yoelli*, effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053

## GPI-PLD (glycosylphosphatidylinositol-specific phospholipase D), serum, IR effects on, 138-139

GR, *see* Glucocorticoid receptorGrowth factor (GF) receptors, emergence of, in activated CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes, 117-122

## Growth hormone (GH)

- long-term monitoring of insulin sensitivity in GH-deficient subjects on GH therapy, 740-743

## LY117018 effects on secretion of, 563-570

## nighttime and daytime differences in counterregulation of hypoglycemia and, 895

in smokers, *see* Growth hormone in smokers

## Growth hormone-binding protein (GHBP) in lipodystrophic HIV-infected subjects, 1565-1563

## Growth hormone (GH) in smokers

- acute effects of nicotine on, 578-582

- Growth hormone (GH) in smokers (*Continued*)  
 response of, to exercise by nondiabetic and IDDM smokers, 1140-1144
- GS (glycogen synthase), exercise effects on GLUT<sub>4</sub> mRNA and activity of, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242
- GSH (glutathione), effects of hypoxia and hypoxic training on levels of hepatic, 716-719
- GSK-3 $\beta$  (glycogen synthase kinase-3 $\beta$ ) mRNA messenger ribonucleic acid in skeletal muscle of transgenic male subjects, 1322-1330
- G276T adiponectin polymorphism in Japanese NIDDM subjects with incipient nephropathy, 1223-1226
- Gut  
 portal venous hyperinsulinemia effects on glucose absorption by, in conscious subjects, 1290-1295  
 short, regulation of serum lipid EFAD in subjects with, and on lipid-containing total parenteral nutrition, 273-277
- Haptoglobin, serum, correlation between HbA<sub>1c</sub>, retinocytes, serum bilirubin and, 1498
- Hb (hemoglobin)  
 in disabled hospitalized older subjects, HHcy and, 1018  
 WPG effects on, 1312  
*see also* HbA<sub>1c</sub>
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>)  
 and *ABCA1* gene expression-fasting glucose relationship in normoglycemic men, 19  
 in blood samples kept frozen at -80°C, analysis of, 1496-1499  
 carotid atherosclerosis, vascular dementia and, 477  
 in DM, *see* HbA<sub>1c</sub> in DM  
 in hypercholesterolemia, serum LPL concentration and, 528  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 in IR, *see* HbA<sub>1c</sub> in IR  
 in Japanese subjects, *see* HbA<sub>1c</sub> in Japanese subjects  
 in obesity, *see* HbA<sub>1c</sub> in obesity  
 and smoking-ADMA-obesity relationship, 1575, 1576  
 in young subjects, *see* HbA<sub>1c</sub> in young subjects
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in DM  
 effects of ATPCL inhibitors on, 68  
 and relation between plasma VEGF, ET-1 concentration, and glycemic control, 551  
*see also* HbA<sub>1c</sub> in IDDM; HbA<sub>1c</sub> in NIDDM
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in IDDM  
 energy substrate oxidation and, 656  
 glycemic control effects on F<sub>2</sub> isoprostane level at IDDM onset, 1119  
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641  
 oxidation of glycated and nonglycated LDLs and, 970  
 plasma apo C-3 polymorphisms and, 1299
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in IR  
 with cardiovascular autonomic dysfunction and microalbuminuria, 1360, 1362  
 in non-obese subjects, BMI and, 143
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in Japanese subjects  
 in insulin-resistant obese subjects, 651, 652  
 with NIDDM and incipient nephropathy, 1224  
 and relation between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms of leptin receptor gene, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in NIDDM  
 HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in NIDDM (*Continued*)  
 ACP-1 and ADA effects on, 998, 999  
 alcohol effects on PP lipemia and, 78  
 and association of corrected QT intervals with carotid artery IMT, 1153, 1155, 1156  
 and at-risk for NIDDM subjects, 224, 226  
 correlation between erythrocyte membrane lipid composition and, 123-127  
 glyburide and nateglinide effects and, 1332  
 insulin therapy effects on, 694  
 metformin effects on, 160, 161  
 microalbuminuria and, 354  
 in obesity, *see* HbA<sub>1c</sub> in obesity  
 in older NIDDM men with partial androgen deficiency, 668, 670  
 Pancreas Tonic effects on, 1169  
 with retinopathy, 585, 586  
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301  
*see also* HbA<sub>1c</sub> in NIDDM nephropathy
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in NIDDM nephropathy  
 in Japanese subjects with incipient nephropathy, 1224  
 pioglitazone effects on, 1383
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in obesity  
 adiponectin, CRP and, 1456, 1457  
 in insulin-resistant obese Japanese subjects, 651, 652  
 with NIDDM, 1456, 1457  
 NN414 and DZ effects on, 443, 444
- HbA<sub>1c</sub> (glycated hemoglobin A<sub>1c</sub>) in young subjects  
 with NIDDM parents, 756  
 in young men with hypertensive parents, 470
- HC diet, *see* High-cholesterol diet
- HC/HF diet, *see* High-fat/high cholesterol diet, lipemic response to
- hCG (human chorionic gonadotropin), low temperature blocking stimulatory effects of, on steroidogenic acute regulatory protein mRNA and testosterone production but not on cAMP production in tumor cells, 955-958
- Hcy, *see* Homocysteine
- HD, *see* Hemodialyzed subjects
- HDL, *see* High-density lipoprotein
- HDL-C, *see* High-density lipoprotein-cholesterol
- Head and neck squamous cell carcinoma (HNSCC), effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-*trans* retinoic acid and on cell proliferation in, 1007-1012
- Heart  
 weight of, in liver disease, 965  
*see also* Heart disease; Heart rate and entries beginning with element: Card-
- Heart disease  
 coronary, *see* Coronary heart disease  
 ischemic, carotid atherosclerosis, vascular dementia and, 477  
*see also* Risk factors for CV disease
- Heart rate (pulse rate; HR)  
 of CAD men, effects of red and white wine drinking on, 320  
 in early NIDDM nephropathy, pioglitazone effects on, 1476  
 effects of red wine drinking and food intake on, 1082  
 exercise effects on, *see* Heart rate, exercise effects on  
 in IR with LVH, candesartan effects on, 778, 779  
 in NIDDM, *see* Heart rate in NIDDM  
 in obese PM women, fluvastatin effects on, 735  
 resting, of young subjects with NIDDM parents, 756
- Heart rate (pulse rate; HR), exercise effects on  
 at cold temperature, 1131-1135  
 in overweight nondiabetic and NIDDM subjects, 1236



- Heart rate (pulse rate; HR) in NIDDM  
with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362  
in overweight NIDDM subjects, 1236
- Height  
of children with glycoprotein PC-1 K121Q polymorphism, 467  
of Ecuadorian Amazon Shur women, 1356  
of hyperinsulinemic young men, whole-body protein synthesis and, 389  
of IDDM subjects, insulin concentration and CHO requirement in IDDM during moderate exercise, 1127  
of insulin-resistant subjects with central HPA dysfunction, 722  
and isotretinoin effects on insulin sensitivity and plasma TGs, 5  
of LBW Pima Indians with normal glucose tolerance, 906  
of lipodystrophic subjects, 514  
of NIDDM subjects, *see* Height of NIDDM subjects  
of obese adolescents, *see* Height of obese adolescents  
of smokers, *see* Height of smokers
- Height of exercising subjects  
of exercising women on or not on ERT, 1194  
and OC effects on glucoregulatory responses to exercise, 350
- Height of NIDDM subjects  
and of at-risk for NIDDM subjects, 224  
of NIDDM women, resistance exercise effects on glycemic control in, 285
- Height of obese adolescents  
with components of MS, 864  
hyperuricemic Japanese male adolescents, 450
- Height of smokers  
acute effects of nicotine and, 579  
and smoking effects on intravascular of HDL particle remodeling, 860
- Hematocrit, WPG effects on, 1312
- Hematologically stable subjects without DM, stability over time of GHb, glucose, and RBC survival in, 1399-1403
- Hemodialyzed subjects (HD)  
for dyslipidemic CRF, atorvastatin effects on lipids, LDLs, and CRP in, 1113-1117  
utility of non-HDLs in, 1013-1015
- Hemoglobin, *see* Hb
- Hemolysis, effects of, on HbA<sub>1c</sub>, 1496-1499
- Hepatic acyl-coenzyme A:cholesterol acyltransferase (ACAT), role of cholesterol absorption and activity of, in lipemic response to HF/HC diet, 817-822
- Hepatic apolipoprotein B (apo B), insulin regulating production of, independently of PKB/Akt1 mass or activity, 228-236
- Hepatic bile, plasma 27-hydroxycholesterol and plasma 7 $\alpha$ -hydroxy-4-cholesten-3-one as markers for synthesis of, dietary cholesterol, 42-48
- Hepatic farnesoid X receptor (FXR), effects of ileal bile transport inhibition on plasma C level through cholesterol 7-hydroxylase stimulation and inactivation of, 927-932
- Hepatic glucose-6-phosphatase (G6Pase), effects of exercise on activity of, in diabetes-prone subjects, 836-841
- Hepatic glucose production (HGP) in response to glucagon, effects of swimming on, 1027-1031
- Hepatic glutathione (GSH), effects of hypoxia and hypoxic training on levels of hepatic 8-OHdG and, 716-719
- Hepatic glycogen  
and GSK-3 $\beta$  in transgenic subjects, 1325-1326  
in obese men, NEFA effects on levels of, 886-893
- Hepatic 8-hydroxydeoxyguanosine (8-OHdG), effects of hypoxia and hypoxic training on levels of hepatic GSH and, 716-719
- Hepatic 11 $\beta$  (beta)-hydroxysteroid dehydrogenase 1 (11 $\beta$ -HSD1) mRNA (messenger ribonucleic acid), responsiveness of body weight and, to 11 $\beta$ -HSD inhibition by glycyrrhetic acid, 600-606
- Hepatic insulin signaling, effects of exercise on hepatic PEPCK and, in diabetes-prone subjects, 836-841
- Hepatic lipase (HL)  
HF/HC diet effects on, 1023  
Lp metabolism and deficiency in, 520-525
- Hepatic lipids, fenofibrate effects on accumulation of, 610
- Hepatic phosphoenolpyruvate carboxykinase (PEPCK), effects of exercise on hepatic insulin signaling and, in diabetes-prone subjects, 836-841
- Hepatic triglyceride lipase (HTGL), endurance exercise effects on, 196, 198-200
- Hepatocytes, thioctic acid effects on pyruvate metabolism and NEFA oxidation in, 165-173
- Hepatoma cells, *see* HepG2 cells, apo A-1 and
- HepG2 (hepatoma) cells, apo A-1 and  
effects of COX inhibition on apo A-1 promoter activity in, 174-181  
glucosamine effects on apo A-1 stabilization and expression in, 766-771
- Herbal supplement, effects of Ayurvedic, in NIDDM, 1166-1173
- Heredity, *see* Genetics
- Hexyl-insulin monoconjugate 2 (HIM2; modified insulin), oral, for IDDM, 54-58
- HF diet, *see* High-fat diet
- HF/HC diet, *see* High-fat/high-cholesterol diet, lipemic response to
- HGP (hepatic glucose production) in response to glucagon, effects of swimming on, 1027-1031
- HHcy, *see* Hyperhomocysteinemia
- High-cholesterol (HC) diet  
effects, on atherogenic LDL particles, 823-830  
*see also* High-fat/high-cholesterol diet, lipemic response to
- High-density lipoprotein ( $\alpha$  lipoprotein; HDL)  
erythrocyte membrane, 574  
in hypothyroidism, effects of T<sub>4</sub> therapy on endothelial function and, 279  
in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641  
in NIDDM, PP, alcohol effects on, 78  
plasma, *see* Plasma high-density lipoprotein  
plasma vitamin K transport and, 216, 218  
 $\omega$ -3 PUFA and exercise effects on subfractions of, 749-754  
RCT system and smoking effects on intravascular remodeling of particles of, 858-862  
in SCI men, MS and, 1373, 1374  
utility of non-HDLs in HD subjects, 1013-1015  
*see also* High-density lipoprotein-cholesterol
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C)  
in acute SCI, 991  
in atherosclerosis, *see* High-density lipoprotein-cholesterol in atherosclerosis  
in CAD men, *see* High-density lipoprotein-cholesterol in CAD men  
and CV disease risk factors, 1437  
in dyslipidemic CRF subjects on HD, 1114  
and erythrocyte membrane lipid composition, 574  
during estrous cycle, 140  
exercise and, *see* High-density lipoprotein-cholesterol, exercise effects and  
in HD subjects, 1014

- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) (*Continued*)
- in hypercholesterolemia, *see* High-density lipoprotein-cholesterol in hypercholesterolemia
  - in IDDM, *see* High-density lipoprotein-cholesterol in IDDM
  - in IGT first-degree relatives of African American NIDDM subjects, 1553
  - in IR, *see* High-density lipoprotein-cholesterol in IR
  - in Korean women, AT distribution and, 1541
  - leptin levels and, 1412-1414
  - in mild hypercholesterolemia, 1073
  - in mixed hyperlipidemia, S-2E and PRV effects on, 682-683
  - in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
  - in non-obese subjects, *see* High-density lipoprotein-cholesterol in non-obese subjects
  - in obesity, *see* High-density lipoprotein-cholesterol in obesity
  - in overweight women, serum TNF soluble receptors, TNF- $\beta$ , and NO and, 1269
  - plasma, *see* Plasma high-density lipoprotein-cholesterol
  - and plasma LDL clearance, 484
  - and plasma vitamin K transport, 216
  - in PM women, *see* High-density lipoprotein-cholesterol in PM women
  - in postpubertal Asian Indian adolescents, 1338
  - and  $\omega$ -3 PUFA effects on, in FCHL, 154
  - and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, in Japanese subjects, 881-883
  - serum, *see* Serum high-density lipoprotein-cholesterol
  - in subclinical hypothyroidism, 1513
  - in Vietnamese children with apo E polymorphism, 1519
  - WPG effects on, 1311-1312
  - in young subjects, *see* High-density lipoprotein-cholesterol in young subjects
  - see also* High-density lipoprotein<sub>2</sub>-cholesterol; High-density lipoprotein<sub>3</sub>-cholesterol
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C), exercise effects and
- blood, apo E polymorphism association with changes in  $\dot{V}O_{2max}$  and, 111-113
  - endurance exercise effects, 196, 198-200
  - in overweight nondiabetic and NIDDM subjects, 1236
  - relationship of exercise, alcohol intake, and adiposity to levels of, 700-709
  - soccer playing effects, 1264
  - see also* High-density lipoprotein-cholesterol in exercising PM women on ERT
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in atherosclerosis
- in carotid atherosclerosis, vascular dementia and, 477
  - in normocholesterolemic premature atherosclerosis with daytime hypertriglyceridemia, 50
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in CAD men
- red and white wine drinking effects on, 320
  - risk factors for myocardial infarction and, 325, 326
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in exercising PM women on ERT
- or not on ERT, 1194
  - with risk for CAD, aerobic exercise and high-fiber, low-fat diet effects on, 378
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in hypercholesterolemia
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in hypercholesterolemia (*Continued*)
  - in mild hypercholesterolemia, 1073
  - serum LPL concentration and, 527, 528
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in IDDM
- energy substrate oxidation and, 656
  - and oxidation of glycated and nonglycated LDLs, 970
  - plasma apo C-3 polymorphisms and, 1299
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in IR, 312, 1524
- CV disease risk factors and, in obese and overweight subjects, 498
  - with LVH, candesartan effects on, 779
  - with microalbuminuria, *see* High-density lipoprotein-cholesterol in microalbuminuric IR; High-density lipoprotein-cholesterol in microalbuminuric NIDDM
  - in non-obese subjects, *see* High-density lipoprotein-cholesterol in non-obese insulin-resistant subjects
  - in normoglycemic men, *ABCA1* gene expression-fasting glucose relationship and, 19
  - serum GPI-PLD and, 139
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in microalbuminuric IR
- cilostazol effects on, 1407
  - see also* High-density lipoprotein-cholesterol in microalbuminuric NIDDM
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in microalbuminuric NIDDM
- cardiovascular autonomic dysfunction and, 1360, 1362
  - effects of glycemic control on, 354
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in NIDDM
- and association of corrected QT intervals with carotid artery IMT, 1155
  - and in at-risk for NIDDM subjects, 224, 226
  - and HbA<sub>1c</sub> in RBC membrane, 124
  - insulin therapy effects on, 694, 697, 698
  - Japanese NIDDM subjects, insulin secretion and insulin sensitivity and, 832
  - metformin effects on, 160, 161
  - with microalbuminuria, *see* High-density lipoprotein-cholesterol in microalbuminuric NIDDM
  - Pancreas Tonic effects on, 1169
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in non-obese insulin-resistant subjects
- CV disease risk factors and, 498
  - in non-obese NIDDM Korean subjects, 143, 144
  - serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in non-obese subjects
- in men, AT as fibrinogen level predictor and, 985, 986
  - in premenopausal women, metabolic risk and, 1068-1070
  - see also* High-density lipoprotein-cholesterol in non-obese insulin-resistant subjects
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in obese women
- effects of moderate weight loss and sibutramine or orlistat on, 432
  - in PM women, fluvastatin effects on, 736
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in obesity
- CV disease risk factors and, 498
  - in Korean subjects, -3826A $\rightarrow$ G UCP-1 polymorphism effects on level of LDL-C and, 1057

- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in obesity (*Continued*)  
 with MS in chronic renal disease, 1257  
 smoking-ADMA-obesity relationship and, 1575, 1576  
*see also* High-density lipoprotein-cholesterol in obese women;  
 High-density lipoprotein-cholesterol in obesity with MS
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in obesity with MS  
 in adolescents, 864, 865  
 in treatment-seeking subjects, 436
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in PM women  
 of exercising women on ERT, 1194  
 obese women, fluvastatin effects on, 736  
 simvastatin effects on BMD and, 745, 746
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in young men  
 with hypertensive parents, 470  
 serum adiponectin association with, 589-593
- High-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C) in young subjects  
 with NIDDM parents, 756  
*see also* High-density lipoprotein-cholesterol in young men
- High-density lipoprotein, *see* Lipoprotein(a)
- High-density lipoprotein<sub>2</sub>-cholesterol ( $\alpha$  lipoprotein<sub>2</sub>-cholesterol; HDL<sub>2</sub>-C)  
 erythrocyte membrane, 574  
 exercise and, *see* High-density lipoprotein<sub>2</sub>-cholesterol, exercise and  
 HF/HC diet effects on, 1023  
 in MS, 312, 313, 315  
 plasma, in FCHL,  $\omega$ -3 PUFA effects on levels of paraoxonase and, 153-158  
 serum, *see* Serum high-density lipoprotein<sub>2</sub>-cholesterol
- High-density lipoprotein<sub>2</sub>-cholesterol ( $\alpha$  lipoprotein<sub>2</sub>-cholesterol; HDL<sub>2</sub>-C), exercise and  
 blood, apo E polymorphism association with  $\dot{V}O_{2\max}$  and, 111-113  
 serum, apo E genotype and changes in  $\dot{V}O_{2\max}$  and, in endurance exercise, 196, 198-200  
 soccer playing effects on, 1264
- High-density lipoprotein<sub>3</sub>-cholesterol ( $\alpha$  lipoprotein<sub>3</sub>-cholesterol; HDL<sub>3</sub>-C)  
 erythrocyte membrane, 574  
 exercise and, *see* High-density lipoprotein<sub>3</sub>-cholesterol, exercise and  
 in FCHL,  $\omega$ -3 PUFA effects and, 154, 155  
 HF/HC diet effects on, 1023  
 serum, *see* Serum high-density lipoprotein<sub>3</sub>-cholesterol
- High-density lipoprotein<sub>3</sub>-cholesterol ( $\alpha$  lipoprotein<sub>3</sub>-cholesterol; HDL<sub>3</sub>-C), exercise and  
 blood, apo E polymorphism association with  $\dot{V}O_{2\max}$  and, 111-113  
 serum, apo E genotype and changes in  $\dot{V}O_{2\max}$  and, in endurance exercise, 196, 198-200  
 soccer playing effects on, 1264
- High-fat (HF) diet  
 fenofibrate and, *see* High-fat diet, fenofibrate and  
 and intracellular  $Ca^{2+}$  chelator effects on IR and spontaneous hypertension, 269-272  
 NO-1886 effects on fatty liver in STZ-DM due to, 260-263  
 obesity and, *see* High-fat diet, obesity and  
 SM and, *see* High-fat diet, effects of, on SM  
*see also* High-fat/high-cholesterol diet, lipemic response to
- High-fat (HF) diet, effects of, on SM  
 High-fat (HF) diet, effects of, on SM (*Continued*)  
 effects of fiber type and, on skeletal muscle TAG and FATP-1 content, 1032-1036  
 and insulin-nonspecific reduction in SM glucose transport, 912-917  
 on insulin-resistant lipolysis in SM, 794-798
- High-fat (HF) diet, fenofibrate and  
 fenofibrate effects on white adipose tissue and HF diet-induced weight gain by ovariectomized subjects, 1284-1289  
 fenofibrate prevention of HF diet-induced obesity and HTG in LDL-receptor null subjects, 607-613
- High-fat (HF) diet, obesity and  
 fenofibrate prevention of HF diet-induced obesity in LDL-receptor null subjects, 607-613  
 leptin therapy to augment leptin circadian rhythm after weight loss in HF diet-induced obesity, 782-789  
 role of caloric intake and low-fat diet versus, in development of NIDDM with obesity, 454-457
- High-fat/high-cholesterol (HF/HC) diet, lipemic response to  
 exercise effects on PP lipemic response after, 1021-1026  
 role of cholesterol absorption and hepatic ACAT activity in, 817-822
- High-fiber/low-fat diet, effects of exercise and, on inflammatory and adhesion molecules in postmenopausal women on ERT and at risk for CAD, 377-381
- High-sensitivity C-reactive protein (CRP), effect of insulin therapy of NIDDM on, 693-699
- High-sucrose (S) diet, NOS inhibition and pioglitazone effects on insulin action in subjects on, 22-27
- HIM2 (hexyl-insulin monoconjugate 2), oral, for IDDM, 54-58
- Hindlimb suspension, 1-day, whole-body and skeletal muscle IR development after, 1215-1222
- Hirsutism in PCOS, 366
- Histidine (His), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Histology, pancreatic islet, bezafibrate effects on, in obese NIDDM subjects, 408-409
- HIV (human immunodeficiency virus)-infected subjects, lipodystrophic, IGFs, GHBP, IGFs, and IGFBP-3 protease, in 1565-1573
- HL, *see* Hepatic lipase
- HNF-4 $\alpha$*  gene, triple mutations of, associated with early-onset NIDDM in Filipino family, 959-963
- HNSCC (head and neck squamous cell carcinoma), effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-*trans* retinoic acid and on cell proliferation in, 1007-1012
- HOMA (homeostasis model assessment) IR index  
 adiponectin and, *see* HOMA IR index, adiponectin and  
 in Ecuadorian Amazon Shur women, 1356  
 effects of interaction between FABP-4 and PPAR $\gamma$ -activated receptor polymorphism on, 304  
 and glycoprotein PC-1 K121Q polymorphism association with race but not IR in children, 466, 467  
 in insulin sensitivity, 1109, 1110  
 in Japanese subjects with beta-cell dysfunction, 950  
 in liver cirrhosis, 922-926  
 in NIDDM, *see* HOMA IR index in NIDDM  
 in obesity, *see* HOMA IR index in obesity  
 in PM women, *see* HOMA IR index in PM women  
 in postpubertal Asian Indian adolescents, 1338, 1339  
 serum GPI-PLD and, 139
- HOMA (homeostasis model assessment) IR index, adiponectin and adiponectin levels and, 2

- HOMA (homeostasis model assessment) IR index, adiponectin and  
(Continued)  
in daytime hypertriglyceridemic prematurely atherosclerotic  
normocholesterolemic subjects and their first-degree relatives,  
50  
in hypercholesterolemia, serum LPL concentration and, 528  
and NEFA regulation of adiponectin, 791  
relationship between serum adiponectin, serum soluble leptin  
receptor, serum leptin, lipids, leptin receptor gene Lys109Arg  
and Gln223Arg polymorphisms and, in Japanese subjects,  
879-885
- HOMA (homeostasis model assessment) IR index in NIDDM  
and BMI in non-obese insulin-resistant NIDDM Korean subjects,  
142-146  
in Japanese subjects, insulin sensitivity and insulin secretion and,  
831-835  
with obesity, pioglitazone effects on, 490
- HOMA (homeostasis model assessment) IR index in obesity  
in children, 1244  
in Japanese subjects, 652  
with NIDDM, pioglitazone effects on, 490  
in PM women, fluvastatin effects on, 736
- HOMA (homeostasis model assessment) IR index in PM women  
on ERT and at risk for CAD, 378  
obese women, fluvastatin effects on, 736
- Homeostasis model assessment, *see* HOMA IR index
- Homocysteine (Hcy)  
plasma, effects of elevated, on endothelial function recovery after  
denudation of carotid arteries, 760-765  
remethylation and trans-sulfuration of, 1480-1483  
total, in subclinical hypothyroidism, 1513  
*see also* Hyperhomocysteinemia
- HPA, *see* Hypothalamic-pituitary-adrenal axis
- HPRT (hypoxanthine phosphoribosyl transferase), point mutation in,  
responsible for hyperuricemia in women, 1500-1502
- HR, *see* Heart rate
- 11-HSD, *see* 11 $\beta$ -Hydroxysteroid dehydrogenase; Hepatic 11 $\beta$ -  
hydroxysteroid dehydrogenase 1 mRNA; 11 $\beta$ -hydroxysteroid  
dehydrogenase 2 mRNA
- HTG, *see* Hypertriglyceridemia
- HTGL (hepatic triglyceride lipase), endurance exercise effects on,  
196, 198-200
- HTN, *see* Hypertension
- Human chorionic gonadotropin (hCG), low temperature blocking  
stimulatory effects of, on steroidogenic acute regulatory  
protein mRNA and testosterone production but not on cAMP  
production in tumor cells, 955-958
- Human immunodeficiency virus (HIV)-infected subjects,  
lipidotropic, IGFs, GHBP, IGFBPs, and IGFBP-3 protease,  
in 1565-1573
- Hydrocortisone, *see* Cortisol
- Hydrophilic 7 $\beta$  (beta)-hydroxy bile acids, effectiveness of lovastatin,  
cholestyramine, and chenodeoxycholic acid in  
cerebrotendinous xanthomatosis, compared, 556-562
- 7 $\beta$  (beta)-Hydroxy bile acids, hydrophilic, effectiveness of  
lovastatin, cholestyramine, and chenodeoxycholic acid in  
cerebrotendinous xanthomatosis, compared, 556-562
- 7 $\alpha$ -Hydroxy-4-cholesten-3-one, plasma 27-hydroxycholesterol and  
plasma, as markers for hepatic bile synthesis, dietary  
cholesterol and, 42-48
- 27-Hydroxycholesterol, plasma, and plasma 7 $\alpha$ -hydroxy-4-cholesten-  
3-one and plasma, as markers for hepatic bile synthesis,  
dietary cholesterol and, 42-48
- (-)-Hydroxycitrate, effects of, on platelet function in DM, 66-72
- 8-Hydroxydeoxyguanosine (8-OHdG), effects of hypoxia and  
hypoxic training on hepatic levels of, 716-719
- 7 $\alpha$  (alpha)-Hydroxylase, cholesterol, effects of ileal bile transport  
inhibition on plasma C level through FXR inactivation and  
stimulation of, 927-932
- 17 $\alpha$  (alpha)-Hydroxylase/17,20-lyase deficiency, mutant CYP17  
genes in, 1527-1531
- Hydroxyproline, urinary excretion of, in severe lipodystrophy, leptin  
replacement therapy effects on, 516
- 11 $\beta$ -Hydroxysteroid dehydrogenase (11 $\beta$ -HSD)  
CDCA effects on, in various tissues, 811-816  
*see also* 11 $\beta$ -Hydroxysteroid dehydrogenase 1 mRNA; 11 $\beta$ -  
Hydroxysteroid dehydrogenase 2 mRNA
- 11 $\beta$  (beta)-Hydroxysteroid dehydrogenase 1 (11 $\beta$ -HSD1) mRNA  
(messenger ribonucleic acid)  
in AT, effects of restricted diet on, 30-31  
hepatic, responsiveness of body weight and, to 11 $\beta$ -HSD  
inhibition by glycyrrhetic acid, 600-606
- 11 $\beta$  (beta)-Hydroxysteroid dehydrogenase 2 (11 $\beta$ -HSD2) mRNA  
(messenger ribonucleic acid), responsiveness of body weight  
and, to 11 $\beta$ -HSD inhibition by glycyrrhetic acid, 600-606
- 1,25 Hydroxyvitamin D, serum, in severe lipodystrophy, leptin  
replacement therapy effects on, 516
- 25 Hydroxyvitamin D, serum, in severe lipodystrophy, leptin  
replacement therapy effects on, 516
- Hypercholesterolemia  
familial, effects of S-2E and PRV in, compared, 680-685  
mild, diet composition as determinant of plasma ADMA in, 1072-  
1075  
in obese hyperuricemic Japanese male adolescents, 450  
serum LPL concentration related to TG metabolism in, 526-531  
simvastatin effects on BMD in PM women with, 744-748
- Hyperglycemia  
beta-cell dysfunction and development of, in Japanese subjects,  
943-954  
effects of glucagon, epinephrine and, on renal glucose release in  
conscious subjects, 933-941  
FPFS-410 effects on, 1532-1537  
and hyperinsulinemia, *see* Hyperglycemia, hyperinsulinemia and  
Hyperglycemia, hyperinsulinemia and  
in maturity-onset hyperinsulinemia with polygenic obesity and  
hyperglycemia, CL316,243 effects on, 799-808  
PP, MNH-01 effects on PP hyperinsulinemia, 977-983
- Hyperglycemic-glycogenolytic factor, *see* Glucagon
- Hyperhomocysteinemia (HHcy)  
causes of, 1481  
in disabled hospitalized older subjects, 1016-1020
- Hyperinsulinemia  
contribution of cardiorespiratory fitness and visceral AT to  
dyslipidemia, hypertension and, in NIDDM with IGT, 644-  
649  
effects of portal venous, on gut glucose absorption in conscious  
subjects, 1290-1295  
hyperglycemia and, *see* Hyperglycemia, hyperinsulinemia and  
normoglycemic, *see* Normoglycemic hyperinsulinemia  
obesity and, *see* Hyperinsulinemia, obesity and  
plasma amino acid concentrations and whole-body protein  
synthesis in, in young men, 388-396  
tempol effects on hypertension and, based on increase in  
medullary BF, 1305-1308
- Hyperinsulinemia, obesity and  
in obese PCOS women, 359  
polygenic obesity, CL316,243 effects on hyperglycemia and  
maturity-onset hyperinsulinemia, 799-808



## Hyperlipidemia

- carotid atherosclerosis, vascular dementia and, 477
- familial combined,  $\omega$ -3 PUFA effects on levels of plasma HDL<sub>2</sub>-C and paraoxonase in, 153-158
- in hypothyroidism, 278
- mixed, effects of S-2E and PRV in, compared, 680-685
- in obese PCOS women, 366
- see also* Hypercholesterolemia; Hypertriglyceridemia

## Hypertension (HTN)

- in CAD men, 424-426
- carotid atherosclerosis, vascular dementia and, 477
- effects of increased medullary blood flow by tempol on hyperinsulinemia and, 1305-1308
- in exercise, *see* Hypertension in exercise
- of hypercholesterolemic PM women, simvastatin effects on, 745
- in hypothyroidism, 278
- insulin secretion, insulin sensitivity and, and metabolic profile of young men with hypertensive parents, 469-475
- IR and, *see* Hypertension, IR and
- in NIDDM, *see* Hypertension in NIDDM
- in obesity, *see* Hypertension in obesity

## Hypertension (HTN), IR and

- cardiovascular autonomic dysfunction, microalbuminuria and, 1360
- GLUT<sub>4</sub> in adipocytes and, 382-387
- intracellular Ca<sup>2+</sup> chelator effects on, high-fat diet and, 269-272

## Hypertension (HTN) in exercise

- in nondiabetic and IDDM smokers, 1140-1144
- resistance exercise effects on insulin-mediated glucose disposal and TNF- $\alpha$  in older subjects with, 397-402

## Hypertension (HTN) in NIDDM

- and association of corrected QT intervals with carotid artery IMT, 1155
- with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360
- with IGT, contribution of cardiorespiratory fitness and visceral AT to hyperinsulinemia, dyslipidemia and, 644-649
- serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301

## Hypertension (HTN) in obesity

- in obese PCOS women, 366
- and smoking-ADMA-obesity relationship, 1575

## Hyperthyroidism

- parathyroidectomy for primary, serum PTH relation to vitamin D profile in eucalcemia after, 1101-1106
- 3,3'-T<sub>2</sub>S in, 540

## Hypertriglyceridemia (HTG)

- daytime, in normocholesterolemic prematurely atherosclerotic subjects with, and in their first-degree relatives, 49-53
- fenofibrate preventing obesity and, due to high-fat diet in LDL-receptor null subjects, 607-613

## Hypertrophy, left ventricular, candesartan effects on IR and, 777-781

## Hyperuricemia

- in obese Japanese male adolescents, 448-453
- in women, point mutation in HPRT responsible for, 1500-1502

## Hypoglycemia

- in IDDM during moderate exercise, CHO intake to prevent, 1129-1130
- insulin-induced, *see* Insulin-induced hypoglycemia
- muscle glutamine release of, during normoglycemia, normoglycemic hyperinsulinemia and, 1208-1214
- nighttime and daytime differences in counterregulation of, 894-898

## Hypoglycemia (Continued)

- pramlintide effects on response of catecholamines, glucagon, and symptoms of, 1227-1232

## Hypogonadism, cortisol production in men with, 1174-1176

## Hypolactatemia, DCA-induced, in cirrhotic and noncirrhotic subjects, 1087-1094

## Hypothalamic-pituitary-adrenal axis (HPA)

- central, CRH test of relation between MS and dysregulation of, 720-726
- leptin effects on weight loss, dysphagia, and activity of, in STZ-DM, 1558-1564

## Hypothyroidism

- effects of T<sub>4</sub> therapy of, on endothelial function, 278-279
- subclinical, CV disease risk factors in, 1512-1515
- 3,3'-T<sub>2</sub>S in, 540

## Hypoxanthine, plasma, sauna bathing and beer ingestion effects on concentration of, 772-776

## Hypoxanthine phosphoribosyl transferase (HPRT), point mutation in, responsible for hyperuricemia in women, 1500-1502

## Hypoxemia-stimulated glucose transport in SM, 914

## Hypoxia, effects of hypoxic training and, on hepatic 8-OHdG and GSH levels, 716-719

ICAM-1, *see* Intercellular adhesion molecule-1IDDM, *see* Insulin-dependent diabetes mellitusIDL, *see* Intermediate-density lipoproteinIDL-C, *see* Intermediate-density lipoprotein-cholesterolIGF, *see* entries beginning with terms: Insulin-like growth factorIGT, *see* Impaired glucose toleranceIL-1 $\beta$  (interleukin-1 $\beta$ ), effects of  $\omega$ -3 PUFAs alone or with *all-rac*  $\alpha$ -tocopherol on, 236-240IL-6, *see* Interleukin-6Ile (isoleucine), *see* Plasma isoleucineIleal bile transport, effects of inhibition of, on plasma cholesterol level through hepatic farnesoid X receptor inactivation and cholesterol 7 $\alpha$ -hydroxylase stimulation, 927-932IMCD (inner medullary collecting duct), ET effects on AVP<sub>2</sub> mRNA in, 1177-1183

## IM-FSIVGTT (insulin-modified frequently sampled intravenous glucose tolerance test), population and individual minimal modeling of, 1349-1354

## Immunofluorescence of eNOS and iNOS in early NIDDM nephropathy, 1474

## Immunoreactive insulin (IRI)

- fasting, in IR with LVH, 779
- in NIDDM, microalbuminuria and, 354

## Impaired glucose tolerance (IGT)

- effects of weight loss on IR with normal FPG or, in obese subjects 1095-1100
- insulin regulating kinetics of NEFAs in adult CF with, 1467-1472
- in NIDDM, *see* Impaired glucose tolerance in NIDDM
- in non-obese subjects, insulin secretion, GLP-1, and glucose-dependent insulinotropic polypeptide after glucose ingestion in, 624-631

## Impaired glucose tolerance (IGT) in NIDDM

- contribution of visceral AT and cardiorespiratory fitness to hyperinsulinemia, dyslipidemia, and hypertension in, 644-649
- see also* First-degree relatives, IGT, of African American NIDDM subjects

IMT (intimal-media thickness), *see* Carotid artery intimal-media thickness

## Incipient nephropathy in Japanese NIDDM subjects, G276T adiponectin polymorphism and, 1223-1226



## Incretins

alcohol intake effects on PP lipemia and PP levels of, in NIDDM, 77-83

*see also specific incretins*

Individual minimal modeling, population and, of IM-FSIVGTT, 1349-1354

Inducible nitric oxide synthase (iNOS) in early NIDDM nephropathy, 1474

Infants, *see* Newborns

Infarction, risk factors for myocardial, as predictors of CAD in men, 324-329

Infertility in obese PCOS women, 366

## Inflammation

in chronic disease, markers of, 899-903

in established preeclampsia, IR and, 1433-1435

low-grade, and MS in CHD, 852-857

*see also* Inflammation-sensitive molecules; Inflammatory molecules

Inflammation-sensitive molecules in men with CAD, acute effects of red and white wine drinking on circulating, 318-323

## Inflammatory molecules

effects of different oils on neutrophil FA composition and generation of, 59-65

in postmenopausal women on ERT and at risk for CAD, effects of high-fiber, low-fat diet and exercise on adhesion molecules and, 377-381

*see also specific inflammatory molecules*

Inner medullary collecting duct (IMCD), ET effects on AVP<sub>2</sub> mRNA in, 1177-1183

iNOS (inducible nitric oxide synthase) in early NIDDM nephropathy, 1474

INS-1 cells, effects of long-term exposure of, to *cis* and *trans* FAs, on insulin secretion and FA oxidation, 1158-1165

## Insulin

acute effects of nicotine on, in smokers, 578-582

in CAD men, risk factors for myocardial infarction and, 325

in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1090

diet and, *see* Insulin, diet and

effects of high glucose and high, on protein synthesis in cardiac myocytes and DNA, and collagen synthesis in cardiac fibroblasts, 710-715

in exercising PM women on or not on ERT, 1194

exogenous, unresponsiveness of NEFA multiphasic profile to, during FSIVGTT, 1202-1207

fasting, *see* Fasting insulin

hepatic apo B production regulated by, independently of PKB $\alpha$ /Akt1 mass or activity, 228-236

leptin levels and, 1412-1414

and leucine turnover in third trimester of uncomplicated pregnancy, 547

in obese and overweight women, serum TNF soluble receptors, TNF- $\beta$ , and NO and, 1269

plasma, *see* Plasma insulin

PP, OC effects on, 350, 351

in premenopausal women, sex steroids, plasma Lp and, 189, 190

regulation of NEFA kinetics by, in adult cystic fibrosis with impaired glucose tolerance, 1467-1472

and relation of intracellular cord blood platelet magnesium to birth weight, 1545

serum, *see* Serum insulin

smoking and, *see* Insulin, smoking effects and

## Insulin (Continued)

*see also* Diabetes mellitus; Hyperinsulinemia; Hypoglycemia; Insulin analogue; Insulin-dependent diabetes mellitus; Insulin-induced hypoglycemia; Insulin/insulin-like growth factor hypothesis; Insulin-like growth factor-1; Insulin-mediated glucose disposal; Insulin monoconjugate 2; Insulin in obesity; Insulin in PM women; Insulin release and secretion; Insulin resistance; Insulin sensitivity; Insulin signaling, effects of exercise on; Insulin-stimulated glucose transport; Insulin therapy; Insulinotropic polypeptide; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus

## Insulin, diet and

NOS inhibition and pioglitazone effects on action of insulin in subjects on high-sucrose diet, 22-27

*see also* Insulin, HF diet effects on, in SM

## Insulin, HF diet effects on, in SM

insulin-nonspecific reduction and HF effects on glucose transport, 912-917

and on SM TAG and FATP-1 content, 1033-1034

## Insulin, smoking effects and

effects on intravascular HDL particle remodeling, 860

smoking-ADMA-obesity relationship and, 1575, 1576

Insulin analogue, glargine as, effects of, on protein and lipid metabolism, 1037-1044

Insulin-dependent diabetes mellitus (IDDM; type 1 diabetes mellitus) ATP-citrate lyase role in acetyl-CoA and function of platelets in, 66-72

cardiovascular disease risk factors associated with serum sialic acid in Kuwaiti children and adolescents with, 638-643

energy substrate oxidation in, 655-659

glycated and nonglycated LDL oxidation in, compared, 969-975

glycemic control of, *see* Glycemic control of IDDM

insulin concentration and CHO requirement in, during moderate exercise, 1126-1130

kinetics of interstitial glucose in, 1484-1492

oral HIM2 for, 54-58

pituitary response to exercise by smokers with, 1140-1144

plasma apo C-3 polymorphisms in, 1296-1304

serum resistin levels in, before and after pancreatic islet transplantation, 403-404

## Insulin-induced hypoglycemia

acute, effects of normoglycemic hyperinsulinemia and, on retinal glucose uptake and ocular glucose metabolism, 1274-1283

effects of, on plasma PTH level in adrenal insufficiency 1251-1254

Insulin/insulin-like growth factor (IGF) hypothesis of PCOS, 360, 363-365

## Insulin-like growth factor(s) (IGF)

IGFBPs, IGFBP-3 protease, GHBP and, in lipodystrophic HIV-infected subjects, 1565-1573

*see also* Insulin-like growth factor-1

## Insulin-like growth factor-1 (IGF-1)

in acromegaly, 565

carotid atherosclerosis, vascular dementia and, 477

and relation of intracellular cord blood platelet magnesium to birth weight, 1545

rhGH therapy effects on, in GH-deficient subjects, 741

## Insulin-like growth factor-binding protein(s) (IGFBP), IGFs,

IGFBPs, IGFBP-3 protease, GHBP and, in lipodystrophic HIV-infected subjects, 1565-1573

Insulin-like growth factor-binding protein 3 (IGFBP-3) protease, IGFs, IGFBPs, GHBP and, in lipodystrophic HIV subjects, 1565-1573

- Insulin-mediated glucose disposal, resistance exercise effects on  
TNF- $\alpha$  and, in older hypertensive subjects, 397-402
- Insulin-modified frequently sampled intravenous glucose tolerance  
test (IM-FSIVGTT), population and individual minimal  
modeling of, 1349-1354
- Insulin monoconjugate 2, oral hexyl-, for IDDM, 54-58
- Insulin in obesity  
men, NEFA effects on hepatic glycogen level and, 892  
women, effects of moderate weight loss and sibutramine or orlistat  
on, 432
- Insulin in PM women  
on ERT and at risk for CAD, aerobic exercise and high-fiber, low-  
fat diet effects on inflammatory and adhesion molecules and,  
378  
sex steroids and plasma Lp and, 189, 190
- Insulin release and secretion  
dose-, glucose-, and calcium-dependent rebaudioside A effects on,  
1378-1381  
effects of long-term exposure of INS-1 cells to *cis* and *trans* FAs  
on, 1158-1165  
exercise effects on inhibitory effects of NE on, 1424-1432  
glucose-stimulated, LSF effects on, in STZ-DM, prediabetic, and  
normal subjects, 290-296  
in IGT, *see* Insulin release and secretion in IGT  
insulin sensitivity, *see* Insulin release and secretion,  $S_i$  and  
in NIDDM, *see* Insulin release and secretion in NIDDM  
normal glucose tolerance and, *see* Normal glucose tolerance,  
insulin release and secretion in  
in obesity, *see* Insulin release and secretion in obesity  
 $S_i$ , *see* Insulin release and secretion,  $S_i$  and
- Insulin release and secretion,  $S_i$  and  
in Japanese subjects at different stages of glucose tolerance, 831-  
835  
metabolic profile and, in young men with hypertensive parents,  
469-475  
in normal glucose-tolerant Pima Indians with LBW, 904-911  
rosiglitazone effects on plasma adiponectin and, in IGT first-  
degree relatives of African American NIDDM subjects, 1552-  
1557
- Insulin release and secretion in IGT  
effects of weight loss by obese subjects with IGT on, 1095-1100  
GLP-1, glucose-dependent insulinotropic polypeptide and, after  
glucose ingestion by non-obese IGT subjects, 624-631
- Insulin release and secretion in NIDDM  
insulin sensitivity and, at different stages of glucose tolerance in  
Japanese subjects, 831-835  
with obesity, pioglitazone effects on prevention of beta-cell mass  
loss and, 488-494
- Insulin release and secretion in obesity  
effects of weight loss on, in IGT or normal glucose-tolerant  
subjects, 1095-1100  
with NIDDM, pioglitazone effects on prevention of beta-cell mass  
loss and, 488-494
- Insulin resistance (IR)  
adiponectin, CRP and, in postpubertal Asian Indian adolescents,  
1336-1341  
candesartan effects on LVH and, 777-781  
in cirrhosis, levels of serum soluble TNF-R associated with, 922-  
926  
development of whole-body and skeletal muscle, after 1-day  
hindlimb suspension, 1215-1222  
glycoprotein PC-1 K121Q polymorphism associated with race but  
not with, in children, 465-468
- Insulin resistance (IR) (*Continued*)  
HF diet effects on insulin-resistant lipolysis in skeletal muscle,  
794-798  
hypertension and, *see* Hypertension, IR and  
with increased serum glycosylphosphatidylinositol-specific  
phospholipase D, 138-139  
indices of, 1522-1526  
and inflammation in established preeclampsia, 1433-1435  
with microalbuminuria, *see* Microalbuminuria in IR  
HF diet effects on insulin-resistant lipolysis in skeletal muscle,  
794-798  
in non-obese subjects, *see* Non-obese subjects, insulin-resistant  
obesity and, *see* Insulin resistance in obesity  
plasma NEFA regulation in, 1197-1201  
prevalence of, and associated CV disease risk factors in  
overweight and normoponderal subjects with, 495-499  
relationship between BMI, beta-cell function and, 1462-1466  
SSPG in, *see* Steady-state plasma glucose in IR  
stevioside effects on skeletal muscle glucose transport in, 101-107  
*see also* HOMA IR index; Insulin sensitivity; Metabolic syndrome
- Insulin resistance (IR) in obesity  
and HF diet effects on insulin-resistant lipolysis in skeletal  
muscle, 794-798  
with normal FPG or IGT, effects of weight loss on, 1095-1100  
Ob-R gene polymorphism associated with, in Japanese men, 650-  
654  
prevalence of associated CV disease risk factors with, 495-499
- Insulin sensitivity ( $S_i$ )  
effects of interaction between FABP-4 and PPAR $\gamma$ -activated  
receptor polymorphism on body composition and, in men,  
303-309  
erythrocyte membrane lipid composition association with  
arachidonic acid and, 571-577  
estimates of, 1107-1112  
insulin secretion and, *see* Insulin release and secretion,  $S_i$  and  
isotretinoin effects on, 4-10  
long-term monitoring of, in GH-deficient subjects on GH therapy,  
740-743  
in PM women, independent association of androgenicity and  
obesity with, 507-512  
and relationship between BMI, IR, and beta-cell function, 1462-  
1466  
stevioside effects on skeletal muscle glucose transport in, 101-107
- Insulin signaling, effects of exercise on  
on hepatic insulin signaling and hepatic PEPCK, 836-841  
in overweight nondiabetic and NIDDM subjects, 1233-1242
- Insulin-stimulated glucose transport, reduced SM, high-fat diet and,  
912-917
- Insulin therapy  
of NIDDM, effects of, on serum high-sensitivity CRP, 693-699;  
*see also* Glycemic control of NIDDM  
unresponsiveness of NEFA multiphasic profile to, during  
FSIVGTT, 1202-1207  
*see also* entries beginning with terms: Glycemic control
- Insulinotropic polypeptide, glucose-dependent, alcohol effects on, in  
NIDDM, 77-83
- Intercellular adhesion molecule-1 (ICAM-1)  
in CAD, *see* Intercellular adhesion molecule-1, CAD and  
in NIDDM, metformin effects on, 161
- Intercellular adhesion molecule-1 (ICAM-1), CAD and  
high-fiber, low-fat diet and exercise effects on, in postmenopausal  
women on ERT and at risk for CAD, 377-381  
red and white wine effects on, in CAD men, 318-323

- Interleukin-1 (IL-1), effects of  $\omega$ -3 PUFAs alone or with *all-rac* - tocopherol on, 236-240
- Interleukin-6 (IL-6)  
 CAD and, *see* Interleukin-6, CAD and  
 in CHD, IR and, 853, 854  
 effects of  $\omega$ -3 PUFAs alone or with *all-rac*  $\alpha$ -tocopherol on, 236-240  
 in inflammation of chronic disease, 901, 902  
 and IR in liver cirrhosis, 923, 924  
 in non-obese men, and AT as fibrinogen level predictor, 985, 986  
*see also* Interleukin-6 mRNA; Interleukin-6 receptor
- Interleukin-6 (IL-6), CAD and  
 aerobic exercise and high-fiber, low-fat diet effects on, in  
 postmenopausal women on ERT and at risk for CAD, 379  
 plasma, red and white wine effects on, in CAD men, 318-323
- Interleukin-6 (IL-6) mRNA (messenger ribonucleic acid), SM,  
 effects of epinephrine and ionomycin on protein release and,  
 compared, 1492-1495
- Interleukin-6 (IL-6) receptor, and IR in liver cirrhosis, 923, 924
- Intermediate-density lipoprotein (IDL)  
 in HL deficiency, 523  
 plasma, in PM and premenopausal women, sex steroids and, 189  
 and plasma vitamin K transport, 216  
*see also* Intermediate-density lipoprotein-cholesterol
- Intermediate-density lipoprotein-cholesterol (IDL-C)  
 in HD subjects, 1104, 1115  
 in IDDM, plasma apo C-3 polymorphisms and, 1301  
 $\omega$ -3 PUFA and exercise effects on, 751  
 S-2E and PRV effects on, in mixed hyperlipidemia, compared,  
 682-683
- Interstitial glucose, kinetics of, in IDDM, 1484-1492
- Intimal-media thickness, *see* Carotid artery intimal-media thickness
- Intracellular  $\text{Ca}^{2+}$ , *see* Calcium $^{2+}$ ; Calcium $^{2+}$  chelator
- Intracellular cord blood platelet magnesium (Mg), relation of, to  
 birth weight, 1544-1547
- Intramuscular triglycerides (TGs) after 1-day hindlimb suspension,  
 1217
- Intranuclear nuclear factor- $\kappa$ B (NF $\kappa$ B), differential effects of glucose  
 and alcohol on ROS generation and, in mononuclear cells,  
 330-334
- Intravascular remodeling of HDL particles, smoking effects on, and  
 its implications for RCT system, 858-862
- Intravenous glucose tolerance test, *see* Frequently sampled  
 intravenous glucose tolerance test
- Ionomycin, effects of epinephrine and, on skeletal muscle IL-6  
 mRNA and protein release, compared, 1492-1495
- IR, *see* Insulin resistance
- IRI, *see* Immunoreactive insulin
- Ischemic heart disease, carotid atherosclerosis, vascular dementia  
 and, 477
- Islets of Langerhans, *see* Pancreatic islets
- Isoflavone, soy, effects of moderate exercise and, on AT  
 accumulation and bone loss in postmenopausal subjects, 942-948
- Isoleucine, *see* Plasma isoleucine
- Isoprostanol,  $\text{F}_2$ , effects of glycemic control on level of, at IDDM  
 onset, 1118-1120
- Isotretinoin, effects of, on plasma TGs and insulin sensitivity, 4-10
- IVGTT (intravenous glucose tolerance test), *see* Frequently sampled  
 intravenous glucose tolerance test
- Japanese adolescents, hyperuricemic obese, 448-453
- Japanese men, polymorphism in  
 -1562C $\rightarrow$ T MMP-9 polymorphism associated with BMD in,  
 135-137
- Japanese men, polymorphism in (*Continued*)  
 obese, Ob-R gene polymorphism associated with IR in, 650-654  
 young, Pro12Ala PPAR $\gamma$ 2 polymorphism associated with  
 adiponectin levels in, 1548-1551
- Japanese NIDDM subjects  
 with incipient diabetic nephropathy in, G276T adiponectin  
 polymorphism in, 1223-1226  
 insulin secretion and sensitivity at different stages of glucose  
 tolerance in, 831-835
- Japanese subjects  
 NIDDM, *see* Japanese NIDDM subjects  
 role of beta-cell dysfunction in development of hyperglycemia in,  
 943-954  
*see also* Japanese adolescents; Japanese subjects, polymorphism in
- Japanese subjects, polymorphism in  
 ABCA1 gene, serum HDL-C or apo A-1 levels associated with, in  
 Japanese school-age children, 182-186  
 G276T adiponectin polymorphism and incipient diabetic  
 nephropathy in NIDDM subjects, 1223-1226  
 leptin receptor gene Lys109Arg and Gln223Arg polymorphisms,  
 relationship between lipids, serum soluble leptin receptor,  
 serum leptin, HOMA IR index, 879-885  
*see also* Japanese men, polymorphism in
- K (potassium) channel inhibitors, and 4AP effects on delayed  
 vasorelaxation by troglitazone, 147-152
- K121Q polymorphism of glycoprotein PC-1, association of, with  
 race but not with IR in children, 465-468
- Kidney, *see* Nephropathy and entries beginning with term: Renal  
 Kinase  
 creatinine, in dyslipidemic CRF subjects on HD, 1116  
*see also* Glycogen synthase; Glycogen synthase kinase- $\beta$ 3 mRNA;  
 Protein kinase; Protein kinase B $\alpha$ /Akt1
- Kinetics  
 apo A-1, apo B-48, and apo B-100, in obese MS subjects with  
 chronic renal disease, 1255-1261  
 of apo B-100 in HL deficiency, 523  
 interstitial glucose, in IDDM, 1488-1492  
 plasma leucine, and whole-body leucine synthesis in  
 hyperinsulinemic young men, 392-393  
 regulation of NEFA, by insulin in adult cystic fibrosis with  
 impaired glucose tolerance, 1467-1472
- Korean subjects  
 effects of PPAR $\gamma$ 2 Pro12Ala polymorphism on AT distribution, in  
 Korean women, 1538-1543  
 non-obese insulin-resistant NIDDM, BMI as determining factor of  
 IR degree in, 142-146  
 obese, effects of UCP-1 -3826A $\rightarrow$ G polymorphism on LDL-C  
 level in, 1054-1059
- Kuwaiti children and adolescents, IDDM, cardiovascular disease risk  
 factors associated with serum sialic acid in, 638-643
- Lactate, DCA-induced hypolactatemia in cirrhotic and noncirrhotic  
 subjects, 1087-1094
- Lactate dehydrogenase (LDH), DM effects on, 68
- Lactic acid, beer ingestion and sauna bathing effects on, 774-775
- Lard in HF diet, 1033
- Late-onset propionic acidemia, fatal outcome of, 809-810
- LBM (lean body mass), *see* Fat-free mass
- LBW (low birth weight) Pima Indians with normal glucose  
 tolerance, insulin secretion, insulin sensitivity in, 904-911
- LCAT, *see* Lecithin:cholesterol acyltransferase
- LDH (lactate dehydrogenase), DM effects on, 68
- LDL, *see* Low-density lipoprotein

- LDL-C, *see* Low-density lipoprotein-cholesterol
- LDLR (low-density lipoprotein receptor)-null subjects, fenofibrate preventing obesity and hypertriglyceridemia in, 607-613
- Lean body mass, *see* Fat-free mass
- Lean subjects, *see* entries beginning with terms: Non-obese subjects
- Lecithin:cholesterol acyltransferase (LCAT)  
smoking effects on concentrations of, 858-862  
*see also* Lecithin:cholesterol acyltransferase,  $\omega$ -3 PUFA effects on
- Lecithin:cholesterol acyltransferase (LCAT),  $\omega$ -3 PUFA effects on in FCHL, 155  
on LCAT activity, 752
- Left ventricular hypertrophy (LVH), candesartan effects on IR and, 777-781
- Leptin  
circulating, as marker of fat mass in acute spinal cord injury, 989-994  
effects of, on HPA activity, weight loss, and dysphagia in STZ-DM, 1558-1564  
effects of agricultural versus traditional lifestyle on, in Ecuadorian Amazon Shuar women, 1355-1358  
increased levels of, associated with Trp64Arg polymorphism of  $\beta_2$ -adrenergic receptor but not with  $-3826A \rightarrow G$  polymorphism of UCP-1 gene in Spanish subjects, 1411-1416  
and relation of intracellular cord blood platelet magnesium to birth weight, 1545  
in young Japanese men, Pro12Ala PPAR $\gamma$ 2 polymorphism, adiponectin and, 1549  
*see also* Leptin mRNA; Leptin in obesity; Leptin receptor; Leptin receptor gene; Leptin therapy; Plasma leptin; Serum leptin
- Leptin mRNA (messenger ribonucleic acid), fenofibrate effects on, in ovariectomized subjects, 1286
- Leptin in obese women  
effects of moderate weight loss and sibutramine or orlistat on, 432  
with PCOS, 362-363
- Leptin in obesity  
effects of leptin therapy on circadian rhythm of, and weight loss after HF diet-induced obesity, 782-789  
in insulin-resistant obese Japanese subjects, 652  
plasma, NN414 and DZ effects on, compared, 443, 444  
*see also* Leptin in obese women
- Leptin receptor, soluble, relationship between serum leptin, serum adiponectin levels, HOMA IR index, lipids, and leptin receptor gene Lys109Arg and Gln223Arg polymorphisms in Japanese subjects, 879-885
- Leptin receptor gene, relationship between serum leptin, serum adiponectin levels, HOMA IR index, lipids, and Lys109Arg and Gln223Arg polymorphisms of, in Japanese subjects, 879-885
- Leptin therapy  
leptin circadian rhythm after weight loss by diet-induced obese subjects increased by, 782-789  
severe lipodystrophy on body composition, 513-519
- Leucine (Leu)  
turnover of, during third trimester of uncomplicated pregnancy, 545-549  
*see also* Plasma leucine
- Leukocyte ABCA1 gene, expression of, associated with fasting glucose concentration in normoglycemic men, 17-21
- LF (low-fat diet), role of caloric intake and high-fat diet versus, in development of NIDDM and obesity, 454-457
- LH, *see* Luteinizing hormone; Luteinizing hormone hypothesis of PCOS
- Lifestyle  
association between diet, cardiovascular risk factors, plasma CRPs and, 1436-1442
- Lifestyle (Continued)  
effects of, on leptin in Ecuadorian Amazon Shuar women, 1355-1358  
effects of, on risk for metabolic syndrome, 1503-1511
- Linoleic acid  
effects of, on SP1-induced apo A-1 promoter, 1343  
TG content of, in MS, 312  
(gamma)-Linoleic acid in MS, 312
- Linolenic acid, effects of, on Sp1-induced apo A-1 promoter, 1344
- Linolenic acid, effects of, on Sp1-induced apo A-1 promoter, 1343  
3n3  $\alpha$  (alpha)-Linolenic acid in MS, 312
- Lipase, *see* Hepatic lipase; Hepatic triglyceride lipase; Lipoprotein lipase; Phospholipase D
- Lipemia, *see* Blood lipids
- Lipid(s)  
blood, *see* Blood lipids  
endurance exercise effects on, 195-196  
erythrocyte membrane, *see* Erythrocyte membrane, lipid composition of  
glargine action on metabolism of, 1037-1044  
hepatic, fenofibrate effects on accumulation of, 610  
in HL deficiency, 520-525  
in obesity, *see* Lipid(s) in obesity  
plasma, *see* Plasma lipids  
relationship between serum soluble leptin receptor, serum leptin, HOMA IR index, leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, and levels of, in Japanese subjects, 879-885  
serum, *see* Serum lipids  
smoking effects on concentrations of, 858-862  
*see also* Lipid peroxides; Phospholipid(s) entries beginning with element: Lip- and specific lipids
- Lipid(s) in obesity  
effects of NN414 and DZ on glucose tolerance and, compared, 441-447  
with NIDDM, bezafibrate effects on glucose metabolism and, 405-413
- Lipid peroxides, carotid atherosclerosis, vascular dementia and, 477, 479
- Lipid transfer inhibitor protein (LTIP), smoking effects on, 858-862
- Lipodystrophic human immunodeficiency virus
- Lipodystrophy  
with HIV infection, IGFs, IGFBPs, GHBP, and IGFBP-3 protease in 1565-1573  
severe, effects of leptin replacement therapy of, on body composition, 513-519
- Lipogenic enzyme mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in white adipose tissue of CRF subjects, 1060-1065
- R-(+)- $\alpha$ -Lipoic acid (R-LA; thioctic acid), effects of, on pyruvate metabolism and NEFA oxidation in hepatocytes, 165-173
- Lipolysis in IR  
IR estimates and, 1199  
skeletal muscle, HF diet effects on, 794-798
- Lipoprotein (Lp)  
during estrous cycle, 140-141  
metabolism of, in hepatic lipase deficiency, 520-525  
plasma, *see* Plasma lipoprotein  
triglyceride-rich, plasma vitamin K transport and, 215-221  
*see also* High-density lipoprotein; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein lipase; Low-density lipoprotein
- Lipoprotein(a) [Lp(a)]  
carotid atherosclerosis, vascular dementia and, 477, 479



- Lipoprotein(a) [Lp(a)] (*Continued*)  
 in FCHL,  $\omega$ -3 PUFA effects in, 154  
 serum, in CAD men, 425  
 smoking effects on, 860  
 in subclinical hypothyroidism, 1513
- Lipoprotein lipase (LPL)  
 effects of NO-1886 as activator of, on fatty liver in STZ-DM subjects due to high-fat diet, 260-263  
 endurance exercise effects on, 196, 198-200  
 HF/HC diet effects on, 1023  
 serum, relation between concentration of, and TG metabolism in hypercholesterolemia, 526-531  
 smoking effects on, 861
- Lisofylline (LSF), effects of, on glucose-stimulated insulin secretion in STZ-DM, and prediabetic and normal subjects, 290-296
- Liver  
 fatty, in STZ-DM, due to high-fat diet, NO-1886 effects on, 260-263  
*see also* Liver weight and *entries beginning with element: Hepat- and specific conditions*
- Liver adipose tissue (AT), and metabolic risk in non-obese premenopausal women, 1066-1071
- Liver cirrhosis, *see* Cirrhosis
- Liver disease, effects of bile duct ligation- and galactosamine-induced, on cardiac protein synthesis, 964-968
- Liver weight  
 leptin replacement therapy effects on, in severe lipodystrophy, 515-516  
 MHN-01 effects on, 981  
 in STZ-DM, NO-1886 effects on, 261
- Long-term exposure of INS-1 cells to *cis* and *trans* FAs, effects of, on insulin secretion and FA oxidation, 1158-1165
- Long-term monitoring of insulin sensitivity in GH-deficient subjects on rhGH therapy, 740-743
- Long-term stored frozen blood samples, analysis of HbA<sub>1c</sub> in, 1497, 1498
- Lovastatin, effectiveness of hydrophilic 7 $\beta$ -hydroxy bile acids, lovastatin, and cholestyramine and, in CTX, compared, 556-562
- Low birth weight (LBW) Pima Indians with normal glucose tolerance, insulin secretion, and insulin sensitivity in, 904-911
- Low-density lipoprotein ( $\beta$  lipoprotein; LDL)  
 atorvastatin effects on, dyslipidemic CRF subjects on HD, 1113-1117  
 diet and, *see* Low-density lipoprotein, diet and  
 effects of T<sub>4</sub> therapy in hypothyroidism on endothelial function and, 279  
 in MS, 312, 313, 315  
 in NIDDM, *see* Low-density lipoprotein in NIDDM  
 oxidation of, *see* Oxidation, LDL  
 plasma, *see* Plasma low-density lipoprotein  
 plasma vitamin K transport and, 218  
 $\omega$ -3 PUFA and exercise effects on subfractions of, 749-754  
 serum adiponectin association with particle size of, in young men, 589-593  
 small-dense, *see* Small-dense low-density lipoprotein  
*see also* Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor-null subjects; Very-low-density lipoprotein
- Low-density lipoprotein ( $\beta$  lipoprotein; LDL), diet and and CV disease risk factors, 1438  
 HC diet effects on atherogenic particles of, 823-830
- Low-density lipoprotein ( $\beta$  lipoprotein; LDL) in NIDDM  
 insulin therapy effects on, 694, 697
- Low-density lipoprotein ( $\beta$  lipoprotein; LDL) in NIDDM (*Continued*)  
 plasma oxidized, correlation between vascular complications, serum PON1 polymorphism and, 297-302  
 PP, alcohol effects on, 78
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C)  
 $\beta$ <sub>2</sub>-ADR Arg16Gly polymorphism and, 1184  
 carotid artery IMT and, 1155  
 carotid atherosclerosis, vascular dementia and, 477, 479  
 in children, *see* Low-density lipoprotein-cholesterol in children  
 diet and, *see* Low-density lipoprotein-cholesterol, diet and  
 in dyslipidemic CRF subjects on HD, 1114  
 during estrous cycle, 140  
 exercise and, *see* Low-density lipoprotein-cholesterol, exercise effects on  
 in HD subjects, 1014  
 in hypercholesterolemia, *see* Low-density lipoprotein-cholesterol in hypercholesterolemia  
 in hyperlipidemia, *see* Low-density lipoprotein-cholesterol in hyperlipidemia  
 in IDDM, *see* Low-density lipoprotein-cholesterol in IDDM  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 in IR, *see* Low-density lipoprotein-cholesterol in IR  
 in Japanese school-age children, *ABCA1* gene polymorphism association with, 183  
 in Korean women, AT distribution and, 1541  
 leptin and, *see* Low-density lipoprotein-cholesterol, leptin and  
 in MS *see* Low-density lipoprotein-cholesterol in MS  
 in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM  
 in non-obese men, and AT as level of fibrinogen predictor, 985, 986  
 in obesity, *see* Low-density lipoprotein-cholesterol in obesity  
 in overweight women, serum TNF soluble receptors, TNF- $\beta$ , NO and, 1269  
 plasma, anti-inflammatory effects of  $\omega$ -3 PUFA alone or combined with *all-rac*  $\alpha$ -tocopherol on, 237  
 plasma LDL clearance and, 484  
 plasma vitamin K transport and, 216  
 in PM women, *see* Low-density lipoprotein-cholesterol in PM women  
 in postpubertal Asian Indian adolescents, 1338  
 serum, in CAD men, 425  
 smoking effects on, 860  
 in subclinical hypothyroidism, 1513  
 WPG effects on, 1311-1312  
 in young subjects, *see* Low-density lipoprotein-cholesterol in young subjects
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C), diet and  
 aerobic exercise and high-fiber, low-fat diet effects in postmenopausal women on ERT and at risk for CAD, 378  
 and CV disease risk factors, 1437  
 HF/HC diet effects, 1023
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C), exercise effects on  
 exercise effects on, in overweight nondiabetic and NIDDM subjects, 1236  
 in PM women, *see* Low-density lipoprotein-cholesterol, exercise effects on, in PM women on ERT  
 $\omega$ -3 PUFA and exercise effects, 749-751  
 in soccer players, 1264



- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C), exercise effects on (*Continued*)  
 see also Low-density lipoprotein-cholesterol in exercise,  $\dot{V}O_{2\max}$  and
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C), exercise effects on, in PM women on ERT  
 or not on ERT, 1194  
 with risk for CAD, aerobic exercise and high-fiber, low-fat diet effects, 378
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C), leptin and  
 leptin levels and, 1412-1414  
 and leptin receptor gene polymorphism, 881-883
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in children  
 in Japanese school-age children, *ABCA1* gene polymorphism association with, 183  
 in Vietnamese children with apo E polymorphism, 1519
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in exercise,  $\dot{V}O_{2\max}$  and  
 blood, apo E polymorphism and, 111-113  
 serum, in endurance exercise, apo E genotype and changes in  $\dot{V}O_{2\max}$ , 196, 198-200
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in hypercholesterolemia  
 in mild hypercholesterolemia, 1073  
 serum LPL concentration and, 527, 528
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in hyperlipidemia  
 anti-inflammatory effects of  $\omega$ -3 PUFAs in FCHL and, 154  
 S-2E and PRV effects on, in mixed hyperlipidemia, 682-683
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in IDDM  
 and oxidation of glycated and nonglycated LDLs, 970  
 plasma apo C-3 polymorphisms and, 1299, 1301
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in IR  
 associated with CV disease risk factors, 498  
 in insulin-resistant obese Japanese subjects, 651  
 in non-obese Korean NIDDM subjects, 143, 144  
 see also Low-density lipoprotein-cholesterol in obesity with IR
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in MS, 312  
 with acute SCI, 991  
 with obesity and chronic renal disease, 1257
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in NIDDM  
 and at-risk for NIDDM subjects, 224, 226  
 HbA<sub>1c</sub>-lipid composition correlation in RBC membrane and, 124  
 metformin effects on, 160, 161  
 in non-obese insulin-resistant Korean subjects, 143, 144  
 Pancreas Tonic effects on, 1169  
 rosiglitazone effects on, 1123  
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 301
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in obese women  
 fluvastatin effects on, 736  
 sibutramine or orlistat effects on, after moderate weight loss, 432
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in obesity  
 with MS and chronic renal disease, 1257  
 in obese adolescents, 864
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in obesity (*Continued*)  
 in obese Korean subjects, -3826A  $\rightarrow$  G UCP-1 polymorphism effects on level of, 1054-1059  
 and smoking-ADMA-obesity relationship, 1575, 1576  
 see also Low-density lipoprotein-cholesterol in obese women;  
 Low-density lipoprotein-cholesterol in obesity with IR
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in obesity with IR  
 in obese Japanese men, 651  
 prevalence of associated CV disease risk factors with, 498
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in PM women  
 simvastatin effects on BMD and, 745, 746  
 see also Low-density lipoprotein-cholesterol, exercise effects on, in PM women on ERT
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in young men  
 with hypertensive parents, 470, 473  
 serum adiponectin association with, 590
- Low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in young subjects  
 with NIDDM parents, 756  
 see also Low-density lipoprotein-cholesterol in young men
- Low-density lipoprotein receptor (LDLR)-null subjects, fenofibrate preventing obesity and hypertriglyceridemia in, 607-613
- Low-fat (LF) diet, role of caloric intake and high-fat diet versus, in NIDDM and obesity development, 454-457
- Low-fat/high-fiber diet, effects of exercise and, on inflammatory and adhesion molecules in postmenopausal women on ERT and at risk for CAD, 377-381
- Low-grade inflammation, role of, in MS with CHD, 852-857
- Low temperature, hCG stimulatory effects on steroidogenic acute regulatory protein mRNA and testosterone production blocked by, but not cAMP production in tumor cells, 955-958
- Lp, see Lipoprotein
- Lp(a), see Lipoprotein(a)
- LPL, see Lipoprotein lipase
- LSF (lisofylline), effects of, on glucose-stimulated insulin secretion in STZ-DM, prediabetic, and normal subjects, 290-296
- LTIP (lipid transfer inhibitor protein), smoking effects on, 858-862
- Luteinizing hormone (LH)  
 in older NIDDM men with partial androgen deficiency, 668  
 plasma Lp and, in PM women, 189, 190
- Luteinizing hormone (central) hypothesis of PCOS, 359-361
- LVH (left ventricular hypertrophy), candesartan effects on IR and, 777-781
- LY117018, effects of, on GH secretion, 563-570
- Lyase, see Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA; 17 $\alpha$  (alpha)-Hydroxylase/17,20-lyase deficiency
- Lymphocytes, activated CD4<sup>+</sup> and CD8<sup>+</sup> T, in growth factor receptors, 117-122
- Lys109Arg and Gln223Arg polymorphisms, relation between leptin receptor gene, HOMA IR index, serum soluble leptin receptor, serum leptin, lipids and, in Japanese subjects, 879-885
- Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution, effects of GLP-1(7-36) amide, on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Lysine (Lys)  
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

Lysine (Lys) (*Continued*)

see also Lys109Arg and Gln223Arg polymorphisms; Lys<sup>9</sup>-for-Glu<sup>9</sup> substitution

Macrophages, effects of caffeine on alveolar, via its effects on synthesis of cAMP and prostaglandin, 687-692

Macrovascular diseases in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 298-300

## Magnesium (Mg)

erythrocyte levels in, and metabolism of, 660-665

in primary hyperthyroidism, 1102

relationship of intracellular cord blood platelet, to birth weight, 1544-1547

serum, in adrenal insufficiency, 1252

Male adolescents, Japanese obese hyperuricemic, 448-453

## Male subjects

transgenic, glucose intolerance development in, with GSK-3 $\beta$  overexpression in skeletal muscle, 1322-1330

see also Male adolescents; Men

Malic enzyme (ME) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065

Malonyl dialdehyde (MDA), DM effects on, 66-72

Maltose dextrin in obesity-inducing HF diet, 783

Margarine, PP TG response to, 621, 622

Matrix metalloproteinase-9 (MMP-9), -1562C $\rightarrow$ T polymorphism of, associated with BMD in Japanese men, 135-137

Maturity-onset hyperinsulinemia and hyperglycemia (diabetes), CL316,243 effects on, in polygenic obesity, 799-808

Maximum oxygen uptake, see  $\dot{V}O_{2max}$

MBF (medullary blood flow), tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308

MCP-1, see Monocyte chemoattractant protein-1

MCR (metabolic clearance rate) of hypogonadic men, 1175

MC3T3-E1 osteogenic cells, strontium ranelate-induced bone matrix mineralization in, 532-537

MDA (malonyl dialdehyde), DM effects on, 66-72

ME (malic enzyme) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065

Medullary blood flow (MBF), tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308

Medullary collecting duct, inner, ET effects on AVP<sub>2</sub> mRNA in, 1177-1183

Melanoma-associated cachexia, ghrelin mRNA in, 84-88

## Men

with CAD, see Coronary artery disease in men

cortisol in, see Cortisol in men

erythrocyte membrane lipid composition in, associated with arachidonic acid and insulin sensitivity, 571-577

HC diet effects on atherogenic LDL particles in, 823-830

Japanese, see Japanese men, polymorphism in

non-obese, adipose tissue as marker of fibrinogen level in, 994-998

normoglycemic, fasting glucose concentration and leukocyte ABCA1 gene expression in, 17-21

obese, see Men, obese

older NIDDM, partial androgen deficiency and glycemic control in, 666-672

plasma vitamin K transport and deuterium-labeled collard green intake by, 215-221

spinal cord-injured, MS in, 1372-1377

young, see Young men

see also Sex entries beginning with term: Male and specific conditions

## Men, obese

Japanese, Ob-R gene polymorphism associated with IR in, 650-654

NEFA effects on hepatic glycogen content in, 886-893

Mental stress, and lipolysis activation in IR, 1199

Messenger ribonucleic acid, see mRNA

Met, see Methionine

Metabolic clearance rate (MCR) of hypogonadic men, 1175

## Metabolic rate (MR)

effects of dietary zinc restriction on substrate utilization and, 727-732

resting, in advanced NIDDM nephropathy, 1395-1398

Metabolic research, accuracy and precision of peristaltic and syringe pumps in, compared, 875-878

Metabolic risk in non-obese premenopausal women, abdominal and liver AT and, 1066-1071

## Metabolic syndrome (MS)

in CHD, low-grade inflammation and, 852-857

CRH test of relation between central HPA dysfunction and, 720-726

exercise effects on abdominal AT, body composition and, in PM women on or not on ERT, 1192-1196

fatty acid TG content and VAT accumulation associated with components of, 310-317

lifestyle effects on risk for, 1503-1511

with obesity, see Metabolic syndrome with obesity

in SCI men, 1372-1377

## Metabolic syndrome (MS) with obesity

and chronic renal disease, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261

serum TNF- $\beta$  and components of, in obese adolescents, 863-867 in treatment-seeking subjects, 435-440

## Metformin (dimethylbiguanide)

effects of, on multiple CV disease risk factors in NIDDM, 159-164

effects of, Pancreas Tonic and, in NIDDM, compared, 1169 for obese PCOS women, 366, 368, 370

## Methionine (Met)

in HF diet, 1033

plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

[<sup>2</sup>H<sub>3</sub>]-3-Methylhistidine, contractile skeletal muscle protein breakdown estimated with, 1076-1080

Mg, see Magnesium

MI (myocardial infarction), risk factors for, as predictors of CAD in men, 324-329

## Microalbuminuria

in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641

see also Microalbuminuria in IR; Microalbuminuria in NIDDM

## Microalbuminuria in IR

with cardiovascular autonomic dysfunction and IR, 1359-1364 cilostazol effects on, 1405-1410

## Microalbuminuria in NIDDM

and in at-risk for NIDDM subjects, 228

with cardiovascular autonomic dysfunction and IR, 1359-1364 glycemic control effects on, 353-357

## Microangiopathies, diabetic, in NIDDM, serum PON1

polymorphism, plasma oxidized LDL level and, 301

Micromolar concentrations of Cu, effects of, on endothelium-dependent on aorta relaxation in DM, 1315-1321

Mild hypercholesterolemia, diet composition as determinant of plasma ADMA in, 1072-1075

- Mildly elevated plasma cholesterol (C), wheat germ policosanols effects on, 1309-1314
- Mineral content, changes in bone, after RYBG and ASGB for morbid obesity, 918-921
- Mineral density, *see* Bone mineral density
- Mineral mix in HF diet, 1033
- Mineralization, *see* Bone mineralization
- Minimal model analysis  
   population and individual, of FSIVGTT, 1349-1354  
   of relationship between BMI, beta-cell function, and IR, 1462-1466  
   of weight loss effects in obese subjects with normal FPG or IGT on IR and insulin release, 1095-1100
- Mixed hyperlipidemia, effects of S-2E and PRV in, compared, 680-685
- MMP-9 (matrix metalloproteinase-9), -1562C→T polymorphism of, associated with BMD in Japanese men, 135-137
- MNCs (mononuclear cells), differential effects of glucose and alcohol on ROS generation and intranuclear nuclear factor- $\kappa$ B in, 330-334
- MNH-01 formula (palatinose-based liquid balanced formula), effects of, on PP hyperglycemia and hyperinsulinemia, 977-983
- Moderate exercise  
   effects of soy isoflavone and, on AT accumulation and bone loss in postmenopausal subjects, 942-948  
   insulin concentration and CHO requirement in IDDM during, 1126-1130
- Moderate weight loss by obese women  
   effects of sibutramine or orlistat treatment and, on waist circumference and serum adipocytokines, 430-434  
   by insulin-resistant obese women, effects of, on plasma adiponectin, 280-283
- Modified insulin (hexyl-insulin monoconjugate 2), oral, for IDDM, 54-58
- Monocyte chemoattractant protein-1 (MCP-1)  
   effects of insulin therapy of NIDDM on, 695, 697  
   effects of  $\omega$ -3 PUFAs alone or with *all-rac* on, 238
- Monodrug therapy, adiponectin, C-reactive protein and, in obesity and NIDDM, 1454-1461
- Mononuclear cells (MNCs), differential effects of glucose and alcohol on ROS generation and intranuclear nuclear factor- $\kappa$ B in, 330-334
- Monophosphate, *see* Adenosine monophosphate
- Monounsaturated fatty acids (MUFAs)  
   CV disease risk factors and intake of, 1439  
   intake of, by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51  
   in MNH-01 formula, 978  
   plasma ADMA in mild hypercholesterolemia and, 1073  
   WPG effects and, 1312
- Morbid obesity, changes in BMC after RYBG and ASGB for, 918-921
- Morbidity of STZ-DM, effects of oral vanadate with tea extract on, 1145-1151
- Morphometry of early NIDDM nephropathy subjects, pioglitazone effects on, 1476
- Mortality  
   late-onset propionic acid, 809-810  
   low CHD, in Spain, plasma HDL-C level in Spanish children and, 1045-1047  
   STZ-DM-associated, effects of oral vanadate with tea extract on, 1145-1151
- MR, *see* Metabolic rate
- mRNA (messenger ribonucleic acid)  
   apo A-1, in HepG2 cells, glucosamine effects on, 766-771  
   AVP<sub>2</sub>, in IMCD, ET effects on, 1177-1183  
   CRABP-1, effects of, on CYP26-mediated catabolism of A11-*trans* retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012  
   effects of epinephrine and ionomycin on protein release and IL-6, in SM, compared, 1492-1495  
   fibronectin, *see* Fibronectin mRNA  
   ghrelin peptide, in melanoma-associated cachexia, 84-88  
   glucocorticoid receptor, leptin effects on, in STZ-DM, 1560-1561  
   GLUT<sub>4</sub>, exercise effects on glycogen synthase activity and, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242  
   GSK-3 $\beta$ , in skeletal muscle of transgenic male subjects, 1322-1330  
   11 $\beta$ -HSD1, *see* 11 $\beta$ -Hydroxysteroid dehydrogenase 1 mRNA  
   leptin, fenofibrate effects on, in ovariectomized subjects, 1286  
   leukocyte *ABCA1*, relationship of fasting glucose to, in normoglycemic men, 19  
   PPAR $\alpha$ , *see* Peroxisome proliferator-associated receptor  $\alpha$  mRNA  
   PPAR $\gamma$ , effects of restricted diet on, 30-31  
   preproglucagon, palmitate effects on, 1445-1446  
   renal CHPT, in NIDDM, 842-846  
   renal 11 $\beta$ -HSD2, responsiveness of body weight and, to 11 $\beta$ -HSD inhibition by glycyrrhetic acid, 600-606  
   renal TGF- $\beta$ <sub>1</sub>, fibronectin, and collagen, cilostazol effects on, in IR, 1405-1410  
   steroidogenic acute regulatory protein, low temperature blocking testosterone production and stimulatory effects of hCG on, but not on cAMP production in tumor cells, 955-958  
   TGF- $\beta$ 1 endothelin-1, effects high glucose and insulin on, in cardiac fibroblasts, 712  
   UCP-1, *see* Uncoupling protein-1 mRNA  
   UCP-2, adipin, and myostatin, in diabetes, CL316,243 effects on, 804  
   UCP-3, C316,243 effects on, in diabetes, 804  
   upregulation of lipogenic enzyme and SREBP-1, in WAT of CRF subjects, 1060-1065
- MS, *see* Metabolic syndrome
- MUFAs, *see* Monounsaturated fatty acids
- Multiphasic profile of NEFAS, unresponsiveness of, to exogenous insulin during FSIVGTT, 1202-1207
- Multiple cardiovascular (CV) disease, metformin effects on risk factors for, 159-164
- Muscle, *see* Muscle glutamine; Skeletal muscle and entries  
   beginning with element: Myo-
- Muscle glutamine (Gln), changes in release of, during normoglycemic hyperinsulinemia and hypoglycemia, 1208-1214
- Mutations  
   of CYP17 genes in 17( $\alpha$ )-hydroxylase/17,20-lyase deficiency, 1527-1531  
   hypoxanthine phosphoribosyl transferase point, responsible for hyperuricemia in women, 1500-1502  
   triple *HNF-4 $\alpha$*  gene, associated with early-onset NIDDM in Filipino family, 959-963  
   *see also* Polymorphism
- Myocardial infarction (MI), risk factors for, as predictors of CAD in men, 324-329
- Myocytes  
   cardiac, high glucose and insulin effects on protein synthesis in, 710-715  
   DNA synthesis from different pathways in fibroblasts, 128-133

- Myofibrillar protein in skeletal muscle, effects of dietary protein restriction on conservation of, 340-347
- Myostatin mRNA (messenger ribonucleic acid), CL316,243 effects on, in diabetes, 804
- Myristic acid  
effects of, on Sp1-induced apo A-1 promoter, 1343  
TG content of, in MS, 312
- Na (sodium), serum, beer ingestion and sauna bathing effects on urinary excretion of, 774
- Nateglinide in NIDDM  
effects of glyburide and, compared, 1331-1335  
with obesity, effects of pioglitazone and, on beta-cell mass loss and insulin secretion in, 488-494
- Natriuretic peptide, brain, in IR with LVH, candesartan effects on, 778-780
- NE, *see* Norepinephrine
- NEFAs, *see* Nonesterified fatty acids
- Neonates, *see* Newborns
- Nephropathy  
chronic, with obesity and MS, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261  
NIDDM, *see* Non-insulin-dependent diabetes mellitus nephropathy
- Neuropathy, peripheral, in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Neutrophils, dietary oil effects on FA composition in, 59-65
- Newborns (infants)  
with respiratory distress and sepsis, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age versus, 209-214  
and 3,3'-T<sub>2</sub>S in neonatal life, 538-543
- NF $\kappa$ B (nuclear factor- $\kappa$ B), intranuclear, differential effects of glucose and alcohol on ROS generation and, in mononuclear cells, 330-334
- Nicotine  
acute effects of, on serum glucose, insulin, GH, and cortisol, 578-582  
*see also* Smoking
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nighttime hypoglycemia, differences between daytime and, in counterregulation of, 894-898
- Nitrate/nitrite (No<sub>x</sub>)  
OGTT of plasma, in sedentary and endurance training subjects, 673-679  
renal cortex, effects of different glucose levels on, 868-874
- Nitric oxide (NO)  
effects of different glucose levels on arginase activity and production of, in renal cortex, 868-874  
serum concentration of TNF soluble receptors, TNF- $\beta$  and, in overweight and obese women, 1268-1273
- Nitric oxide synthase (NOS)  
effects of inhibition of, on pioglitazone action on insulin in subjects on high-sucrose diet, 22-27  
inducible and endothelial, in early NIDDM nephropathy, 1474  
renal cortex, effects of different glucose levels on, 868-874  
and smoking-ADMA-obesity relationship, 1575, 1576
- Nitrite, *see* Nitrate/nitrite
- Nitrogen, *see* BUN
- NN414, effects of DZ and, on glucose tolerance and lipids in obesity, compared, 441-447
- NO, *see* Nitric oxide
- NO-1886, effects of, on fatty liver in STZ-DM subjects due to high-fat diet, 260-263
- Noncirrhotic subjects, DCA-induced hypolactatemia in, 1087-1094
- Nondiabetic subjects  
LSF effects on glucose-stimulated insulin secretion in, 290-296  
overweight, effects of exercise on GLUT<sub>4</sub> mRNA and glycogen synthase activity in, but not on insulin signaling, 1233-1242  
pituitary response to exercise by nondiabetic smokers, 1140-1144
- Nonesterified fatty acids (NEFAs; free fatty acids)  
adiponectin regulation by, 790-793  
in adult CF, insulin regulating kinetics of, 1467-1472  
in hypercholesterolemia, serum LPL concentration and, 528  
insulin regulating kinetics of, in adult cystic fibrosis with impaired glucose tolerance, 1467-1472  
in IR, and cilostazol effects on microalbuminuria, 1407  
isotretinoin effects on, 6  
MHN-01 effects on concentration of, 981  
in obesity, *see* Nonesterified fatty acids in obesity  
oxidation of, *see* Oxidation, NEFA  
plasma, *see* Plasma nonesterified fatty acids  
short-term effects of, on glucagon secretion at low-to-normal glucose concentrations, 1443-1448  
smoking effects on, 860  
unresponsiveness of multiphasic profile of, to exogenous insulin during FSIVGTT, 1202-1207
- Nonesterified fatty acids (NEFAs; free fatty acids) in obesity  
effects of, on hepatic glycogen content in obese men, 886-893  
effects of weight loss by obese subjects with normal FPG or IGT on, 1097  
fasting serum, in obese NIDDM subjects, bezafibrate effects on, 407-408  
in obese PM women, fluvastatin effects on, 736
- Nonglycated low-density lipoprotein (LDL), susceptibility to oxidation of glycated LDLs and, in IDDM, compared, 969-975
- Non-high-density lipoprotein ( $\alpha$  lipoprotein; HDL), utility of, in hemodialyzed subjects, 1013-1015
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus)  
alcohol effects on PP lipemia in, 77-83  
association of corrected QT intervals with carotid artery IMT in, 1152-1157  
coronary heart disease in, *see* Coronary heart disease in NIDDM  
dyslipidemia in, *see* Dyslipidemia in NIDDM  
early-onset, triple mutations of *HNF-4 $\alpha$*  associated with, in Filipino family, 959-963  
glycemic control in, *see* Glycemic control of NIDDM  
HbA<sub>1c</sub> in, *see* HbA<sub>1c</sub> in NIDDM  
hypertension in, *see* Hypertension in NIDDM  
with IGT, *see* Impaired glucose tolerance in NIDDM  
in Japanese subjects, *see* Japanese NIDDM subjects  
LDL oxidation in, *see* Non-insulin-dependent diabetes mellitus, LDL oxidation in  
microalbuminuria in, *see* Microalbuminuria in NIDDM  
in non-obese Korean subjects, BMI as determining factor of IR degree in, 141-146  
with obesity, *see* Obesity, NIDDM with  
overweight subjects with, effects of exercise on GLUT<sub>4</sub> mRNA and glycogen synthase activity in, but not on insulin signaling, 1233-1242  
Pancreas Tonic effects in, 1166-1173  
polymorphism in, *see* Non-insulin-dependent diabetes mellitus, polymorphism in  
renal CHPT in, 842-846  
risk factors for CV disease in, *see* Risk factors for CV disease in NIDDM  
stevioside effects on, 73-76



- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) (*Continued*)  
*see also* Non-insulin-dependent diabetes mellitus nephropathy;  
 Non-insulin-dependent diabetes mellitus retinopathy
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), LDL oxidation in  
 correlation between vascular complications, plasma oxidized LDL level, serum PON1 polymorphism in, 297-302
- LDL susceptibility to oxidation and circulating cell adhesion molecules in young subjects with NIDDM parents, 755-759
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), pioglitazone effects on  
 on beta-cell mass loss prevention and insulin secretion in obese subjects, 488-494
- effects of NOS inhibition and, on insulin action in subjects on high-sucrose diet, 22-27
- on microalbuminuria, 353-357
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), polymorphism in  
 ACPI polymorphism-ADA interaction in, 995-1001
- correlation between vascular complications, plasma oxidized LDL level, and serum PON1 polymorphism in, 297-302
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) nephropathy  
 advanced, resting metabolic rate in, 1395-1398
- incipient, in Japanese NIDDM subjects, G276T adiponectin polymorphism in, 1223-1226
- see also* Non-insulin-dependent diabetes mellitus nephropathy, pioglitazone effects in
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) nephropathy, pioglitazone effects in  
 on carotid artery IMT and stiffness in, 1382-1386
- in early NIDDM nephropathy, 1473-1479
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) retinopathy  
 microalbuminuria and, 354
- postprandial plasma fructose in, 583-588
- serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Non-obese subjects  
 apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
- hepatic 11 $\beta$ -HSD1 and renal 11 $\beta$ -HSD2 mRNA responsiveness to 11 $\beta$ -HSD inhibition by glycyrrhetic acid in, 600-606
- IGT, insulin secretion and GLP-1 and glucose-dependent insulinotropic polypeptide after glucose ingestion by, 624-631
- in IR, *see* Non-obese subjects, insulin-resistant
- non-obese men, AT as marker of fibrinogen level in, 994-998
- preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by, 1449-1453
- see also* Non-obese women
- Non-obese subjects, insulin-resistant  
 and HF diet effects on insulin-resistant lipolysis in skeletal muscle, 794-798
- in NIDDM Korean subjects, BMI as determining factor in IR degree in, 142-146
- Non-obese women  
 clinical manifestations of PCOS in, 365-367
- premenopausal, abdominal and liver AT and metabolic risk in, 1066-1071
- Nonthyroidal diseases  
 3,3'-T<sub>2</sub>S in, 538-543
- see also specific conditions*
- Noradrenaline, *see* Norepinephrine
- Norepinephrine (NE; noradrenaline) (*Continued*)  
 effects of exercise on inhibitory effects of, on insulin secretion, 1424-1432
- 4AP effects on delayed vasorelaxation of, by troglitazone, 147-152
- nighttime and daytime differences in counterregulation of hypoglycemia and, 895
- in obese men, NEFA effects on levels of, 892
- plasma, *see* Plasma norepinephrine
- Normal fasting plasma glucose (FPG), effects of weight loss by obese subjects with IGT or, on insulin release and IR, 1095-1100
- Normal glucose tolerance, insulin release and secretion in and effects of weight loss by obese subjects with, on insulin release, 1095-1100
- and insulin sensitivity in LBW Pima Indians with, 904-911
- Normocholesterolemia  
 daytime hypertriglyceridemia and, in prematurely atherosclerotic subjects and in their first-degree relatives, 49-53
- wheat germ policosanols effects on, 1309-1314
- Normoglycemic hyperinsulinemia  
 effects of acute insulin-induced hypoglycemia and, on retinal glucose uptake and ocular glucose metabolism, 1274-1283
- muscle glutamine release during hypoglycemia and, 1208-1214
- Normoglycemic men, fasting glucose concentration and leukocyte ABCA1 gene expression in, 17-21
- Normoponderal subjects, *see* Non-obese subjects
- NOS, *see* Nitric oxide synthase
- NO<sub>x</sub>, *see* Nitrate/nitrite
- Nuclear factor- $\kappa$ B (NF $\kappa$ B), intranuclear, differential effects of glucose and alcohol on ROS generation and, in mononuclear cells, 330-334
- Nutrition, *see* Diet
- Nutritional status of Vietnamese children, apo E polymorphism and, 1518-1519
- O<sub>2</sub>, *see* Oxygenation; VO<sub>2max</sub>
- Obesity  
 adaptive thermogenesis and resistance to, 1417-1423
- chronic renal disease with MS and, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
- CV disease risk factors and, 1439
- effects of *P. yoelli* GPIs on glucose homeostasis in STZ-DM with, 1048-1053
- fenofibrate effects on hypertriglyceridemia and, in LDL-receptor null subjects, 607-613
- hepatic 11 $\beta$ -HSD1 and renal 11 $\beta$ -HSD2 mRNA responsiveness to 11 $\beta$ -HSD inhibition by glycyrrhetic acid in, 600-606
- high-fat diet and, *see* High-fat diet, obesity and
- hyperinsulinemia and, *see* Hyperinsulinemia, obesity and
- insulin release in, *see* Insulin release and secretion in obesity
- insulin sensitivity and, 1109
- IR and, *see* Insulin resistance in obesity
- in Korean subjects, -3826A $\rightarrow$ G UCP-1 polymorphism effects on level of LDL-C in, 1054-1059
- lipids in, *see* Lipid(s) in obesity
- morbidity, changes in BMC after RYBG and ASGB for, 918-921
- MS with, *see* Metabolic syndrome with obesity
- NIDDM with, *see* Obesity, NIDDM with
- omental and subcutaneous AT in, *see* Omental adipose tissue, subcutaneous and, in obese subjects
- preclinical changes in abdominal aorta of children with, 1243-1246
- relationship between smoking, ADMA and, 1574-1579
- weight loss in, *see* Weight loss by obese subjects



Obesity (*Continued*)

see also Adolescents, obese; Men, obese; Polycystic ovary syndrome, obesity and; Postmenopausal women, obese; Women, obese

## Obesity, NIDDM with

adiponectin, C-reactive protein, and monodrug therapy in, 1454-1461  
bezafibrate effects on lipids and glucose metabolism in, 405-413  
CL316.243 effects on NIDDM with polygenic obesity, 799-808  
GITS preventing NIDDM in IGT first-degree relatives of obese NIDDM African American subjects, 414-422  
pioglitazone and nateglinide effects on insulin secretion and beta-cell mass loss in, 488-494  
role of HF versus LF diet and caloric intake in development of, 454-457

## Ob-R gene polymorphism associated with IR in Japanese men, 650-654

OCs, *see* Oral contraceptives

## Ocular glucose metabolism, effects of acute insulin-induced hypoglycemia and normoglycemic hyperinsulinemia on retinal glucose uptake and, 1274-1283

OGTT, *see* Oral glucose tolerance test

## 8-OHdG (8-hydroxydeoxyguanosine), hepatic, effects of hypoxia and hypoxic training on levels of, 716-719

## Oil(s)

effects of different dietary, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65  
see also Oil in HF diet; Olive oil

## Oil in HF diet

soybean, 783  
sunflower, 1033

## Older (elderly) subjects

disabled hospitalized, HHcy in, 1016-1020  
hypertensive, resistance exercise effects on insulin-mediated glucose disposal with minimal effect on TNF- $\alpha$  in, 397-402  
older NIDDM men, partial androgen deficiency and glycemic control in, 666-672

## Oleate, short-term effects of, on glucagon secretion, 1444-1445

## Oleic acid

effects of, on Spl-induced apo A-I promoter, 1343, 1344  
TG content of, in MS, 312

## Oligomenorrhea in obese PCOS women, 366

## Olive oil (OO)

effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65  
PP TG response to, 621, 622

Omega-3 polyunsaturated fatty acids, *see*  $\omega$ -3 Polyunsaturated fatty acids

## Omental adipose tissue (AT), subcutaneous and, in obese subjects proliferation and differentiation of adipocyte precursor cells from obese subjects, compared, 632-637

racial differences in  $\beta$ -adrenergic receptor density in subcutaneous and, in obese women, 247-251

## One-day hindlimb suspension, whole-body and skeletal muscle IR development after, 1215-1222

Onset of IDDM, effects of glycemic control on F<sub>2</sub> isoprostane level at, 1118-1120OO, *see* Olive oil

## Oral contraceptives (OCs)

effects of, on glucoregulatory responses to exercise, 348-352  
for PCOS in obese women, 366, 370

## Oral glucose tolerance test (OGTT)

in CF with impaired glucose tolerance, 1468  
exercise and, *see* Oral glucose tolerance test of exercising subjects

Oral glucose tolerance test (OGTT) (*Continued*)

insulin sensitivity and, *see* Oral glucose tolerance test, insulin sensitivity and  
of lisofylline effects on glucose-stimulated insulin secretion, 290, 291

nicotine effects on, 578-582

after 1-day hindlimb suspension, 1217

plasma nitrate/nitrite assessment with, in sedentary subjects, 673-679

of stevioside effects on glucose transport in skeletal muscle of insulin-resistant subjects, 101-103, 106

of young men with hypertensive parents, 471

*see also* Impaired glucose tolerance

## Oral glucose tolerance test (OGTT), insulin sensitivity and estimates of insulin sensitivity based on, 1107-1112

normal, in LBW Pima Indians, 904-911

of stevioside effects on glucose transport in skeletal muscle of insulin-sensitive subjects, 101-103, 106

## Oral glucose tolerance test (OGTT) of exercising subjects

of exercising NIDDM women, 284, 285, 287

and OC effects on glucoregulatory responses to exercise, 348-352  
plasma nitrate/nitrite assessment of, 673-679

## Oral modified insulin (hexyl-insulin monoconjugate 2) for IDDM, 54-58

## Oral vanadate with tea extract, effects of, on morbidity and mortality of STZ-DM, 1145-1151

## Organ weight

heart, in liver disease, 965

kidney, in IR, with microalbuminuria, 1407

*see also* Liver weight

## Orlistat, effects of moderate weight loss and, on waist circumference and serum adipocytokines in obese women, 430-434

## Ornithine, hyperinsulinemia effects on whole-body synthesis of, in young men, 392

## Osteocalcin, serum, in severe lipodystrophy, leptin replacement therapy effects on, 516

## Osteogenic cells, MC3T3-E1, strontium ranelate-induced bone matrix mineralization in, 532-537

## Ovarian (peripheral) hypothesis of PCOS, 360, 361

## Ovariectomized subjects, fenofibrate effects on white adipose tissue and HF diet-induced weight gain by, 1284-1289

## Overweight

L-carnitine effects on fat oxidation, protein turnover, and body composition in slight, 1001-1006

concentration of serum TNF soluble receptors, TNF- $\beta$ , and NO in overweight women, 1268-1273

in nondiabetic and NIDDM subjects, effects of exercise on

GLUT<sub>4</sub> mRNA and glycogen synthase activity in, but not on insulin signaling, 1233-1242

preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by overweight subjects, 1449-1453

prevalence of IR with associated CV disease risk factors in, 495-499

*see also* Obesity

## Oxidase, plasma diamine, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41

## Oxidation

AT, L-carnitine effects on fat, in slightly overweight subjects, 1001-1006

energy substrate, in IDDM, 655-659

*cis* and *trans* FA, effects of long-term exposure of INS-1 cells to, on insulin secretion and, 1158-1165

Oxidation (*Continued*)

see also Oxidation, glucose; Oxidation, LDL; Oxidation, NEFA; Oxidative stress

## Oxidation, glucose

*P. yoelli* GPI effects on, in STZ-DM with obesity, 1050  
whole-body, and oral glucose metabolism in born small-for-gestational-age children, 847-851

## Oxidation, LDL

circulating cell adhesion molecules and susceptibility to, in young NIDDM men, 755-759  
of glycated and nonglycated LDLs in IDDM, 969-975  
see also Oxidized low-density lipoprotein

## Oxidation, NEFA

R-(+)- $\alpha$ -lipoic acid effects on pyruvate metabolism and, in hepatocytes, 165-173  
see also Exercise at cold temperature, NEFA oxidation during  
Oxidative stress in NIDDM with obesity, pioglitazone protecting beta cells from, 488-494

## Oxidized low-density lipoprotein (ox-LDL)

smoking-ADMA-obesity relationship and, 1575-1576  
see also Oxidation, LDL; Plasma oxidized low-density lipoprotein

Oxygen uptake, see  $\dot{V}O_{2max}$ 

## Oxygenation, renal cortex, water diuresis-induced changes in endothelial function and, in NIDDM and in at-risk for NIDDM subjects, 222-227

## P (phosphorus), see Serum phosphorus

*P. yoelli* (*Plasmodium yoelli*) GPIs (glycosylphosphatidylinositols), effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053

## PA (plasminogen activator)-antigen, tissue, in NIDDM and at-risk for NIDDM subjects, 224, 226

## PAI (plasminogen activator inhibitor)-antigen, in NIDDM and at-risk for NIDDM subjects, 224, 226

## PAI-1, see Plasminogen activator inhibitor-1

## Palatinose-based liquid balanced formula (MNH-01), effects of, on PP hyperglycemia and hyperinsulinemia, 977-983

## Palmitate, short-term effects of, on glucagon secretion, 1444-1446

## Palmitic acid

effects of, on Sp1-induced apo A-1 promoter induction, 1343

TG content of, in MS, 312

## Palmitoleic acid, TG content of, in MS, 312

## Pancreas, MNH-01 effects on, 981

## Pancreas Tonic, effects of, in NIDDM, 1166-1173

## Pancreatic islets

bezafibrate effects on, in obese NIDDM subjects, 408-409, 411  
effects of transplantation of, on serum resistin levels in IDDM, 403-404

see also Beta cells

## PAO, see Paraoxonase

## Paraoxonase (PON1; PAO)

in FCHL,  $\omega$ -3 PUFA effects on levels of plasma HDL<sub>2</sub>-C and, 153-158

polymorphism of serum, correlation between vascular complications, plasma oxidized LDL level and, in NIDDM, 297-302

## Parathyroid hormone (PTH)

plasma, in adrenal insufficiency, insulin-induced hypoglycemia effects on levels of, 1251-1254

relation of serum, to vitamin D profile in eucalcemia after parathyroidectomy for primary hyperthyroidism, 1101-1106

## Parathyroidectomy for primary hyperthyroidism, serum PTH relation to vitamin D profile in eucalcemia after, 1101-1106

## Parent(s)

insulin secretion, insulin sensitivity, and metabolic profile of young men with hypertensive, 469-475

see also Children; Parental diabetes mellitus and entries beginning with term: Familial

## Parental diabetes mellitus (DM)

and insulin secretion and sensitivity in normal glucose-tolerant LBW Pima Indians, 906

NIDDM, LDL susceptibility to oxidation and circulating cell adhesion molecules in young adult offspring of, 755-759

## Parenteral nutrition, total, lipid-containing, regulation of serum lipid EFAD in short-gut subjects on, 273-277

## Partial androgen deficiency in aging NIDDM men, glycemic control and, 666-672

## PCOS, see Polycystic ovary syndrome, obesity and

## PDH (pyruvate dehydrogenase), DM effects on, 66-72

## Pentols, plasma, in CTX, 558

## PEPCK (phosphoenolpyruvate carboxykinase), hepatic, effects of exercise on hepatic insulin signaling and activity of, in diabetes-prone subjects, 836-841

## Peptides, see specific peptides

## Peripheral (ovarian) hypothesis of PCOS, 360, 361

## Peripheral neuropathy in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299

## Peristaltic pumps in metabolic research, accuracy and precision of, 875-878

## Peroxides, lipid, carotid atherosclerosis, vascular dementia and, 477, 479

Peroxisome proliferator-associated receptor  $\alpha$  (PPAR $\alpha$ ) mRNA (messenger ribonucleic acid)

CL316,243 effects on, in diabetes, 804

fenofibrate effects on, see Peroxisome proliferator-associated receptor mRNA, fenofibrate effects on

Peroxisome proliferator-associated receptor  $\alpha$  (PPAR $\alpha$ ) mRNA (messenger ribonucleic acid), fenofibrate effects on

in LDLR-null subjects, 610

in ovariectomized subjects, 1286

Peroxisome proliferator-associated receptor  $\gamma$  (PPAR $\gamma$ )

effects of, on glucocorticoid receptor signaling and, in AT, 28-36  
FFPS-410 effects on activation of, 1533

see also Pro12Ala polymorphism of PPAR $\gamma$

Peroxisome proliferator-associated receptor  $\gamma$ 2, see Pro12Ala polymorphism of PPAR $\gamma$ 2

## PG (prostaglandin), caffeine effects on alveolar macrophages via its effects on synthesis of cAMP and, 687-692

## 6-PGDH (6-phosphogluconate-dehydrogenase) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065

PGE<sub>1</sub> (prostaglandin E<sub>1</sub>), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177PGE<sub>2</sub> (prostaglandin E<sub>2</sub>), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177PGI<sub>2</sub> (prostaglandin I<sub>2</sub>), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177

## Phenylalanine (Phe), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

## Phosphatase, see Acid phosphatase locus 1; Alkaline phosphatase; Biphosphatase; Glucose-6-phosphatase

## Phosphate

serum, in adrenal insufficiency, 1252

see also Adenosine monophosphate; Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA; Glucose-6-phosphate dehydrogenase mRNA and entries beginning with element: Phosph-

- Phosphoenolpyruvate carboxykinase (PEPCK), hepatic, effects of exercise on hepatic insulin signaling and activity of, in diabetes-prone subjects, 836-841
- 6-Phosphogluconate-dehydrogenase (6-PGDH) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Phospholipase D (PLD), serum glycosylphosphatidylinositol-specific, IR and increased, 138-139
- Phospholipid(s) (PLs)  
in FCHL,  $\omega$ -3 PUFA effects on, 154  
serum, regulation of EFAs in, in short-gut subjects on PL-containing TPN, 273-277  
smoking effects on, 860  
in soccer players, 1264
- Phospholipid transfer protein (PLTP), smoking effects on, 858-862
- Phosphoribosyl transferase, point mutation in hypoxanthine, responsible for hyperuricemia in women, 1500-1502
- Phosphorus, *see* Serum phosphorus
- Phylloquinone (vitamin K), transport of plasma, in men consuming deuterium-labeled collard greens, 215-221
- Physical activity  
effects of interaction between FABP-4 and PPAR $\gamma$ -activated receptor polymorphism and, 305, 306  
*see also* Exercise
- Pima Indians, LBW, with normal glucose tolerance, insulin secretion and insulin sensitivity in, 904-911
- Pinelectomy (PINX), effects of, on AT adaptability to fasting, 500-506
- Pioglitazone, *see* Non-insulin-dependent diabetes mellitus nephropathy, pioglitazone effects in
- Pituitary response to exercise by nondiabetic and IDDM smokers, 1140-1144
- PK (protein kinase), HF diet effects on adenosine monophosphate-activated glucose transport in SM, 914
- PKB $\alpha$  (protein kinase B $\alpha$ /Akt1), hepatic apo B production regulated by insulin independently of mass or activity of, 228-236
- PL(s), *see* Phospholipid(s)
- Plasma adiponectin  
adiponectin levels and, 2  
effects of moderate weight loss by insulin-resistant obese women on, 280-283  
effects of rosiglitazone on insulin sensitivity, insulin secretion and, in IGT first-degree relatives of African-American NIDDM subjects, 1552-1557  
in NIDDM Japanese subjects with incipient nephropathy, 1224
- Plasma adrenocorticotropin hormone (ACTH; corticotropin)  
effects of restricted diet on, 30  
leptin effects on, in STZ-DM, 1560
- Plasma alanine (Ala), effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Plasma alanine aminotransferase (ALT), NO-1886 effects on, in STZ-DM, 261
- Plasma albumin in disabled hospitalized older subjects, HHcy and, 1018
- Plasma alcohol, beer ingestion and sauna bathing effects on, 774-775
- Plasma amino acids (AA), concentrations of, and whole-body protein synthesis in young men, 388-396
- Plasma apolipoprotein (apo)  
in HL deficiency, 521-522  
*see also* specific apolipoproteins
- Plasma apolipoprotein A-1 (apo A-1)  
in HL deficiency, 522-524  
in PM and premenopausal women, sex steroids and, 189
- Plasma apolipoprotein A-2 (apo A-2) in HL deficiency, 522-524
- Plasma apolipoprotein B (apo B) in PM and premenopausal women, sex steroids and, 189
- Plasma apolipoprotein C-3 (apo C-3) polymorphisms in IDDM, 1296-1304
- Plasma aspartate aminotransferase (AST), NO-1886 effects on, in STZ-DM, 261
- Plasma asymmetric dimethylarginine (ADMA), diet composition as determinant of, in mild hypercholesterolemia, 1072-1075
- Plasma ceruloplasmin, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Plasma cholestanol in CTX, 558
- Plasma cholesterol (C)  
in CT, 558  
in Ecuadorian Amazon Shur women, 1356  
ileal bile transport inhibition effects on, through hepatic farnesoid receptor inactivation and cholesterol 7 $\alpha$ -hydroxylase stimulation, 927-932  
normal or mildly elevated, wheat germ policosanols effects on, 1309-1314  
in PM and premenopausal women, sex steroids and, 189  
PP, in NIDDM, alcohol effects on, 79  
total, *see* Total plasma cholesterol
- Plasma cholesteryl ester transfer protein (CETP), smoking effects on, 858-862
- Plasma corticosterone, effects of 11 $\beta$ -HSD inhibition by glycyrrhetic acid on, 602
- Plasma corticotropin (adrenocorticotropin hormone), effects of restricted diet on, 30
- Plasma cortisol (hydrocortisone) in adrenocortical disorders, 89-94
- Plasma C-reactive proteins (CRP), association between lifestyle, cardiovascular risk factors and, 1436-1442
- Plasma diamine oxidase, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Plasma endothelin (ET) in DM, relation between concentration of plasma VEGF, glycemic control and, 550-555
- Plasma epinephrine (adrenaline), leptin effects on, in STZ-DM, 1560
- Plasma fibrinogen in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Plasma fructose (F), postprandial, in NIDDM retinopathy, 583-588
- Plasma glucagon (Glc; hyperglycemic-glycogenolytic factor) in Ecuadorian Amazon Shur women, 1356
- Plasma glucose  
in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089  
in DM, *see* Plasma glucose in DM  
in Ecuadorian Amazon Shur women, 1356  
effects of ATPCL inhibitors on, 68  
fasting, *see* Fasting plasma glucose  
HF diet and reduced glucose transport in SM and, 913  
in hyperinsulinemia, *see* Plasma glucose in hyperinsulinemia  
isotretinoin effects on, 6  
in lipodystrophic HIV-infected subjects, 1567  
in obesity, NN414 and DZ effects on, compared, 444  
preservation of circadian rhythm of serum insulin concentration at low concentration of during fasting by lean and overweight subjects, 1449-1453  
steady-state, *see* Steady-state plasma glucose in IR
- Plasma glucose in DM  
effects of ATPCL inhibitors on, 68  
in IDDM, *see* Plasma glucose in IDDM  
in NIDDM, *see* Plasma glucose in NIDDM in STZ-DM, NO-1886 effects on, 261
- Plasma glucose in hyperinsulinemia  
with hypertension, 1306

- Plasma glucose in hyperinsulinemia (*Continued*)  
 in young men, whole-body protein synthesis and, 391
- Plasma glucose in IDDM  
 HIM2 effects on, 56-57  
 relationship between interstitial glucose and, 1487
- Plasma high-density lipoprotein ( $\alpha$  lipoprotein; HDL)  
 in PM and premenopausal women, sex steroids and, 189  
*see also* Plasma high-density lipoprotein-cholesterol
- Plasma high-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C)  
 effects of  $\omega$ -3 PUFAs alone or combined with *all-rac*  $\alpha$ -tocopherol on, 237  
 HF/HC diet effects on, 819  
 high, in Spanish children, and low CHD mortality in Spain, 1045-1047  
 in HL deficiency, 522
- Plasma high-density lipoprotein<sub>2</sub>-cholesterol ( $\alpha$  lipoprotein<sub>2</sub>-cholesterol; HDL<sub>2</sub>-C),  $\omega$ -3 PUFA effects on, in FCHL, 153-158
- Plasma high-density lipoprotein<sub>3</sub>-cholesterol ( $\alpha$  lipoprotein<sub>3</sub>-cholesterol; HDL<sub>3</sub>-C),  $\omega$ -3 PUFA effects on levels of, in FCHL, 154, 155
- Plasma homocysteine (Hcy), effects of elevated, on endothelial function recovery after denudation of carotid arteries, 760-765
- Plasma hydrocortisone (cortisol) in adrenocortical disorders, 89-94
- Plasma 7 $\alpha$ -hydroxy-4-cholesten-3-one, as marker for hepatic bile synthesis, dietary cholesterol and, 42-48
- Plasma 27-hydroxycholesterol, as marker for hepatic bile synthesis, dietary cholesterol and, 42-48
- Plasma hypoxanthine, sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasma insulin  
 in Ecuadorian Amazon Shur women, 1356  
 and GSK-3 $\beta$  in transgenic subjects, 1328  
 HF diet effects on, 913  
 isotretinoin effects on, 6  
 leptin effects on, in STZ-DM, 1559  
 in NIDDM, *see* Plasma insulin in NIDDM  
 NOS inhibition effects on pioglitazone action on, in subjects on high-sucrose diet, 23  
 in obesity, *see* Plasma insulin in obesity
- Plasma insulin in NIDDM  
 and in at-risk for NIDDM subjects, 224, 226  
 with obesity, effects of LF versus HF diet and caloric intake on, 456
- Plasma insulin in obesity  
 with NIDDM, effects of LF versus HF diet and caloric intake on, 456  
 NN414 effects on, 443, 444  
 with STZ-DM, *P yoelli* GPI effects on, 1050
- Plasma intercellular adhesion molecule-1 (ICAM-1), effects of red and white wine on, in CAD men, 318-323
- Plasma interleukin-6 (IL-6), effects of red and white wine on, in CAD men, 318-323
- Plasma intermediate-density lipoprotein (IDL) in PM and premenopausal women, sex steroids and, 189
- Plasma isoleucine (Ile)  
 effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392  
 effects of dietary proline with and without glucose on concentration of, 244
- Plasma leptin  
 effects of glycyrrhetic acid 11 $\beta$ -HSD inhibition on, 602, 604
- Plasma leptin (*Continued*)  
 in obesity, NN414 and DZ effects on, compared, 443, 444
- Plasma leucine (Leu)  
 effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392  
 effects of dietary proline with and without glucose on, 244
- Plasma lipids  
 NO-1886 effects on, in STZ-DM, 261  
 in obesity, NN414 and DZ effects on, compared, 443  
 in PM women, effects of moderate exercise and soy isoflavone on, 945  
 relationship of apo E polymorphism to, in Vietnamese children, 1517-1521  
*see also specific plasma lipids*
- Plasma lipoprotein (Lp)  
 relationship of apo E polymorphism to, in Vietnamese children, 1517-1521  
 sex steroids and, in women, 187-192
- Plasma lipoprotein(a) [Lp(a)] in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Plasma low-density lipoprotein ( $\gamma$  lipoprotein; LDL)  
 correlation between vascular complications, serum PON1 polymorphism and, 297-302  
 particle diameter and clearance of, 483-487  
 in PM and premenopausal women, sex steroids and, 189  
*see also* Plasma low-density lipoprotein-cholesterol; Plasma oxidized low-density lipoprotein
- Plasma low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C)  
 anti-inflammatory effects of  $\omega$ -3 PUFAs alone or combined with *all-rac*  $\alpha$ -tocopherol on, 237  
 HF/HC diet effects on, 819  
 in HL deficiency, 522, 523  
 in Spanish children, 1046
- Plasma methionine (Met), effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Plasma nitrate/nitrite, OGTT assessment of, in sedentary subjects and after endurance training, 673-679
- Plasma nonesterified fatty acids (NEFAs; free fatty acids)  
 acipimox-induced reduction of, during exercise at cold temperature, 1131-1135  
 in obesity, NN414 and DZ effects on, compared, 444  
 regulation of, in IR, 1197-1201  
 restricted diet effects on, 30  
 stevioside effects on, 102
- Plasma norepinephrine (NE)  
 leptin effects on, in STZ-DM, 1560  
 in NIDDM with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1362
- Plasma oxidized low-density lipoprotein (ox-LDL)  
 correlation between vascular complications, serum PON1 polymorphism, and levels of, in NIDDM, 297-302  
 serum HDL-C level effects on association between CAD and, in men, 423-429  
 and smoking-ADMA-obesity relationship, 1575, 1576
- Plasma parathyroid hormone (PTH) in adrenal insufficiency, insulin-induced hypoglycemia effects on levels of, 1251-1254
- Plasma pentols in CTX, 558
- Plasma  $\omega$  (omega)-3 polyunsaturated fatty acids (PUFAs), anti-inflammatory effects of, alone or with *all-rac*  $\alpha$ -tocopherol, 236-240
- Plasma proline (Pro), effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392



- Plasma protein, total, beer ingestion and sauna bathing effects on, 774
- Plasma purine bases, sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasma 25-tetrol in CTX, 558
- Plasma triacylglycerol (TAG) during exercise at cold temperature, 204
- Plasma triglycerides (TGs)
- in Ecuadoran Amazon Shur women, 1356
  - effects of  $\omega$ -3 PUFAs alone or combined with *all-rac*  $\alpha$ -tocopherol on, 237
  - fasting, pioglitazone effects on, 489-490
  - in HL deficiency, 522
  - in IDDM, *see* Plasma triglycerides in IDDM
  - isotretinoin effects on, 4-10
  - in obesity, NN414 effects on, 444
  - in PM and premenopausal women, sex steroids and, 189, 190
  - in prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and in their first-degree relatives, 50
  - self-monitoring of, in evaluation of PP TG response to nutrients, 620-623
  - smoking effects on, 858-860
- Plasma triglycerides (TGs) in IDDM
- plasma apo C-3 polymorphisms and, 1299
  - total, oxidation of glycated and nonglycated LDLs and, 970
- Plasma tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) in older hypertensive subjects, resistance exercise effects on insulin-mediated glucose disposal with minimal effects on, 399-400
- Plasma urea in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- Plasma uric acid (UA), sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasma valine (Val)
- effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
  - effects of dietary proline with and without glucose on, 244
- Plasma vascular cell adhesion molecule-1 (VCAM-1), effects of red and white wine on, in CAD men, 318-323
- Plasma vascular endothelial growth factor (VEGF), relation between plasma ET, glycemic control and, in DM, 550-555
- Plasma very-low-density lipoprotein(s) (VLDL) in PM and premenopausal women, sex steroids and, 189, 190
- Plasma very-low-density lipoprotein-cholesterol (VLDL-C), HF/HF diet effects on, 819
- Plasma vitamin K (phyloquinone), transport of, in men consuming deuterium-labeled collard greens, 215-221
- Plasma xanthine, sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasminogen activator (PA) antigen, tissue, in NIDDM and at-risk for NIDDM subjects, 224, 226
- Plasminogen activator inhibitor (PAI) antigen, in NIDDM and at-risk for NIDDM subjects, 224, 226
- Plasminogen activator inhibitor-1 (PAI-1)
- fasting, effects of weight loss with normal FPG or IGT on, 1097
  - in inflammation of chronic disease, 901
  - in young subjects with NIDDM patents, 756
- Plasmodium yoelii* (*P. yoelii*) glycosylphosphatidylinositol (GPI), effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053
- Platelet(s)
- relationship between intracellular magnesium of cord blood, to birth weight, 1544-1547
  - WPG effects on, 1312
- Platelet acetyl-coenzyme (CoA), ATPCL role in metabolism and function of, in DM, 66-72
- PLD (phospholipase D), serum glycosylphosphatidylinositol-specific, IR and increased, 138-139
- PLTP (phospholipid transfer protein), smoking effects on, 858-862
- PM subjects, *see* Postmenopausal subjects
- PO (primrose oil), evening, effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
- Point mutation in hypoxanthine phosphoribosyl transferase responsible for hyperuricemia in women, 1500-1502
- Policosanol, effects of wheat germ, on normal and mildly elevated plasma cholesterol, 1309-1314
- Polycystic ovary syndrome (PCOS), obesity and, 358-376
- adrenal androgens and cortisol in, 361
  - clinical manifestations of, in obese and non-obese women, 365-367
  - definition, genetics, and epidemiology of PCOS, 358-359
  - estrogen and progesterone in, 361-362
  - gonadatropins and central hypothesis of, 359-361
  - insulin/insulin growth factor hypothesis of, 360, 363-365
  - IR, hyperinsulinemia and, 359
  - leptin in, 362-363
  - ovarian androgens and ovarian hypothesis of, 360, 361
  - therapy of, 367-370
- Polygenic obesity, CL316,243 effects on NIDDM with, 799-808
- Polymorphism, 458-468
- $\beta_2$ -ADR, interaction of, with  $\beta_2$ -ADR Trp64Arg and Arg16Gly polymorphisms of, 1184-1191; *see*  $\beta_2$ -Adrenergic receptor, Trp64Arg polymorphism of
  - apo E, *see* Apolipoprotein E polymorphism
  - in Japanese subjects, *see* Japanese subjects, polymorphism in
  - K121Q glycoprotein PC-1, associated with race but not with IR in children, 465-468
  - Lys109Arg and Gln223Arg, relation between leptin receptor gene, HOMA IR index, serum soluble leptin receptor, serum leptin, lipids and, in Japanese subjects, 879-885
  - in NIDDM, *see* Polymorphism in NIDDM
  - plasma apo C-3, in IDDM, 1296-1304
- Pro12Ala, *see* Pro12Ala polymorphism of PPAR $\gamma$ ; Pro12Ala polymorphism of PPAR $\gamma$ 2
- UCP-1 gene, *see* Uncoupling protein-1 -3826A $\rightarrow$ G polymorphism
- UCP-3, food intake and body composition associated with, 458-464
- Polymorphism in NIDDM
- ACPI, and adenosine deaminase-NIDDM interaction, 995-1001
  - serum PON1, correlation between vascular complications, plasma oxidized LDL level and, 297-302
- Polypeptides, *see specific polypeptides*
- Polyphenols, red and white wine drinking effects on, in CAD men, 320
- Polyunsaturated fatty acids (PUFA)
- CV disease risk factors and intake of, 1439
  - effects of, in premature atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and in their first-degree relatives, 51
  - in MNH-01 formula, 978
  - plasma ADMA in mild hypercholesterolemia and, 1073
  - WPG and, 1312
  - see also*  $\omega$ -3 Polyunsaturated fatty acids;  $\omega$ -6 Polyunsaturated fatty acids
- $\omega$  (omega)-3 Polyunsaturated fatty acids (PUFA)
- skeletal muscle cell and erythrocyte membrane, in men, 573-575
  - see also*  $\omega$ -3 Polyunsaturated fatty acids, effects of



- $\omega$  (omega)-3 Polyunsaturated fatty acids (PUFA), effects of anti-inflammatory effects of, alone or combined with *all-rac*  $\alpha$ -tocopherol, on IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , 236-240  
on CV disease risk factors, 1439  
on plasma HDL<sub>2</sub>-C and paraoxonase levels in FCHL, 153-158  
*see also* Exercise, effects of  $\omega$ -3 PUFAs with
- $\omega$  (omega)-6 Polyunsaturated fatty acids (PUFA)  
CV disease risk factors and intake of, 1439  
skeletal muscle cell and erythrocyte membrane, in men, 573-575
- PON1, *see* Paraoxonase
- Population minimal modeling, individual and, of IM-FSIVGTT, 1349-1354
- Portal venous hyperinsulinemia, effects of, on gut glucose absorption in conscious subjects, 1290-1295
- Postheparin lipoprotein lipase (LPL), relation between concentration of, and TG metabolism in hypercholesterolemia, 526-531
- Postmenopausal (PM) subjects  
moderate exercise and soy isoflavone effects on AT accumulation and bone loss in, 942-948  
*see also* Postmenopausal women
- Postmenopausal (PM) women  
exercising, *see* Postmenopausal women, effects of diet with exercise in; Postmenopausal women on ERT, exercise effects in  
hypercholesterolemic, simvastatin effects on BMD in, 744-748  
MP-9 gene polymorphism association with BMD and, 136  
obese, *see* Postmenopausal women, obese  
sex steroids and plasma Lp in, 187-192
- Postmenopausal (PM) women, effects of diet with exercise in  
low-fat, high-fiber diet and aerobic exercise effects on inflammatory and adhesion molecules in PM women on ERT and at risk for CAD, 377-381  
soy isoflavone and exercise effects on AT accumulation and bone loss, 942-948
- Postmenopausal (PM) women, obese  
androgenicity and obesity association with insulin sensitivity in, 507-512  
fluvastatin effects on endothelial function in, via sdLDL reduction, 733-739
- Postmenopausal (PM) women on ERT, exercise effects in  
on abdominal AT and MS, 1192-1196  
with risk for CAD, effects of high-fiber, low-fat diet and exercise on inflammatory and adhesion molecules in, 377-381  
*see also* Body composition of PM women, exercise effects on
- Postprandial (PP) blood pressure (BP) in NIDDM, stevioside effects on, 75
- Postprandial (PP) cholesterol (C), plasma, alcohol effects on, in NIDDM, 79
- Postprandial (PP) C-peptide (CP), and effects of OCs on glucoregulatory responses to exercise, 350, 351
- Postprandial (PP) fructose (F), plasma, in NIDDM retinopathy, 583-588
- Postprandial (PP) glucagon (Glc; hyperglycemic-glycogenolytic factor), stevioside effects on, in NIDDM, 75
- Postprandial (PP) glucagon-like peptide-1 (GLP-1), stevioside effects on, in NIDDM, 75
- Postprandial (PP) glucose  
and effects of OCs on glucoregulatory responses to exercise, 350, 351  
in IDDM, HIM2 effects on, 54-58  
in IGT first-degree relatives of African American NIDDM subjects, 1553
- Postprandial (PP) hyperglycemia, MNH-01 effects on PP hyperinsulinemia and, 977-983
- Postprandial (PP) hyperinsulinemia, MNH-01 effects on PP hyperglycemia and, 977-983
- Postprandial (PP) incretins, alcohol effects on, in NIDDM, 77-83
- Postprandial (PP) insulin  
in IGT first-degree relatives of African American NIDDM subjects, 1553  
and OC effects on glucoregulatory responses to exercise, 350, 351
- Postprandial (PP) lipemia, exercise effects on  
effects of alcohol intake on PP incretin levels and, in NIDDM, 77-83  
after HF/HC diet, exercise effects on, 1021-1026  
with  $\omega$ -3 PUFAs, 1365-1371
- Postprandial (PP) low-density lipoprotein ( $\beta$  lipoprotein; LDL) in sedentary subjects and in exercise, apo E polymorphism-VO<sub>2max</sub> association and, 111, 113
- Postprandial (PP) plasma cholesterol (C), alcohol effects on, in NIDDM, 79
- Postprandial (PP) plasma fructose (F) in NIDDM retinopathy, 583-588
- Postprandial (PP) triacylglycerols (TAG) in NIDDM, alcohol effects on, 77-83
- Postprandial (PP) triglycerides (TGs), plasma TG self-monitoring to evaluate response of, 620-623
- Postpubertal Asian Indian adolescents, adiponectin, CRP, and IR in, 1336-1341
- Potassium (K) channel blocker inhibitors, and 4AP effects on delayed vasorelaxation by troglitazone, 147-152
- PP, *see* entries beginning with term: Postprandial
- PPAR, *see* Peroxisome proliferator-associated receptor  $\alpha$  mRNA; Peroxisome proliferator-associated receptor  $\gamma$ ; Peroxisome proliferator-associated receptor  $\gamma$ 2
- Pramlintide, effects of, on responses of catecholamine, glucagon, and symptoms of hypoglycemia, 1227-1232
- Pravastatin (PRV) effects  
in mixed hyperlipidemia, effects of S-2E compared with, 680-685  
on plasma LDL clearance, 484
- Preadipocytes (adipocyte precursor cells)  
FPFS-410 effects on transcription factors in 3T3-L1, 1534  
from omental and subcutaneous AT of obese subjects, proliferation and differentiation of, compared, 632-637
- Preclinical changes in abdominal aorta of obese children, 1243-1246
- Prediabetic subjects  
cardiac function in, 1391-1394  
LSF effects on glucose-stimulated insulin secretion in, 290-296
- Preeclampsia, established, IR and inflammation in, 1433-1435
- Pregnancy  
 $\beta$ <sub>3</sub>-ADR Trp64Arg polymorphism in GDM Taiwanese women, 1136-1139  
with established preeclampsia, IR and inflammation in, 1433-1435  
3,3-T<sub>2</sub>S in, 538-543  
uncomplicated, leucine turnover during third trimester of, 545-549
- Premature atherosclerosis, normocholesterolemic and daytime hypertriglyceridemia in subjects with, 49-53
- Premenopausal women  
non-obese, abdominal and liver AT and metabolic risk in, 1066-1071  
sex steroids and plasma Lp in, 187-192
- Pre-pancreatic islet transplantation, effects of, on serum resistin levels in IDDM, 403-404
- Preproglucagon mRNA (messenger ribonucleic acid), palmitate effects on, 1445-1446
- Prevalence of IR and associated CV disease risk factors in normal weight, overweight, and obese subjects, 495-499

## Prevention

- beta-cell mass loss, effects of pioglitazone on insulin secretion and, in obese NIDDM subjects, 488-494
- of NIDDM in IGT first-degree relatives of obese African American NIDDM subjects with GITS, 414-422
- Primary hyperthyroidism, serum PTH relation to vitamin D profile in eucalcemia after parathyroidectomy for, vitamin D profile relation to, 1101-1106
- Primrose oil (PO), evening, effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
- PRL (prolactin) in older NIDDM men with partial androgen deficiency, 668
- Pro, *see* Proline
- Pro12Ala polymorphism of PPAR $\gamma$  (peroxisome proliferator-activated receptor  $\gamma$ )
  - effects of, on dietary fat and physical activity association with fasting insulin level, 11-16
  - effects of interaction between FABP-4 polymorphism and, on insulin secretion and body composition, 303-309
- Pro12Ala polymorphism of PPAR $\gamma$ 2 (peroxisome proliferator-associated receptor  $\gamma$ 2)
  - associated with adiponectin concentrations in young Japanese men, 1548-1551
  - effects of, on AT distribution in Korean women, 1538-1543
- Progesterone in PCOS, 361-362
- Proinsulin in CHD, IR, 853, 854
- Prolactin (PRL) in older NIDDM men with partial androgen deficiency, 668
- Proliferation, *see* Cell proliferation
- Proline (Pro)
  - dietary, with and without glucose, metabolic response to, 241-246
  - plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
  - see also* Hydroxyproline; Pro12Ala polymorphism of PPAR $\gamma$ ; Pro12Ala polymorphism of PPAR $\gamma$ 2
- Propeptide type 1 collagen, aminoterminal, in adrenal insufficiency, 1252
- Propionic acidemia, late-onset, fatal outcome and, 809-810
- Prostaglandin (PG), caffeine effects on alveolar macrophages via its effects on synthesis of cAMP and, 687-692
- Prostaglandin E $_1$  (PGE $_1$ ), effects of inhibition of, on apo A-I promoter activity in hepatoma cells, 177
- Prostaglandin E $_2$  (PGE $_2$ ), effects of inhibition of, on apo A-I promoter activity in hepatoma cells, 177
- Prostaglandin I $_2$  (PGI $_2$ ), effects of inhibition of, on apo A-I promoter activity in hepatoma cells, 177
- Protease, IGFs, GHBP, IGFs, and IGFBP-3, in lipodystrophic HIV-infected subjects, 1565-1573
- Proteasome, dietary protein restriction effects on production of, in skeletal muscle, 340-347
- Protein
  - binding, *see* Fatty acid-binding protein-4; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s); Insulin-like growth factor-binding protein 3 protease; Retinoic acid binding protein-1 mRNA; Sterol regulatory element binding protein-1
  - cardiac, effects of galactosamine-induced liver disease and bile duct ligation on synthesis of, 964-968
  - cardiac myocyte, high glucose and insulin effects on synthesis of, 710-715
  - L-carnitine effects on body composition, AT oxidation, and turnover of, in slightly overweight subjects, 1001-1006
  - C-reactive, *see* C-reactive protein
  - dietary, *see* Dietary protein intake

## Protein (Continued)

- glargine effects on metabolism of, 1037-1044
- in Korean women, AT distribution and, 1541
- mRNA of steroidogenic acute regulatory, low temperature blocking hCG effects on testosterone production and, but not cAMP production in tumor cells, 955-958
- SM, *see* Protein in SM
- total plasma, beer ingestion and sauna bathing effects on, 774
- transfer, *see* Cholesteryl ester transfer protein; Phospholipid transfer protein
- whole-body, plasma AA concentration and synthesis of, in young men, 388-396
- see also* Glycoprotein; Protein kinase; Protein kinase Ba/Akt1
- entries beginning with terms: Uncoupling protein and specific proteins
- Protein-1, *see* Fatty acid transporter protein-1; Monocyte chemoattractant protein-1; Retinoic acid binding protein-1 mRNA; Sterol regulatory element binding protein-1; Uncoupling protein-1 mRNA; Uncoupling protein-1 -3826A $\rightarrow$ G polymorphism
- Protein in SM
  - effects of epinephrine and ionomycin on IL-6 mRNA and release of, in compared, 1492-1495
  - estimation of breakdown of contractile, with [ $^3$ H]-3-methylhistidine, 1076-1080
- Protein kinase (PK), HF diet effects on glucose transport in SM stimulated by adenosine monophosphate-activated, 914
- Protein kinase Ba/Akt1 (PKBa/Akt1), insulin regulation of hepatic apo B production independently of mass or activity of, 228-236
- Proteinuria
  - in preeclampsia, 1434
  - see also* Albuminuria
- Prothrombin time in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- PRV, *see* Pravastatin effects
- PTH, *see* Parathyroid hormone
- PUFA, *see* Polyunsaturated fatty acids
- Pulse rate, *see* Heart rate
- Pumps, syringe and peristaltic, in metabolic research, accuracy and precision of, compared, 875-878
- Purine bases, plasma, sauna bathing and beer ingestion effects on concentration of, 772-776
- Pyruvate, thioctic acid effects on NEFA oxidation and metabolism of, in hepatocytes, 165-173
- Pyruvate dehydrogenase (PDH), DM effects on, 66-72
- QT intervals, corrected, associated with carotid artery IMT in NIDDM, 1152-1157
- Race and ethnicity
  - adiponectin, *see* Race and ethnicity, adiponectin and
  - of children, *see* Race and ethnicity of children
  - insulin secretion and insulin sensitivity in normal glucose-tolerant LBW Pima Indians, 904-911
  - of kidney transplantation recipients, 615
  - Kuwaiti IDDM adolescents, cardiovascular disease risk factors associated with serum sialic acid in, 638-643
  - lifestyle effects on leptin in Ecuadorian Amazon Shur women, 1355-1358
  - of NIDDM subjects, *see* Race and ethnicity of NIDDM subjects
  - of obese women,  $\beta$ -adrenergic receptor density in subcutaneous and omental AT and, 247-251
  - polymorphism and, *see* Race and ethnicity, polymorphism and

- Race and ethnicity (*Continued*)  
  see also Japanese subjects; Korean subjects; Spanish subjects
- Race and ethnicity, adiponectin and  
  adiponectin, CRP, and IR in postpubertal Asian Indian  
    adolescents, 1336-1341  
  adiponectin levels and, 1-3  
  and NEFA regulation of adiponectin, 791
- Race and ethnicity, polymorphism and  
   $\beta_2$ -ADR Arg16Gly polymorphism and, 1184, 1185  
   $\beta_3$ -ADR Trp64Arg polymorphism in GDM Taiwanese women,  
    1136-1139  
  apo E polymorphism association with blood lipids and  $\dot{V}O_{2\max}$   
    and, in exercise, 110-113  
  caloric intake, UCP-3 polymorphism, body composition and, 461  
  effects of interaction between FABP-4 and PPAR $\gamma$  Pro12Ala  
    polymorphism and, 305, 306  
  effects of Pro12Ala polymorphism of PPAR $\gamma$ 2 on AT distribution  
    in Korean women, 1538-1543  
  and exercise effects in overweight nondiabetic subjects, 1236
- Race and ethnicity of children  
  apo E polymorphism in Vietnamese children, relation of, to  
    plasma lipids and Lp, 1517-1521  
  associated with glycoprotein PC-1 K121Q polymorphism but not  
    with IR, 465-468  
  high plasma HDL-C level in Spanish children, and low CHD  
    mortality in Spain, 1045-1047  
  Kuwaiti IDDM children, and cardiovascular disease risk factors  
    association with serum sialic acid, 638-643  
  serum HDL-C or apo A-I levels associated with *ABCA1* gene  
    polymorphism in Japanese school-age children, 182-186
- Race and ethnicity of NIDDM subjects  
  and exercise effects in overweight NIDDM subjects, 1236  
  non-obese insulin-resistant NIDDM Korean subjects, 142-146  
  and Pancreas Tonic effects in NIDDM, 1169  
  triple *HNF-4 $\alpha$*  gene mutations associated with early-onset NIDDM  
    in Filipino family, 959-963  
  see also First-degree relatives, IGT, of African American NIDDM  
    subjects
- RBCs, see entries beginning with term: Erythrocyte
- RCT (reverse cholesterol transport), implications of smoking effects  
  on intravascular remodeling of HDL particles for, 858-862
- Reactive oxygen species (ROS), differential effects of glucose and  
  alcohol on intranuclear nuclear factor- $\kappa$ B in mononuclear  
  cells and generation of, 330-334
- Rebaudioside A, dose-, glucose-, and calcium-dependent effects of,  
  on insulin secretion, 1378-1381
- Recovery of endothelial function after denudation of carotid arteries,  
  effects of elevated plasma Hcy on, 760-765
- Red blood cells, see entries beginning with term: Erythrocyte(s)
- Red wine drinking  
  effects of white and, on circulating inflammation-sensitive  
    molecules in men with CAD, 318-323  
  lack of acute effects of food intake and, on vascular reactivity,  
    1081-1086
- REE, see Resting energy expenditure
- Relatives, see First-degree relatives
- Remethylation of homocysteine, 1480-1483
- Remnant lipoprotein-cholesterol (RLP-C) in NIDDM, metformin  
  effects on, 161
- Renal cholinephosphotransferase (CHPT) mRNA (messenger  
  ribonucleic acid) in NIDDM, 842-846
- Renal cortex  
  different glucose level effects on arginase activity and NO  
    production in, 868-874
- Renal cortex (*Continued*)  
  water diuresis-induced changes in endothelial function and  
    oxygenation of, in NIDDM and at-risk for NIDDM subjects,  
      222-227
- Renal disease, see Nephropathy
- Renal failure  
  HHcy associated with impaired Hcy trans-sulfuration as cause of,  
    1482  
  see also Chronic renal failure
- Renal fibronectin insulin resistance (IR), cilostazol effects on, 1405-  
  1410
- Renal glucose, effects of hyperglycemia, glucagon, and epinephrine  
  on release of, in conscious subjects, 933-941
- Renal 11 (beta)-hydroxysteroid dehydrogenase 2 (11-HSD2) mRNA  
  (messenger ribonucleic acid), responsiveness of body weight  
  and, to 11 $\beta$ -HSD inhibition by glycyrrhetic acid, 600-606
- Renal medullary blood flow (MBF), tempol effects on hypertension  
  and hyperinsulinemia based on increase of, 1305-1308
- Renal transplantation, correlation between AT, serum leptin, and  
  food intake during 6-month period following, 614-619
- Renal weight in IR with microalbuminuria, 1407
- RER (respiratory exchange ratio) during exercise at cold  
  temperature, 204, 205
- Resistance  
  to obesity, adaptive thermogenesis and, 1417-1423  
  see also Insulin resistance
- Resistance exercise effects  
  on glycemic control in NIDDM women, 284-289  
  on insulin-mediated glucose disposal with minimal effect on TNF- $\alpha$   
    in older hypertensive subjects, 397-402
- Resistin (FIZZ3; ADSF)  
  in obese women, effects of moderate weight loss and sibutramine  
    or orlistat on, 432  
  serum levels of, in IDDM before and after pancreatic islet  
    transplantation, 403-404
- Respiratory distress, circulating ACTH and cortisol concentrations in  
  normal appropriate-for-gestational-age newborns versus  
  newborns with sepsis and, 209-214
- Respiratory exchange ratio (RER) during exercise at cold  
  temperature, 204, 205
- Respiratory quotient (RQ) in DCA-induced hypolactatemia in  
  cirrhotic and noncirrhotic subjects, 1089
- Resting energy expenditure (REE)  
  in DCA-induced hypolactatemia in cirrhotic and noncirrhotic  
    subjects, 1089  
  and hyperinsulinemia effects on whole-body protein synthesis, 389  
  by lipodystrophic subjects, leptin replacement therapy effects on,  
    515
- Resting heart rate (HR) of young subjects with NIDDM parents, 756
- Resting metabolic rate (RMR) in advanced NIDDM nephropathy,  
  1395-1398
- Restricted diet, see Dietary restriction
- Retinal glucose, effects of acute insulin-induced hypoglycemia and  
  normoglycemic hyperinsulinemia on ocular glucose  
  metabolism and uptake of, 1274-1283
- Retinocytes, correlation between HbA<sub>1c</sub>, serum haptoglobin, serum  
  bilirubin and, 1498
- Retinoic acid binding protein-1 mRNA (messenger ribonucleic acid),  
  cellular, effects of, on CYP26-mediated catabolism of A11-  
  trans retinoic acid and cell proliferation in head and neck  
  squamous cell carcinoma, 1007-1012
- Retinopathy, see Non-insulin-dependent diabetes mellitus  
  retinopathy

- Reverse cholesterol transport (RCT), implications of smoking effects on intravascular remodeling of HDL particles for, 858-862
- Ribonucleic acid, *see* mRNA
- Risk factors
- for endometrial cancer in obese PCOS women, 366
  - metabolic, in non-obese premenopausal women, abdominal and liver AT and, 1066-1071
  - for metabolic syndrome, lifestyle effects on, 1503-1511
  - for NIDDM, and water diuresis-induced changes in renal cortex oxygenation and endothelial function, 222-227
  - see also* Risk factors for CV disease
- Risk factors for CV disease
- associated with serum sialic acid in IDDM Kuwaiti children and adolescents, 638-643
  - for CAD, effects of exercise and high-fiber, low-fat diet on inflammatory and adhesion molecules in PM women on ERT and, 377-381
  - diet, lifestyle, and plasma CRPs associated with, 1436-1442
  - for myocardial infarction in CAD men, 324-329
  - in NIDDM, *see* Risk factors for CV disease in NIDDM
  - in obesity, *see* Risk factors for CV disease in obesity
  - in subclinical hypothyroidism, 1512-1515
- Risk factors for CV disease in NIDDM
- with IGT, contribution of visceral AT and cardiorespiratory fitness to risk factors for CHD, 644-649
  - multiple, effects of metformin on, 159-164
- Risk factors for CV disease in obesity
- in obese PCOS women, 366
  - prevalence of IR and associated, 495-499
- R-LA [R-(+)- $\alpha$ -lipoic acid; thioctic acid], effects of, on pyruvate metabolism and NEFA oxidation in hepatocytes, 165-173
- RLP-C (remnant lipoprotein-cholesterol) in NIDDM, metformin effects on, 161
- RMR (resting metabolic rate) in advanced NIDDM nephropathy, 1395-1398
- ROS (reactive oxygen species), differential effects of glucose and alcohol on intranuclear nuclear factor- $\kappa$ B in mononuclear cells and generation of, 330-334
- Rosiglitazone effects
- on insulin regulation and dyslipidemia in NIDDM, 1121-1125
  - on insulin sensitivity, insulin secretion, and plasma adiponectin in IGT first-degree relatives of African American NIDDM subjects, 1552-1557
  - in obese PCOS women, 371
- Roux-en-Y bypass (RYBG), changes in BMC after ASGB and, for morbid obesity, 918-921
- RQ (respiratory quotient) in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- RYBG (Roux-en-Y bypass), changes in BMC after ASGB and, for morbid obesity, 918-921
- S, *see* Sucrose
- SI2911-2 (strontium ranelate), bone matrix mineralization induced by, in MC3T3-E1 osteogenic cells, 532-537
- SAA (serum amyloid A), aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380
- Safety of Pancreatic Tonic, 1170
- Sarafotoxin, effects of, on AVP<sub>2</sub> mRNA in IMCD, 1180
- SAT, *see* Subcutaneous adipose tissue
- Saturated fatty acid(s) (SFA)
- CV disease risk factors and intake of, 1439
  - effects of, on SPI-induced apo A-I promoter, 1342-1348
  - skeletal muscle cell and erythrocyte membrane, 573
- Saturated fatty acid(s) (SFA) (*Continued*)
- WPG and, 1312
  - see also* Saturated fatty acid intake
- Saturated fatty acid (SFA) intake
- with MNH-01 formula, 978
  - plasma ADMA in mild hypercholesterolemia and, 1073
  - by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51
- Sauna bathing, effects of beer ingestion and, on plasma concentration of purine bases, 772-776
- SCC (squamous cell carcinoma), head and neck, effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-*trans* retinoic acid and on cell proliferation in, 1007-1012
- SCI, *see* Spinal cord injury
- sdLDL, *see* Small-dense low-density lipoprotein
- S-2E [(+)-(S)-p-[1-(*p*-*tert*-butylphenyl)-2-oxo-4-pyrrolidinyl] methoxybenzoic acid], effects of PRV and in mixed hyperlipidemia, compared, 680-685
- Sedentary subjects
- apo E polymorphism associated with in blood lipids and  $\dot{V}O_{2\max}$  in, 108-116
  - OGTT assessment of plasma nitrate/nitrite in, 673-679
- Selective estrogen receptor modulators (SERMs), effects of, on GH secretion, 563-570
- Self-monitoring of plasma TGs, PP TG response to nutrients evaluated with, 620-623
- Sepsis, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and, 209-214
- Serine (Ser), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- SERMs (selective estrogen receptor modulators), effects of, on GH secretion, 563-570
- Serum adipocytokines, effects of moderate weight loss and orlistat or sibutramine treatment on waist circumference of obese women, 430-434
- Serum adiponectin
- associated with HDL-C, TGs, and LDL particle size in young men, 589-593
  - in postpubertal Asian Indian adolescents, 1338-1339
  - relationship between serum soluble leptin receptor, serum leptin, HOMA IR index, lipids, leptin receptor gene Lys109Arg and Gln223Arg polymorphisms and levels of, in Japanese subjects, 879-885
- Serum albumin
- in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
  - food intake, AT and, in 6-month period following kidney transplantation, 614-619
  - in HD subjects, 1014
  - in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum amyloid A (SAA), aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380
- Serum apolipoprotein A-I (apo A-1) in CAD men, 425
- Serum apolipoprotein A-2 (apo A-2) in CAD men, 425
- Serum apolipoprotein C-2 (apo C-2) in CAD men, 425
- Serum apolipoprotein C-3 (apo C-3)
- in CAD men, 425
  - in IDDM, 1299, 1301
- Serum apolipoprotein E (apo E) in CAD men, 425
- Serum bilirubin



- Serum bilirubin (*Continued*)  
 correlation between HbA<sub>1c</sub>, retinocytes, serum haptoglobin and, 1498  
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- Serum Ca (calcium) in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum cholesterol (C)  
 effects of ATPCL inhibitors on, 68  
 total, in CAD men, 425
- Serum C-peptide (CP; connecting peptide) in IGT first-degree relatives of obese African American NIDDM subjects, 418
- Serum C-reactive protein (CPR), diet and  
 aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380  
 AT and, in 6-month period following kidney transplantation, 614-619
- Serum C-reactive protein (CRP)  
 diet and, *see* Serum C-reactive protein, diet and  
 high-sensitivity, effect of insulin therapy of NIDDM on, 693-699  
 in preeclampsia, 1434, 1435
- Serum creatinine  
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089  
 in HD subjects, 1014  
 in NIDDM nephropathy, *see* Serum creatinine in NIDDM nephropathy  
 in primary hyperthyroidism, 1102
- Serum creatinine in NIDDM nephropathy  
 in Japanese NIDDM subjects with incipient nephropathy, 1224  
 pioglitazone effects on, 1383
- Serum fatty acids (FAs), PP, in NIDDM, alcohol effects on, 79-80
- Serum glucose  
 acute effects of nicotine on, in smokers, 578-582  
 in obese NIDDM subjects, 408  
*see also* Serum glucose in first-degree relatives
- Serum glucose in first-degree relatives  
 in IGT first-degree relatives of obese African American NIDDM subjects, 418  
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
- Serum glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), IR and levels of, 138-139
- Serum haptoglobin, correlation between HbA<sub>1c</sub>, retinocytes, serum bilirubin and, 1498
- Serum high-density lipoprotein-cholesterol ( $\alpha$  lipoprotein-cholesterol; HDL-C)  
 apo E genotype and changes in maximal oxygen uptake and, in exercise, 196, 198-200  
 effects of levels of, on plasma oxidized LDL-CAD association in men, 423-429  
 levels of apo A-I and, associated with *ABCA1* gene polymorphism in Japanese school-age children, 182-186
- Serum high-density lipoprotein<sub>2</sub>-cholesterol ( $\alpha$  lipoprotein<sub>2</sub>-cholesterol; HDL<sub>2</sub>-C)  
 apo E genotype and changes in, during endurance exercise, 196, 198-200  
 effects of levels of, on plasma oxidized LDL-CAD association in men, 425  
 in preeclampsia, 1434, 1435
- Serum high-density lipoprotein<sub>3</sub>-cholesterol ( $\alpha$  lipoprotein<sub>3</sub>-cholesterol; HDL<sub>3</sub>-C)  
 apo E genotype and changes in VO<sub>2max</sub> and, in endurance exercise, 196, 198-200  
 effects of levels of, on plasma oxidized LDL-CAD association in men, 425
- Serum high-sensitivity C-reactive proteins (CRPs) in NIDDM, effects of insulin therapy on, 693-699
- Serum 1,25 hydroxyvitamin D in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum 25-hydroxyvitamin D in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum insulin  
 preservation of circadian rhythm of concentration of, during fasting by lean and overweight subjects, 1449-1453  
 response of, to IVGTT, of obese NIDDM subjects, 408  
*see also* Serum insulin in first-degree relatives
- Serum insulin in first-degree relatives  
 in IGT first-degree relatives of obese African American NIDDM subjects, 418  
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
- Serum interleukin-6 (IL-6) in preeclampsia, 1434, 1435
- Serum interleukin-6 receptor (IL-6R), and IR in liver cirrhosis, 923, 924
- Serum leptin  
 AT, food intake and, during 6-month period following kidney transplantation, 614-619  
 in preeclampsia, 1434, 1435  
 serum soluble leptin receptor, serum adiponectin levels, HOMA IR index, lipids, leptin receptor gene Lys109Arg and Gln223Arg polymorphisms and, in Japanese subjects, 879-885  
 in severe lipodystrophy, effects of leptin replacement therapy on, 514, 515
- Serum lipids  
 profile of, and interaction of Arg16Gly  $\beta_2$ -ADR polymorphism with  $\beta_2$ -ADR Trp64Arg polymorphism, 1184-1191  
 regulation of EFAs in, in short-gut subjects on lipid-containing TPN, 273-277  
*see also specific serum lipids*
- Serum lipoprotein(a) [Lp(a)] in CAD men, 425
- Serum lipoprotein lipase (LPL), relation between TG metabolism and concentration of, in hypercholesterolemia, 526-531
- Serum low-density lipoprotein-cholesterol ( $\beta$  lipoprotein-cholesterol; LDL-C) in CAD men, 425
- Serum magnesium (Mg) in adrenal insufficiency, 1252
- Serum Na (sodium), beer ingestion and sauna bathing effects on, 774
- Serum nitric oxide (NO), concentration of TNF soluble receptors, TNF- $\beta$  and, in overweight and obese women, 1268-1273
- Serum nonesterified fatty acids (NEFAs; free fatty acids), fasting, in obese NIDDM subjects, bezafibrate effects on, 407-408
- Serum osteocalcin in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum paraoxonase (PON1), polymorphism of, correlated with vascular complications, plasma oxidized LDL level and, in NIDDM, 297-302
- Serum parathyroid hormone (PTH) in eucalcemia after parathyroidectomy for primary hyperthyroidism, relation of, to vitamin D profile, 1101-1106
- Serum phosphate in adrenal insufficiency, 1252
- Serum phospholipids (PL), regulation of, in short-gut subjects on PL-containing TPN, 273-277
- Serum phosphorus (P)  
 in primary hyperthyroidism, 1102



- Serum phosphorus (P) (*Continued*)  
 in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum resistin, pre- and post-pancreatic islet transplantation levels of, in IDDM, 403-404
- Serum sialic acid, cardiovascular disease risk factors associated with, in IDDM Kuwaiti children and adolescents, 638-643
- Serum sodium (Na), beer ingestion and sauna bathing on urinary excretion of, 774
- Serum transferrin, food intake, AT and, in 6-month period following kidney transplantation, 614-619
- Serum triglycerides (TGs)  
 ATPCL inhibitor effects on, 68  
 in CAD men, 425  
 in IDDM, 1301  
 in NIDDM with obesity, bezafibrate effects on, 407-408  
 in postpubertal Asian Indian adolescents, 1338, 1339  
 in preeclampsia, 1434
- Serum tumor necrosis factor (TNF), serum concentration of NO, TNF- $\beta$ , and soluble receptors of, in overweight and obese women, 1268-1273
- Serum tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )  
 levels of, in obese adolescents, MS components and, 863-867  
 in preeclampsia, 1434  
 soluble, associated with IR in liver cirrhosis, 922-926
- Serum tumor necrosis factor- $\beta$  (TNF- $\beta$ ), serum concentrations of NO, TNF soluble receptors and, in overweight and obese women, 1268, 1273
- Serum urea in HD subjects, 1014
- Serum uric acid in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Severe lipodystrophy, effects of leptin replacement therapy of, on body composition, 513-519
- Sex  
 of acromegalic subjects, 565  
 $\beta_2$ -ADR Arg16Gly polymorphism and, 1184, 1185  
 birth weight and, 1545  
 of CT subjects, 557  
 CV disease risk factors and, 1437, 1440  
 of disabled hospitalized older subjects, HHcy and, 1018  
 of DM subjects, *see* Sex of DM subjects  
 effects of, on HbA<sub>1c</sub>, 1497  
 of HD subjects, 1014  
 of hypercholesterolemic subjects, *see* Sex of hypercholesterolemic subjects  
 of hypothyroidic subjects, 278  
 of insulin-resistant subjects, *see* Sex of insulin-resistant subjects  
 of insulin-sensitive subjects, 1109  
 of kidney transplantation recipients, 615  
 of LBW Pima Indians with normal glucose tolerance, 906, 908  
 leptin levels and, 1412-1414  
 of lipodystrophic subjects, *see* Sex of lipodystrophic subjects  
 of NIDDM nephropathy subjects, *see* Sex of NIDDM nephropathy subjects  
 of obese subjects, *see* Sex of obese subjects  
 of overweight subjects, *see* Sex of overweight subjects  
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50  
 and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by non-obese subjects, 1450  
 of primary hyperthyroidism subjects, 1102  
 and risk for metabolic syndrome, 1508  
 serum LPL concentration and, 527, 528
- Sex (*Continued*)  
 and WPG effects on normal or mildly elevated plasma cholesterol, 1311  
*see also* Men; Sex, diet and; Sex, exercise and; Women
- Sex, diet and  
 and acute effects of red wine drinking and food intake on vascular reactivity and, 1082  
 and CV disease risk factors, 1437, 1440  
 and PP TG response to different nutrients, 621
- Sex, exercise and  
 and plasma nitrate/nitrite assessment during OGTT, 675  
 relationship of alcohol, adiposity and, to HDL-C levels and, 704, 706
- Sex, exercise,  $\dot{V}O_{2\max}$  and  
 apo E genotype and changes in serum lipids and  $\dot{V}O_{2\max}$  in endurance exercise, 196-198  
 and apo E polymorphism association with blood lipids and  $\dot{V}O_{2\max}$ , 110-113
- Sex of DM subjects  
 and relation between plasma VEGF, plasma ET-1 concentration, and glycemic control of, 551  
*see also* Sex of IDDM subjects; Sex of NIDDM subjects
- Sex hormone-binding globulin (SHBG)  
 in PM women, *see* Sex hormone-binding globulin in PM women  
 in preeclampsia, 1434, 1435  
 in premenopausal women, plasma Lp and, 189
- Sex hormone-binding globulin (SHBG) in PM women  
 insulin sensitivity and, 508-510  
 plasma Lp and, 189
- Sex of hypercholesterolemic subjects  
 of mildly hypercholesterolemic subjects, 1073  
 serum LPL concentration and, 527, 528
- Sex of IDDM subjects  
 and glycemic control effects on F<sub>2</sub> isoprostane level at IDDM onset, 1119  
 oxidation of glycated and nonglycated LDLs and, 970
- Sex of insulin-resistant subjects  
 indices of IR and, 1525  
 with LVH, 778, 779  
 obese, with normal FPG or IGT, 1097  
 plasma NEFA regulation and, 1198  
 serum GPI-PLD and, 139
- Sex of lipodystrophic subjects  
 with HIV infection, 1567  
 with severe lipodystrophy, 514
- Sex of NIDDM nephropathy subjects  
 of Japanese NIDDM subjects with incipient nephropathy, 1224  
 and pioglitazone effects on carotid artery stiffness and intima-media thickness in NIDDM nephropathy, 1383
- Sex of NIDDM subjects  
 association of corrected QT intervals with carotid artery IMT, 1153, 1154  
 and in at-risk for NIDDM subjects, 224  
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360  
 glyburide and nateglinide effects on NIDDM and, 1332  
 with IGT, 646  
 and insulin therapy effects on serum high-sensitive CRP, 694, 695  
 Japanese subjects, insulin secretion and insulin sensitivity and, 832  
 with obesity, adiponectin and C-reactive protein and, 1457  
 and Pancreas Tonic effects in, 1169  
 with retinopathy, 585  
 and risk factors for CV disease, 160

Sex of NIDDM subjects (*Continued*)

- serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
- see also Sex of NIDDM nephropathy subjects

## Sex of obese subjects

- adipocyte precursor cell proliferation and differentiation and, 633, 635
- adolescents, 864
- Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1055
- with NIDDM, adiponectin, C-reactive protein and, 1457

## Sex of overweight subjects

- of fasting overweight subjects, preservation of circadian rhythm of serum insulin concentration at low plasma glucose in, 1450
- of slightly overweight subjects, effects of L-carnitine and, 1002

## Sex steroids

- plasma Lp and, in women, 187-192
- see also specific sex steroids

## SFA, see Saturated fatty acid(s)

## SHBG, see Sex hormone-binding globulin

## Short-gut subjects on lipid-containing total parenteral nutrition, serum lipid EFAD regulation in, 273-277

Short-term stored frozen blood samples, HbA<sub>1c</sub> in, 1497

## Shuar women, Ecuadorian Amazon, effects of agricultural versus traditional lifestyle on leptin in, 1355-1358

S<sub>i</sub>, see Insulin sensitivity

## Sialic acid

- in inflammation of chronic disease, 901, 902
- serum, cardiovascular disease risk factors associated with, in IDDM Kuwaiti children and adolescents, 638-643

## Sibutramine, effects of moderate weight loss by obese women and, on waist circumference and serum adipocytokines, 430-434

## Silicone gastric banding, adjustable, changes in BMC after RYBG and, for morbid obesity, 918-921

## Simvastatin effects

- on bone mineral density in hypercholesterolemic PM women, 744-748
- on plasma LDL clearance, 484

## Skeletal muscle (SM)

- fiber type- and FA composition-dependent effects of HF diet on TAG and FATP-1 content of, 1032-1036
- of transgenic male subjects, GSK-3 $\beta$  mRNA in, 1322-1330
- see also Glucose transport in SM; Protein in SM; Skeletal muscle, diet effects on; Skeletal muscle cells; Skeletal muscle insulin resistance

## Skeletal muscle (SM), diet effects on

- dietary protein restriction effects on proteasome production in, 340-347

HF diet effects, see High-fat diet, effects of, on SM

## Skeletal muscle (SM) cells, lipid composition of, associated with arachidonic acid and insulin sensitivity in men, 571-577

## Skeletal muscle (SM) insulin resistance (IR), development of, after 1-day hindlimb suspension, 1215-1222

## Slight overweight, L-carnitine effects on fat oxidation, protein turnover, and body composition in, 1001-1006

## SM, see Skeletal muscle; Skeletal muscle cells

## Small-dense low-density lipoprotein (sdLDL)

- carotid atherosclerosis, vascular dementia and, 476-482
- fluvastatin effects on endothelial function in obese PM women via reduction of, 733-739

## Smoking

- acute effects of nicotine on serum glucose, insulin, GH, and cortisol, 578-582
- CAD and, see Smoking, CAD and

Smoking (*Continued*)

- and CV disease risk factors, 1437, 1439
- by disabled hospitalized older subjects, HHcy and, 1018
- effects of, on intravascular remodeling of HDL particles for RCT, 858-862
- FABP-4 and PPAR $\gamma$ -activated receptor polymorphism interaction effects on, 305, 306
- growth hormone in, see Growth hormone in smokers
- by hypercholesterolemic PM women, 745
- in hypothyroidism, 278
- by insulin-resistant subjects, see Smoking by insulin-resistant subjects
- by NIDDM subjects, see Smoking by NIDDM subjects
- pituitary response to exercise by nondiabetic and IDDM smokers, 1140-1144
- relationship between obesity, ADMA and, 1574-1579
- and risk for metabolic syndrome, 1506-1508
- and UCP-3 polymorphism-body composition association, 460, 461
- by young subjects with NIDDM parents, LDL susceptibility to oxidation and circulating adhesion molecules and, 756

## Smoking, CAD and

- by CAD men, as risk for myocardial infarction, 325, 326
- serum HDL-C level effects on association between plasma oxidized LDLs and, 424-426

## Smoking by insulin-resistant subjects

- central HPA dysfunction and, 722
- with CHD, 855

## Smoking by NIDDM subjects

- with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360
- with IGT, as risk factor for CHD, 646
- pituitary response to, 1140-1144
- serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301

## Soccer players, cholesterol efflux in, 1262-1267

## SOD (superoxide dismutase), erythrocyte, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41

## Sodium, see Urinary excretion, sodium

## Sodium nitroprusside, glucose transport in SM stimulated by, 914

## Soluble leptin receptor, relationship between serum leptin, serum adiponectin levels, HOMA IR index, lipids, and leptin receptor gene Lys109Arg and Gln223Arg polymorphisms in Japanese subjects, 879-885

Soluble tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), serum, associated with IR in liver cirrhosis, 922-926

## Soy isoflavone, effects of moderate exercise and, on AT accumulation and bone loss in postmenopausal subjects, 942-948

## Soybean oil in obesity-inducing HF diet, 783

## Sp1, SFA effects on apo A-1 promoter induced by, 1342-1348

## Spanish subjects

- association of Trp64Arg polymorphism of  $\beta_3$ -adrenergic receptor associated with increased leptin levels but not with -3826A→G polymorphism of UCP-1 gene in, 1411-1416
- low CHD mortality in Spain and high-plasma HDL-C in Spanish children, 1045-1047

## Spinal cord injury (SCI)

- acute, circulating leptin as marker of fat mass in, 989-994
- MS in men with, 1372-1377

## Spironolactone for obese PCOS women, 370

Spontaneous hypertension (HTN), intracellular Ca<sup>2+</sup> chelator effects on IR and on, in subjects on high-fat diet, 269-272

- Squamous cell carcinoma (SCC), head and neck, effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-trans retinoic acid and on cell proliferation in, 1007-1012
- SR (strontium ranelate), bone matrix mineralization induced by, in MC3T3-E1 osteogenic cells, 532-537
- SREBP-1 (sterol regulatory element binding protein-1) mRNA (messenger ribonucleic acid), upregulation of lipogenic enzyme and, in white adipose tissue of CRF subjects, 1060-1065
- SSPG, *see* Steady-state plasma glucose in IR
- Stability over time of GHb, RBC survival and, in hematologically stable subjects without DM, 1399-1403
- Starch in HF diet, 1033
- Statins  
in CAD, 319  
in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301  
*see also* Atorvastatin; Fluvastatin; Pravastatin effects; Simvastatin effects
- Steady-state plasma glucose (SSPG) in IR  
with associated CV disease risk factors in overweight and normoponderal subjects, 495-498  
*see also* Steady-state plasma glucose in obesity with IR
- Steady-state plasma glucose (SSPG) in obesity with IR  
with associated CV disease risk factors, 495-498  
effects of moderate weight loss by obese insulin-resistant women on, 280-283
- Stearic acid  
effects of, on Sp1-induced apo A-1 promoter, 1343-1345  
TG content of, in MS, 312
- Steroid(s), *see specific steroids*
- Steroidogenic acute regulatory protein mRNA (messenger ribonucleic acid), low temperature blocking testosterone production and stimulatory effects of hCG on, but not cAMP production in tumor cells, 955-958
- Sterol regulatory element binding protein-1 (SREBP-1) mRNA (messenger ribonucleic acid), upregulation of lipogenic enzyme and, in white adipose tissue of CRF subjects, 1060-1065
- Stevioside (SVS)  
effects of, on glucose transport in insulin-sensitive and insulin-resistant subjects, 101-107  
effects of, in NIDDM, 73-76
- Stiffness, carotid artery, pioglitazone effects on carotid intima-media thickness and, in NIDDM nephropathy, 1382-1386
- Storch-Young model of Hcy remethylation and TS, 1480-1483
- Streptozotocin-induced diabetes mellitus (STZ-DM)  
effects of oral vanadate with tea extract on mortality and morbidity associated with, 1145-1151  
high-fat diet-induced fatty liver in, 260-263  
leptin effects on HPA axis activity, dysphagia, and weight loss in, 1558-1564  
LSF effects on glucose-stimulated insulin secretion in, 290-296  
with obesity, effects of *P. yoelli* GPIs on glucose homeostasis in, 1048-1053
- Stress  
mental, and lipolysis activation in IR, 1199  
oxidative, in NIDDM with obesity, pioglitazone protecting beta cells from, 488-494
- Stromal vascular cells from omental and subcutaneous AT of obese subjects, differentiation and proliferation of, compared, 634
- Strontium ranelate (SR; S12911-2), bone matrix mineralization induced by, in MC3T3-E1 osteogenic cells, 532-537
- STZ-DM, *see* Streptozotocin-induced diabetes mellitus
- Subclinical hypothyroidism, CV disease risk factors in, 1512-1515
- Subcutaneous adipose tissue (SAT)  
abdominal, in lipodystrophic HIV-infected subjects, 1567  
*see also* Omental adipose tissue, subcutaneous and, in obese subjects
- Sucrose (S)  
in HF diet, 1033  
in MNH-01 formula, 978  
NOS inhibition and pioglitazone effects on insulin action in subjects on high-sucrose diet, 22-27
- Sulfonylurea, effects of Pancreas Tonic and, in NIDDM, compared, 1169
- Sunflower oil in HF diet, 1033
- Superoxide dismutase (SOD), erythrocyte, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Supplementation, *see specific supplements*
- Survival, RBC, stability over time of GHb, glucose and, in hematologically stable subjects without DM, 1399-1403
- SVS, *see* Stevioside
- Swimming, effects of, on hepatic glucose production in response to glucagon, 1027-1031
- Symptoms of hypoglycemia, pramlintide effects on response of catecholamines, glucagon and, 1227-1232
- Synthase  
deficiency in cystathionine- $\beta$ -, betaine effects on, 594-599  
fatty acid, upregulation of mRNA SREBP-1 and, in WAT of CRF subjects, 1060-1065  
inducible and endothelial nitric oxide, in early NIDDM nephropathy, 1474  
nitric oxide, *see* Nitric oxide synthase  
*see also* Glycogen synthase; Glycogen synthase kinase-3 $\beta$  mRNA
- Syringe pumps, peristaltic and, in metabolic research, accuracy and precision of peristaltic and, compared, 875-878
- Systolic pressure, *see* Blood pressure
- T lymphocytes, activated, CD4<sup>+</sup> and CD8<sup>+</sup>, emergence of growth factor receptors in, 117-122
- T<sub>3</sub>, *see* Triiodothyronine in hypothyroidism
- T3T3-L1 preadipocytes, FPFS-410 effects on, in preadipocytes 1534
- T<sub>4</sub>, *see* Thyroxine in hypothyroidism
- TAG, *see* Triacylglycerol
- Taiwanese women, GDM and  $\beta_1$ -ADR Trp64Arg polymorphism in, 1136-1139
- Taurine (Tau), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- TC, *see* Total cholesterol
- Tea extract with oral vanadate, effects of, on morbidity and mortality in STZ-DM, 1145-1151
- Telopeptide,  $\beta$ -carboxy terminal, of type 1 collagen in adrenal insufficiency, 1252
- Temperature  
adaptive thermogenesis and resistance to obesity, 1417-1423  
cold, *see* Exercise at cold temperature, NEFA oxidation during low, hCG stimulatory effects on steroidogenic acute regulatory protein mRNA and testosterone production blocked by, in tumor cells, but not cAMP production, 955-958
- Tempol, effects of, on hyperinsulinemia and hypertension based on increase of medullary BF, 1305-1308
- Testosterone  
carotid atherosclerosis, vascular dementia and, 477  
free, *see* Free testosterone  
low temperature blocking stimulatory effects of hCG on steroidogenic acute regulatory protein mRNA and production of, but not on cAMP production in tumor cells, 955-958

- Testosterone (*Continued*)  
 total, *see* Total testosterone
- Tetraacetic acetoxymethyl ester [bis(*o*-aminophenoxy)ethane-N,N,N',N')], effects of, on IR and spontaneous HTN in subjects on HF diet, 269-272
- 25-Tetrol, plasma, in CTX, 558
- TG(s), *see* Triglyceride(s)
- TGF- $\beta$ 1 (transforming growth factor- $\beta$ 1), effects high glucose and insulin on expression of, in cardiac fibroblasts, 712
- TGL (triglyceride lipase), hepatic, endurance exercise effects on, 196, 198-200
- TGZ, *see* Troglitazone
- tHcy (total homocysteine) in subclinical hypothyroidism, 1513
- Thermogenesis  
 adaptive, resistance to obesity and, 1417-1423  
*see also* Temperature
- Thiazolidinediones, *see* FPS-410; Non-insulin-dependent diabetes mellitus, pioglitazone effects on; Rosiglitazone effects; Troglitazone
- Thioctic acid [R-(+)- $\alpha$ -lipoic acid], effects of, on pyruvate metabolism and NEFA oxidation in hepatocytes, 165-173
- Third trimester of uncomplicated pregnancy, leucine turnover in, 545-549
- 3826A $\rightarrow$ G polymorphism of UCP-1 gene, increased leptin level associated with  $\beta_2$ -ADR Trp64Arg polymorphism but not with, in Spanish subjects, 1411-1416
- Threonine (Thr), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Thrombin, effects of, on platelet function in DM, 66-72
- Thromboxane B<sub>2</sub> (TXB<sub>2</sub>), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
- Thyroidal diseases  
 3,3'-T<sub>2</sub>S in, 538-543  
*see also* specific conditions
- Thyrotropin (TSH) in hypothyroidism  
 effects of therapy with, on endothelial function and, 279  
 free, in subclinical hypothyroidism, CV disease risk factors and, 1513
- Thyroxine (T<sub>4</sub>) in hypothyroidism  
 effects of therapy with, on endothelial function, 278-279  
 free, in subclinical hypothyroidism, CV disease risk factors and, 1513
- Tissue plasminogen activator (tPA)-antigen in NIDDM and at-risk for NIDDM subjects, 224, 226
- TNF, *see* Tumor necrosis factor
- $\alpha$  (alpha)-Tocopherol (vitamin E)  
 CV disease risk factors and intake of, 1439  
 and plasma ADMA in mild hypercholesterolemia, 1073  
*see also*: all-*rac* -Tocopherol
- all-*rac*  $\alpha$  (alpha)-Tocopherol (vitamin E)  
 anti-inflammatory effects of  $\omega$ -3 PUFAs alone or combined with, 236-240  
 in obesity-inducing HF diet, 783
- Total adipose tissue (AT)  
 in IR, 722, 723  
 in obese NIDDM subjects, bezafibrate effects on, 407  
 in PM women, androgenicity and, and insulin sensitivity, 508
- Total bilirubin  
 in Korean women, AT distribution and, 1541  
 in obese Korean subjects, -3826A $\rightarrow$ G UCP-1 polymorphism effects on level of LDL-C and, 1057
- Total cholesterol (TC)  
 ABCA1 gene and, *see* Total cholesterol, ABCA1 gene and  $\beta_2$ -ADR Arg16Gly polymorphism and, 1184
- Total cholesterol (TC) (*Continued*)  
 in atherosclerosis, *see* Total cholesterol in atherosclerosis  
 in CAD, *see* Total cholesterol, CAD and  
 in disabled hospitalized older subjects, HHcy and, 1018  
 in dyslipidemic CRF subjects on HD, 1114  
 during estrous cycle, 140  
 exercise effects on, *see* Total cholesterol, exercise effects on  
 fat mass and, in acute SCI subjects, 991  
 HF/HC diet effects on, 1023  
 in hypercholesterolemia, *see* Total cholesterol in hypercholesterolemia  
 in hypothyroidism, *see* Total cholesterol in hypothyroidism  
 in IDDM, *see* Total cholesterol in IDDM  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 in IR, *see* Total cholesterol in IR  
 in Japanese subjects, *see* Total cholesterol in Japanese subjects  
 in Korean women, AT distribution and, 1541  
 leptin levels and, 1412-1414  
 in MS, *see* Total cholesterol in MS  
 in NIDDM, *see* Total cholesterol in NIDDM  
 in non-obese subjects, *see* Total cholesterol in non-obese subjects  
 in obesity, *see* Total cholesterol in obesity  
 plasma, *see* Total plasma cholesterol  
 plasma LDL clearance and, 484  
 plasma vitamin K transport and, 216  
 in postpubertal Asian Indian adolescents, 1338  
 $\omega$ -3 PUFAs and, *see* Total cholesterol,  $\omega$ -3 PUFAs and  
 in SCI, *see* Total cholesterol in SCI  
 serum, *see* Serum cholesterol  
 in Vietnamese children with apo E polymorphism, 1519  
 in young subjects with NIDDM parents, 756
- Total cholesterol (TC), ABCA1 gene and  
 ABCA1 gene expression-fasting glucose relationship in normoglycemic men and, 19  
 ABCA1 gene polymorphism-TC association in Japanese school-age children and, 183
- Total cholesterol (TC), CAD and  
 in PM women on ERT and at risk for CAD, aerobic exercise and high-fiber, low-fat diet effects on, 378  
 red and white wine drinking effects on, 320  
 serum, in CAD men, 425
- Total cholesterol (TC), exercise effects on  
 blood, apo E polymorphism association with VO<sub>2max</sub> and, in exercising and sedentary subjects, 111-113  
 in overweight nondiabetic and NIDDM subjects, 1236  
 serum, apo E genotype and changes in, in endurance exercise, 196, 198-200
- Total cholesterol (TC),  $\omega$ -3 PUFAs and  
 in FCHL, 154  
 plasma, effects of  $\omega$ -3 PUFAs alone or combined with all-*rac*  $\alpha$ -tocopherol on, 237  
 in SCI men with MS, 1373, 1374  
 WPG effects on, 1311
- Total cholesterol (TC) in atherosclerosis  
 carotid atherosclerosis, vascular dementia and, 477  
 in premature atherosclerosis with normocholesterolemia and daytime hypertriglyceridemia, 50
- Total cholesterol (TC) in hypercholesterolemia  
 in mild hypercholesterolemia, 1073  
 serum LPL concentration and, 527, 528
- Total cholesterol (TC) in hypothyroidism  
 and effects of T<sub>4</sub> therapy on endothelial function, 279  
 in subclinical hypothyroidism, CV disease risk factors and, 1513



- Total cholesterol (TC) in IDDM  
energy substrate oxidation and, 656  
in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641  
plasma apo C-3 polymorphisms and, 1299
- Total cholesterol (TC) in IR  
with CHD, 853  
with LVH, candesartan effects on, 779  
plasma NEFA regulation and, 1198  
visceral AT and TG FA content and, 312  
*see also* Total cholesterol in IR with microalbuminuria
- Total cholesterol (TC) in IR with microalbuminuria  
cardiovascular autonomic dysfunction and, 1360, 1362  
and cilostazol effects on microalbuminuria, 1407  
in NIDDM, glycemic control effects on, 354
- Total cholesterol (TC) in Japanese NIDDM subjects  
with incipient nephropathy, 1224  
insulin secretion and insulin sensitivity and, 832
- Total cholesterol (TC) in Japanese subjects  
with beta-cell dysfunction, 950  
and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883  
*see also* Total cholesterol in Japanese NIDDM subjects
- Total cholesterol (TC) in MS, 312  
with obesity and chronic renal disease, 1257  
in SCI men, 1373, 1374
- Total cholesterol (TC) in NIDDM  
and association of corrected QT intervals with carotid artery IMT, 1155  
and in at-risk for NIDDM subjects, 224, 226  
with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362  
and correlation of HbA<sub>1c</sub> with lipid composition in RBC membrane, 124  
with IGT, 646  
insulin therapy effects on, 694, 697, 698  
in Japanese NIDDM subjects, *see* Total cholesterol in Japanese NIDDM subjects  
metformin effects on, 161  
microalbuminuria and, 354  
in overweight NIDDM subjects, 1236  
Pancreas Tonic effects on, 1169  
serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Total cholesterol (TC) in non-obese subjects  
in non-obese men, and AT as fibrinogen level predictor, 985, 986  
in non-obese premenopausal women, metabolic risk and, 1068-1070
- Total cholesterol (TC) in obese adolescents  
in hyperuricemic Japanese male adolescents, 450, 452  
serum TNF- $\alpha$  and, 864, 865
- Total cholesterol (TC) in obese women  
effects of moderate weight loss and sibutramine or orlistat on, 432  
in obese PM women, fluvastatin effects on, 736
- Total cholesterol (TC) in obesity  
in children, 1244  
in insulin-resistant Japanese subjects, 651  
in Korean subjects, -3826A $\rightarrow$ G UCP-1 polymorphism effects on level of LDL-C and, 1057  
with normal FPG or IGT, effects of weight loss on, 1097  
and smoking-ADMA-obesity relationship, 1575, 1576
- Total cholesterol (TC) in obesity (*Continued*)  
*see also* Total cholesterol in obese adolescents; Total cholesterol in obese women
- Total cholesterol (TC) in SCI  
and fat mass in acute SCI subjects, 991  
in SCI men, 1373, 1374
- Total fat mass (FM) of lipodystrophic HIV-infected subjects, 1567
- Total homocysteine (tHcy) in subclinical hypothyroidism, 1513
- Total parenteral nutrition (TPN), lipid-containing, regulation of serum lipid EFAD in short-gut subjects on, 273-277
- Total plasma cholesterol (C)  
and anti-inflammatory effects of  $\omega$ -3 PUFAs alone or combined with *all-rac*  $\alpha$ -tocopherol, 237  
HF/HC diet effects on, 819  
in HL deficiency, 522  
in IDDM, oxidation of glycated and nonglycated LDLs and, 970  
in Spanish children, 1046
- Total plasma protein, beer ingestion and sauna bathing effects on, 774
- Total plasma triglycerides (TGs) in IDDM, oxidation of glycated and nonglycated LDLs and, 970
- Total serum cholesterol (C) in CAD men, 425
- Total testosterone  
in older NIDDM men with partial androgen deficiency, 668  
in PM women, insulin sensitivity and, 508-510
- Total triglyceride(s) (TGs)  
plasma, in IDDM, oxidation of glycated and non-glycated LDLs and, 970  
and plasma vitamin K transport, 216
- TPN (total parenteral nutrition), lipid-containing, regulation of serum lipid EFAD in short-gut subjects on, 273-277
- Traditional lifestyle, effects of agricultural lifestyle versus, on leptin in Ecuadorian Amazon Shuar women, 1355-1358
- Training, *see* Exercise
- Transcription factors in 3T3-L1 preadipocytes, PFPS-410 effects on 1534
- Transfer protein, *see* Cholesteryl ester transfer protein; Phospholipid transfer protein
- Transferase  
point mutation of hypoxanthine phosphoribosyl, responsible for hyperuricemia in women, 1500-1502  
*see also* Acyl-coenzyme A:cholesterol acyltransferase; Alanine aminotransferase; Aspartate aminotransferase
- Transferrin (Trf)  
in disabled hospitalized older subjects, HHcy and, 1018  
serum, food intake, AT and, in kidney transplantation recipients, 614-619
- Transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1), effects of high glucose and insulin on expression of, in cardiac fibroblasts, 712
- Transgenic subjects, male, glucose intolerance development in, with GSK-3 $\beta$  overexpression in skeletal muscle, 1322-1330
- Transplantation  
kidney, correlation between AT, serum leptin, and food intake during 6-month period following, 614-619  
pancreatic islet, serum resistin levels in IDDM before and after, 403-404
- Trans-sulfuration (TS) of homocysteine, 1480-1483
- Trf, *see* Transferrin
- Triacylglycerol (TAG)  
in CRF, 1063  
fiber type- and FA composition-dependent effects of HF diet on content of FATP-1 and, in skeletal muscle, 1032-1036  
plasma, during exercise at cold temperature, 204  
PP, in NIDDM, alcohol effects on, 77-83



- Triacylglycerol (TAG) (*Continued*)  
 WPG effects on, 1311-1312
- Triglyceride(s) (TG)  
*ABCA1* gene and, *see* Triglyceride(s), *ABCA1* gene and  
 blood, *see* Blood triglycerides  
 in CAD men, effects of red and white wine drinking on, 319, 320  
 CV disease risk factors and, *see* Triglyceride(s), CV disease risk factors and  
 diet effects on, *see* Triglyceride(s), diet effects on  
 in DM, *see* Triglyceride(s) in DM  
 in dyslipidemic CRF subjects on HD, 1114, 1115  
 erythrocyte membrane, 574  
 during estrous cycle, 140  
 exercise and, *see* Triglyceride(s), exercise and  
 fasting, *see* Fasting triglycerides  
 and fat mass in acute SCI subjects, 991  
 and GSK-3 $\beta$  in transgenic subjects, 1328  
 in HD subjects, 1014  
 in hypercholesterolemia, *see* Triglyceride(s) in hypercholesterolemia  
 in hypothyroidism, *see* Triglyceride(s) in hypothyroidism  
 in IGT first-degree relatives of African American NIDDM subjects, 1553  
 intramuscular, after 1-day hindlimb suspension, 1217  
 in IR, *see* Triglyceride(s) in IR  
 in Japanese subjects, *see* Triglyceride(s) in Japanese subjects  
 in Korean women, AT distribution and, 1541  
 leptin levels and, 1412-1414  
 MHN-01 effects on concentration of, 981  
 in non-obese subjects, *see* Triglyceride(s) in non-obese subjects  
 in obesity, *see* Triglyceride(s) in obesity  
 in overweight women, serum TNF, TNF- $\beta$ , NO and, 1269  
 plasma, *see* Plasma triglycerides  
 and plasma LDL clearance, 484  
 in PM women, simvastatin effects on BMD and, 745, 746  
 $\omega$ -3 PUFA effects on, *see* Triglyceride(s),  $\omega$ -3 PUFA effects on  
 serum, *see* Serum triglycerides  
 smoking effects on, 860  
 total, *see* Total triglyceride(s)  
 VAT accumulation and fatty acid content of, associated with MS components, 310-317  
 in young subjects, *see* Triglyceride(s) in young subjects
- Triglyceride(s) (TG), *ABCA1* gene and  
*ABCA1* gene expression-fasting glucose relationship in normoglycemic men and, 19  
*ABCA1* gene polymorphism-TG association in Japanese school-age children and, 183, 184
- Triglyceride(s) (TG), CV disease risk factors and  
 in Kuwaiti children, 640, 641  
 in overweight and normoponderal subjects, 498  
 in subclinical hypothyroidism, 1513
- Triglyceride(s) (TG), diet effects on  
 CV disease risk factors and, 1437, 1438  
 effects of aerobic exercise with high-fiber, low-fat diet in PM women on ERT, 378  
 HF diet effects, 1034  
 HF/HC diet effects, 819, 1023
- Triglyceride(s) (TG), exercise and  
 acipimox-induced reduction of, during exercise at cold temperature, 1133  
 blood, apo E polymorphism-VO<sub>2max</sub> association and, 111-113  
 endurance exercise, 196, 198-200  
 in overweight nondiabetic and NIDDM subjects, 1236  
 in PM women on or not on ERT, 1194
- Triglyceride(s) (TG), exercise and (*Continued*)  
 $\omega$ -3 PUFA and exercise effects, 751  
 in soccer players, 1263  
*see also* Triglyceride(s) in exercising PM women on ERT
- Triglyceride(s) (TG),  $\omega$ -3 PUFA effects on  
 with exercise, 751  
 of  $\omega$ -3 PUFAs alone or combined with *all-rac*  $\alpha$ -tocopherol, 154, 155
- Triglyceride(s) (TG) in DM  
 in STZ-DM, NO-1886 effects on, 261  
*see also* Triglyceride(s) in IDDM; Triglyceride(s) in NIDDM
- Triglyceride(s) (TG) in exercising PM women on ERT  
 on or not on ERT, 1194  
 with risk for CAD, effects of aerobic exercise with high-fiber, low-fat diet, 378
- Triglyceride(s) (TG) in hypercholesterolemia  
 in mild hypercholesterolemia, 1073, 1074  
 relation between serum LPL concentration and metabolism of, 526-531
- Triglyceride(s) (TG) in hypothyroidism  
 effects of T<sub>4</sub> therapy on, on, 279  
 in subclinical hypothyroidism, CV disease risk factors and, 1513
- Triglyceride(s) (TG) in IDDM  
 and glycemic control effects on F<sub>2</sub> isopropane level at IDDM onset, 1119  
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
- Triglyceride(s) (TG) in IR  
 with associated CV disease risk factors in overweight and normoponderal subjects, 498  
 central HPA dysfunction and, 722, 724  
 with CHD, 853, 854  
 and cilostazol effects on microalbuminuria, 1407  
 indices of IR and, 1524  
 with LVH, candesartan effects on, 779  
 with microalbuminuria, *see* Triglyceride(s) in microalbuminuric IR  
 plasma NEFA regulation and, 1198  
 serum GPI-PLD and, 139  
 in Vietnamese children with apo E polymorphism, 1519  
*see also* Triglyceride(s) in obesity with IR
- Triglyceride(s) (TG) in Japanese NIDDM subjects  
 with incipient nephropathy, 1224  
 insulin sensitivity, insulin secretion and, 832
- Triglyceride(s) (TG) in Japanese subjects  
 with beta-cell dysfunction, 950  
 with NIDDM, *see* Triglyceride(s) in Japanese NIDDM subjects  
 and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, 881-883
- Triglyceride(s) (TG) in microalbuminuric IR  
 cilostazol effects on, 1407  
 with NIDDM, cardiovascular autonomic dysfunction and, 1360, 1362
- Triglyceride(s) (TG) in microalbuminuric NIDDM, 354  
 adiponectin, C-reactive protein and, 1456, 1457  
 cardiovascular autonomic dysfunction, IR and, 1360, 1362
- Triglyceride(s) (TG) in NIDDM  
 and association of corrected QT intervals with carotid artery IMT, 1155, 1156  
 and in at-risk for NIDDM subjects, 224, 226  
 fasting, *see* Fasting triglycerides  
 with IGT, 646  
 insulin therapy effects on, 694, 697  
 metformin effects on, 161

- Triglyceride(s) (TG) in NIDDM (*Continued*)  
 with microalbuminuria, *see* Triglyceride(s) in microalbuminuric NIDDM  
 rosiglitazone effects on, 1123
- Triglyceride(s) (TG) in non-obese subjects  
 in non-obese men, AT as fibrinogen level predictor and, 985, 986  
 in non-obese premenopausal women, metabolic risk and, 1068-1070
- Triglyceride(s) (TG) in obese women  
 effects of moderate weight loss and sibutramine or orlistat on, 432  
 PM women, fluvastatin effects on, 736
- Triglyceride(s) (TG) in obesity  
 adolescents, 864, 865  
 Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057  
 with MS and chronic renal disease, 1257  
 with NIDDM, adiponectin and C-reactive protein and, 1456, 1457;  
*see also* Fasting triglycerides in obese NIDDM subjects  
 with normal FPG or IGT effects of weight loss on, 1097  
 in obese children, 1244  
 and smoking-ADMA-obesity relationship, 1575, 1576  
*see also* Triglyceride(s) in obese women; Triglyceride(s) in obesity with IR
- Triglyceride(s) (TG) in obesity with IR  
 associated CV disease risk factors and, 498  
 in Japanese men, Ob-R polymorphism associated with, 651  
 in treatment-seeking subjects, 436
- Triglyceride(s) (TG) in young men  
 with hypertensive parents, 470  
 serum adiponectin association with, 589-593
- Triglyceride(s) (TG) in young subjects  
 with NIDDM parents, 756  
*see also* Triglyceride(s) in young men
- Triglyceride lipase (TGL), hepatic, endurance exercise effects on, 196, 198-200
- Triglyceride-rich lipoprotein (TRL), plasma vitamin K transport and, 215-221
- Triiodothyronine ( $T_3$ ) in hypothyroidism  
 free, in subclinical hypothyroidism, CV disease risk factors and, 1513  
 $T_4$  therapy and, 279
- Triphosphate, *see* Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA
- Triple mutations of *HNF-4 $\alpha$*  gene associated with early-onset NIDDM in Filipino family, 953-963
- TRL (triglyceride-rich lipoprotein), plasma vitamin K transport and, 215-221
- Troglitazone (CS-045; TGZ)  
 4-aminopyridine effects on delayed vasorelaxation by, 147-152  
 for obese PCOS women, 366, 371
- Trp64Arg polymorphism, *see*  $\beta_3$ -Adrenergic receptor, Trp64Arg polymorphism of
- Tryptophan (Trp)  
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392  
*see also*  $\beta_3$ -Adrenergic receptor, Trp64Arg polymorphism of
- TS (trans-sulfuration) of homocysteine, 1480-1483
- 3,3'- $T_2S$  (3,3'-diiodothyronine sulfate) in thyroidal diseases, nonthyroidal diseases, pregnancy, and fetal/neonatal life, 538-543
- TSH, *see* Thyrotropin in hypothyroidism
- Tumor cells, low temperature blocking hCG stimulatory effects on steroidogenic acute regulatory protein mRNA and testosterone production but not cAMP production in tumor cells, 955-958
- Tumor necrosis factor (TNF)  
 serum, serum concentration of NO, TNF- $\beta$ , and soluble receptors of, in overweight and obese women, 1268-1273  
*see also* Tumor necrosis factor  $\alpha$ ; Tumor necrosis factor  $\beta$ ; Tumor necrosis factor receptor
- Tumor necrosis factor  $\alpha$  (TNF- $\alpha$ )  
 effects of  $\omega$ -3 PUFAs alone or with *all-rac*  $\alpha$ -tocopherol on, 236-240  
 effects of weight loss by obese subjects with normal FPG or IGT on, 1097  
 in inflammation of chronic disease, 901  
 in NIDDM and in at-risk for NIDDM subjects, 224  
 resistance exercise effects on insulin-mediated glucose disposal with minimal effects on, in older hypertensive subjects, 397-402  
 serum, *see* Serum tumor necrosis factor- $\alpha$
- Tumor necrosis factor  $\beta$  (TNF- $\beta$ ), serum concentration of NO and soluble receptors of, in overweight and obese women, 1268-1273
- Tumor necrosis factor receptor (TNF-R), serum concentration of NO, TNF- $\beta$  and, in overweight and obese women, 1268-1273
- TXB<sub>2</sub> (thromboxane B<sub>2</sub>), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
- Type 1 collagen,  $\beta$ -carboxy terminal telopeptide of, in adrenal insufficiency, 1252
- Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Tyrosine (Tyr), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- TZDs (thiazolidinediones), *see* FPF5-410; Non-insulin-dependent diabetes mellitus, pioglitazone effects on; Rosiglitazone effects; Troglitazone
- UA, *see* Uric acid
- UACR (urinary albumin to creatinine ratio), glycemic control effects on, in NIDDM, 353-357
- UCA (ursocholic acid), effectiveness of, in CTX, 556-562
- UCP-1 (uncoupling protein-1) -3826A→G polymorphism, effects of, on LDL-C level in Korean obese subjects, 1054-1059
- UCP-1 mRNA, *see* Uncoupling protein-1 mRNA
- UCP-2 (uncoupling protein-2) mRNA (messenger ribonucleic acid) in diabetes, CL316,243 effects on, 804
- UCP-3 (uncoupling protein-3) mRNA (messenger ribonucleic acid) in diabetes, CL316,243 effects on, 802, 804
- UCP-3 (uncoupling protein-3) polymorphism, food intake and body composition associated with, 458-464
- UDCA (ursodeoxycholic acid), effectiveness of, in CTX, 556-562
- Uncomplicated pregnancy, leucine turnover in third trimester of, 545-549
- Uncoupling protein-1 (UCP-1) mRNA (messenger ribonucleic acid) in AT, effects of restricted diet on, 30-31  
 in diabetes, CL316,243 effects on, 802, 804
- Uncoupling protein-1 (UCP-1) -3826A→G polymorphism effects of, on LDL-C level in Korean obese subjects, 1054-1059  
 not associated with increased leptin levels in Spanish subjects, 1411-1416
- Uncoupling protein-2 (UCP-2) mRNA (messenger ribonucleic acid) in diabetes, CL316,243 effects on, 804
- Uncoupling protein-3 (UCP-3) mRNA (messenger ribonucleic acid) in diabetes, CL316,243 effects on, 802, 804
- Uncoupling protein-3 (UCP-3) polymorphism, food intake and body composition associated with, 458-464
- Urate in young subjects with NIDDM parents, 756

- Urea  
 plasma, in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089  
 serum, in HD subjects, 1014
- Urea nitrogen, *see* BUN
- Uric acid (UA)  
 in IR with LVH, candesartan effects on, 779  
 in NIDDM, *see* Uric acid in NIDDM  
 plasma, sauna bathing and beer ingestion effects on concentration of, 772-776  
 point mutation in HPRT responsible for hyperuricemia in women, 1500-1502  
 in preeclampsia, 1434  
*see also* Hyperuricemia
- Uric acid (UA) in NIDDM  
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362  
 serum, in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Urinary excretion  
 effects of glycemic control in NIDDM on UACR, 353-357  
 of hydroxyproline, deoxypyridinol, pyridinoline, Ca, phosphorus, and creatinine in severe lipodystrophy, leptin replacement therapy effects on, 516  
 of plasma purines, beer ingestion and sauna bathing effects on, 773-774  
 of serum chloride, beer ingestion and sauna bathing effects on, 774  
 of sodium, *see* Urinary excretion, sodium  
*see also* Albuminuria
- Urinary excretion, sodium  
 in hyperinsulinemia with hypertension, 1306  
 of serum sodium, beer ingestion and sauna bathing effects on, 774
- Urine volume, beer ingestion and sauna bathing effects on, 774
- Ursolic acid (UCA), effectiveness of, in CTX, 556-562
- Ursodeoxycholic acid (UDCA), effectiveness of, in CTX, 556-562
- VaD (vascular dementia), sdLDLs, carotid atherosclerosis and, 476-482
- Valine, *see* Plasma valine
- Vanadate, oral, with tea extract, effects of, on morbidity and mortality in STZ-DM, 1145-1151
- Vascular cell(s)  
 stromal, from omental and subcutaneous AT of obese subjects, differentiation and proliferation of, compared, 634  
*see also* Vascular cell adhesion molecule
- Vascular cell adhesion molecule (VCAM)  
 in NIDDM and in at-risk for NIDDM subjects, 224, 226  
*see also* Vascular cell adhesion molecule-1
- Vascular cell adhesion molecule-1 (VCAM-1)  
 CAD and, *see* Vascular cell adhesion molecule-1, CAD and metformin effects on, in NIDDM, 161
- Vascular cell adhesion molecule-1 (VCAM-1), CAD and plasma, effects of red and white wine on, in CAD men, 318-323  
 in postmenopausal women on ERT and at risk for CAD, effects of high-fiber, low-fat diet and exercise on, 377-381
- Vascular complications, correlation between plasma oxidized LDLs, serum PON1 polymorphism and, in NIDDM, 297-302
- Vascular dementia (VaD), sdLDLs, carotid atherosclerosis and, 476-482
- Vascular disease  
 cerebral and microvascular, in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 298-300  
*see also* Risk factors for CV disease
- Vascular endothelial growth factor (VEGF), plasma, in DM, relation between concentration of plasma ET, glycemic control and, 550-555
- Vascular reactivity, absence of acute effects of red wine drinking and food intake on, 1081-1086
- Vasopressin, *see* Arginine-vasopressin
- Vasorelaxation, 4AP effects on delayed, by troglitazone, 147-152
- VAT, *see* Visceral adipose tissue
- VCAM, *see* Vascular cell adhesion molecule; Vascular cell adhesion molecule-1
- VEGF (vascular endothelial growth factor), relation between concentration of plasma ET, glycemic control and, in DM, 550-555
- Venous hyperinsulinemia, effects of portal, on gut glucose absorption in conscious subjects, 1290-1295
- Ventricular hypertrophy, left, candesartan effects on IR and, 777-781
- Vertebral bone mineral content (BMC) after RYBG and ASGB for morbid obesity, 920
- Vertebral bone mineral density (BMD) after RYBG and ASGB for morbid obesity, 920
- Very-low-density lipoprotein (VLDL)  
 in HL deficiency, 523  
 plasma, in PM and premenopausal women, sex steroids and, 189, 190  
*see also* Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein-cholesterol (VLDL-C)  
 in dyslipidemic CRF subjects on HD, 1115  
 in exercise, *see* Very-low-density lipoprotein-cholesterol in exercise  
 in HD subjects, 1014  
 in hypercholesterolemia, serum LPL concentration and, 528  
 in IDDM, *see* Very-low-density lipoprotein-cholesterol in IDDM  
 plasma, HF/HC diet effects on, 819  
 S-2E effects on, in mixed hyperlipidemia, 682-683
- Very-low-density lipoprotein-cholesterol (VLDL-C) in exercise  
 apo E polymorphism association with changes in  $VO_{2max}$  and, in sedentary subjects and exercising subjects, 111-113  
 in soccer players, 1264
- Very-low-density lipoprotein-cholesterol (VLDL-C) in IDDM  
 and oxidation of glycated and nonglycated LDLs, 970  
 plasma apo C-3 polymorphisms and, 1299, 1301
- Vietnamese children, relationship of apo E polymorphism to plasma lipids and Lps in, 1517-1521
- Visceral adipose tissue (VAT)  
 contribution of cardiorespiratory fitness and, to hyperinsulinemia, dyslipidemia, and hypertension in NIDDM with IGT, 644-649  
 HF diet effects on, 913, 1033  
 in IR with obesity, 436  
 TG fatty acid content and accumulation of, associated with MS components, 310-317
- Vitamin(s) in HF diet, 1033
- Vitamin B<sub>12</sub> in subclinical hypothyroidism, 1513
- Vitamin C (ascorbic acid)  
 CV disease risk factors and intake of, 1439  
 and plasma ADMA in mild hypercholesterolemia, 1073
- Vitamin D, relation of serum PTH level to, in eucalcemia after parathyroidectomy for primary hyperthyroidism, 1101-1106
- Vitamin D<sub>12</sub> in disabled hospitalized older subjects, HHcy and, 1018
- Vitamin E, *see*  $\alpha$ -Tocopherol
- Vitamin K (phylloquinone), transport of plasma, in men consuming deuterium-labeled collard greens, 215-221
- VLDL, *see* Very-low-density lipoprotein
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol

- VO<sub>2max</sub>** (maximum oxygen uptake)  
 by non-obese premenopausal women, 1068  
 and risk factors for CHD in NIDDM with IGT, 646  
*see also* VO<sub>2max</sub> during exercise
- VO<sub>2max</sub>** (maximum oxygen uptake) during exercise  
 apo E genotype and changes in serum lipids in endurance exercise, 193-202  
 apo E polymorphism and changes in blood lipids and exercise effects in overweight nondiabetic and NIDDM subjects, 1236  
 by nondiabetic and IDDM smokers, 1140-1144  
 OC effects on, 350  
 by PM women on or not on ERT on, 1194  
 $\omega$ -3 PUFA and exercise effects on, 750, 1366  
 and resistance exercise effects on insulin-mediated glucose disposal in older hypertensive subjects, 399  
*see also* VO<sub>2max</sub> during exercise at cold temperature
- VO<sub>2max</sub>** (maximum oxygen uptake) during exercise at cold temperature  
 acipimox-induced plasma NEFA reduction and, 1133  
 and substrate oxidation, 204, 205
- Von Willebrand factor (vWF)** antigen in young subjects with NIDDM parents, 756
- Von Willebrand factor (vWF)** in NIDDM and at-risk for NIDDM subjects, 224, 226
- Waist circumference (WC)**  
 and CV disease risk factors, 1437, 1438  
 of Ecuadorian Amazon Shur women, 1356  
 exercise and, *see* Waist circumference, exercise and  
 insulin therapy of NIDDM effects on, 694, 697  
 of MS subjects, 312  
 of non-obese subjects, *see* Waist circumference of non-obese subjects  
 of obese subjects, *see* Waist circumference of obese subjects  
 of postpubertal Asian Indian adolescents, 1338-1340  
 of young men with hypertensive parents, 470
- Waist circumference (WC), exercise and**  
 and alcohol, exercise, and adiposity relation to HDL-C levels and, 704  
 exercise effects on NIDDM women's, 285  
 exercise effects on PM women's, on or not on ERT on, 1194  
 oral contraceptives and, 350
- Waist circumference (WC) of non-obese subjects**  
 of men, and AT as fibrinogen level predictor, 985, 986  
 of premenopausal women, 1068
- Waist circumference (WC) of obese subjects**  
 of adolescents, 864  
*see also* Waist circumference of obese women
- Waist circumference (WC) of obese women**  
 effects of moderate weight loss and orlistat or sibutramine treatment on serum adipocytokines and, 430-434  
 fluvastatin effects on, 735, 736  
 insulin-resistant women, 281
- Waist-to-hip ratio (WHR)**  
 adiponectin and, *see* Waist-to-hip ratio, adiponectin and  
 and AT distribution in Korean women, 1539, 1541  
 and CV disease risk factors, 1437, 1438  
 exercise effects on, *see* Waist-to-hip ratio, exercise effects on  
 of insulin-resistant subjects, 722  
 and isotretinoin effects on insulin sensitivity and plasma TGs, 5  
 leptin levels and, 1412-1414  
 of lipodystrophic HIV-infected subjects, 1567  
 of non-obese men, and AT as fibrinogen level predictor, 985, 986
- Waist-to-hip ratio (WHR) (Continued)**  
 of obese subjects, *see* Waist-to-hip ratio of obese subjects  
 of PM women, *see* Waist-to-hip ratio of PM women  
 of postpubertal Asian Indian adolescents, 1338-1340  
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50  
 or premenopausal women, sex steroids, plasma Lp and, 189  
 and smoking effects on intravascular remodeling of HDL particles, 860  
 of young subjects, *see* Waist-to-hip ratio of young subjects
- Waist-to-hip ratio (WHR), adiponectin and**  
 and levels of adiponectin, 2  
 NEFA regulation of adiponectin and, 791
- Waist-to-hip ratio (WHR), exercise effects on**  
 apo E genotype, changes in serum lipids and, 195, 198, 199  
 and OC effects on glucoregulatory responses to exercise, 350  
 with  $\omega$ -3 PUFAs, 750, 1366  
 in soccer players, 1263
- Waist-to-hip ratio (WHR) of obese subjects**  
 of obese adolescents, 864  
*see also* Waist-to-hip ratio of obese women
- Waist-to-hip ratio (WHR) of obese women**  
 PM women, fluvastatin effects on, 735, 736  
 sex steroids and plasma Lp and, 189
- Waist-to-hip ratio (WHR) of PM women**  
 effects of exercise by PM women's on or not on ERT on, 1194  
 of obese women, fluvastatin effects on, 735, 736  
 sex steroids, plasma Lp and, 189
- Waist-to-hip ratio (WHR) of young subjects**  
 with NIDDM parents, LDL susceptibility to oxidation and circulating adhesion molecules and, 756  
 of young men with hypertensive parents, 470, 473
- WAT, *see* White adipose tissue**
- Water diuresis, changes induced by, in renal cortex oxygenation and endothelial function in NIDDM and in at-risk for NIDDM subjects, 222-227**
- WC, *see* Waist circumference**
- Weight, *see* Body weight; Organ weight; Weight gain; Weight loss**
- Weight gain**  
 fenofibrate effects on white adipose tissue and HF diet-induced, in ovariectomized subjects, 1284-1289  
 in GDM,  $\beta_3$ -ADR Trp64Arg polymorphism and, 1137
- Weight loss**  
 leptin effects on HPA axis activity, dysphagia and, in STZ-DM, 1558-1564  
*see also* Weight loss by obese subjects
- Weight loss by obese subjects**  
 due to HF diet-induced obesity, leptin therapy to augment leptin circadian rhythm after, 782-789  
 with normal fasting plasma glucose or impaired glucose tolerance, effects of, on insulin release and IR, 1095-1100  
*see also* Weight loss by obese women
- Weight loss by obese women**  
 moderate, *see* Moderate weight loss by obese women  
 with PCOS, 367-368  
 and racial differences in  $\alpha$ -adrenergic receptor density in subcutaneous and omental AT, 247-251
- Wheat germ policosanol (WGP), effects of, on normal and mildly elevated plasma cholesterol, 1309-1314**
- White adipose tissue (WAT)**  
 in CRF, upregulation of lipogenic enzyme and SREBP-1 mRNA in, 1060-1065  
 fenofibrate effects on, and HF diet-induced weight gain in ovariectomized subjects, 1284-1289

- White blood cells, WPG effects on, 1312
- White wine drinking, effects of red and, on circulating inflammation-sensitive molecules in men with CAD, 318-323
- Whole-body glucose, oral glucose metabolism and, in born small-for-gestational-age children and, 847-851
- Whole-body insulin resistance (IR), development of, after 1-day hindlimb suspension, 1215-1222
- Whole-body protein, plasma AA concentration and synthesis of, in young men, 388-396
- WHR, *see* Waist-to-hip ratio
- Wine drinking  
effects of white, on circulating inflammation-sensitive molecules in men with CAD, 318-323  
*see also* Red wine drinking
- Women  
Ecuadoran Amazon Shur, effects of agricultural versus traditional lifestyle on leptin in, 1355-1358  
exercising, *see* Women, exercising  
HC diet effects on atherogenic LDL particles in, 823-830  
hyperuricemic, HPRT point mutation in, 1500-1502  
Korean, effects of PPAR $\gamma$ 2 Pro12Ala polymorphism on AT distribution in, 1538-1543  
obese, *see* Women, obese  
postmenopausal, *see* Postmenopausal women  
pregnant, *see* Pregnancy  
premenopausal, *see* Premenopausal women  
*see also* Sex and specific conditions
- Women, exercising  
NIDDM, effects of resistance exercise on glycemic control in, 284-289  
*see also* Exercise
- Women, obese  
*(Continued)*  
concentration of serum TNF soluble receptors, TNF- $\beta$ , and NO in overweight and, 1268-1273  
*see also* Obesity; Polycystic ovary syndrome, obesity and; Postmenopausal women, obese; Weight loss by obese women
- WPG (wheat germ policosanol), effects of, on normal and mildly elevated plasma cholesterol, 1309-1314
- Xanthine, plasma, sauna bathing and beer ingestion effects on concentration of, 772-776
- Xanthomatosis, cerebrotendinous, effectiveness of hydrophilic 7 $\beta$ -hydroxy bile acids, lovastatin, cholestyramine, and chenodeoxycholic acid in, compared, 556-562
- Xylitol in MNH-01 formula, 978
- Young men  
with hypertensive parents, insulin secretion, insulin sensitivity, and metabolic profile of, 469-475  
Japanese, Pro12Ala PPAR $\gamma$ 2 polymorphism associated with adiponectin levels in, 1548-1551  
plasma AA concentration and whole-body protein synthesis in, 388-396  
serum adiponectin association with LDL particle size, HDL-C, and TGs in, 589-593
- Young subjects  
with NIDDM parents, LDL susceptibility to oxidation and circulating adhesion molecules in, 755-759  
*see also* Young men
- Zinc (Zn)  
effects of Cu enzymes in CF before and after Cu supplementation with or without, 37-41  
effects of dietary restriction of, on metabolic rate and substrate utilization, 727-732